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»Und wenn ich dann Kunde von Heilmann und Coppi erhielte, würde meine
Hand auf dem Papier lahm werden. Ich würde mich vor den Fries begeben,
auf dem die Söhne und Töchter der Erde sich gegen die Gewalten erhoben,
die ihnen immer wieder nehmen wollten, was sie sich erkämpft hatten, Coppis
Eltern und meine Eltern würde ich sehn im Geröll, es würde pfeifen und dröh-
nen von den Fabriken, Werften und Bergwerken, Tresortüren würden schlagen,
Gefängnistüren poltern, ein immerwährendes Lärmen von eisenbeschlagnen
Stiefeln würde um sie sein, ein Knattern von Salven aus Maschinenpistolen,
Steine würden durch die Luft fliegen, Feuer und Blut würden aufschießen,
bärtige Gesichter, zerfurchte Gesichter, mit kleinen Lampen über der Stirn,
schwarze Gesichter, mit glitzernden Zähnen, gelbliche Gesichter unterm Helm
aus geflochtnem Bast, junge Gesichter, fast kindlich noch, würden anstürmen
und wieder untertauchen im Dampf, und blind geworden vom langen Kampf
würden sie, die sich auflehnten nach oben, auch herfallen übereinander, einan-
der würgen und zerstampfen, wie sie oben, die schweren Waffen schleppend,
einander überrollten und zerfleischten, und Heilmann würde Rimbaud zitieren,
und Coppi das Manifest sprechen, und ein Platz im Gemenge würde frei sein,
die Löwenpranke würde dort hängen, greifbar für jeden und solange sie unten
nicht abließen voneinander, würden sie die Pranke des Löwenfells nicht sehn,
und es würde kein Kenntlicher kommen, den leeren Platz zu füllen, sie müßten
selber mächtig werden dieses einzigen Griffs, dieser weit ausholenden und
schwingenden Bewegung, mit der sie den furchtbaren Druck, der auf ihnen
lastete, endlich hinwegfegen könnten.«
— Peter Weiss, Die Ästhetik des Widerstands
Meiner Familie

Abstract
Human and murine humoral immune responses are associated with changes of
both the composition and the concentration of serum antibodies. Signal intensity-
based antibody binding profiles measured with random-sequence peptide microarrays
attempt to capture these changes to render them applicable to serological diagnostics.
Diagnostics based on antibody profiling rest primarily on the assumption that profiles
of diseased and healthy individuals differ consistently from one another. The challenge
for antibody profiling lies in reflecting the change in the antibody mixture induced
by the disease while taking into account the variability of antibody profiles of healthy
individuals. In this work, the antibody repertoire’s impact on antibody binding
profiles is studied. Since the characterizing components of polyclonal antibody
mixtures, such as composition and concentration, are difficult to study in vitro a
mathematical model for antibody-peptide binding was formulated.
This model is based on the law of mass action and incorporates as parameters
(i) antibody and peptide sequences and (ii) antibody concentrations. The binding
affinity of simulated monoclonal antibodies depends non-linearly on amino acid
positions in the peptide sequences. The model was both mathematically analyzed
and implemented in silico to simulate antibody-peptide binding data. Mathematical
analysis and simulations predicted that mixtures of highly diverse random antibodies
which are not dominated concentration-wise by few antibodies—termed unbiased
mixtures—could be linearly predicted based only on the amino acid composition of
the peptide library used. Thus, any unbiased mixture independent of its specific
antibody composition yields the same antibody binding profile for a given peptide
library. This linear relationship led to the formulation of a linear regression model
of which amino acid associated-weights (AAWS) emerge as near perfect predictors
of antibody binding profiles. AAWS indicate the contribution of every amino acid
to signal intensity and are a compact, lossless representation of unbiased mixtures’
antibody binding profiles. For low-diversity antibody mixtures, this linear regression
model breaks down.
In order to test the in vitro relevance of the mathematically predicted ensemble
properties of antibody mixtures, monoclonal (low antibody diversity) and serum
antibodies (high antibody diversity) were incubated with the same peptide library.
Indeed, as predicted by theory, the predictive performance of AAWS was significantly
higher for antibody binding profiles of serum than of monoclonal antibodies. In
addition, AAWS, and to a lesser extent antibody binding profiles, were found to
be consistent across healthy individuals, both murine and human, thereby showing
the independence of antibody binding profiles and AAWS on the specific antibody
mixture. The concept of unbiased mixtures best approximates sera of healthy
individuals.
Simulated antibody binding profiles of mixtures biased by random dominant anti-
bodies were found to be isotropically distributed in the variance space. Consequently,
to separate simulated antibody binding profiles into different groups, antibody-peptide
binding of dominant antibodies had to be consistent across individuals of a given
group but different from any other. The intra-group consistency of antibody-peptide
binding is a basic premise of serological diagnostics: the mathematical model does
not only fulfill this premise, but also predicts antibody dominance as a condition
which is able to establish classifiable intra-group consistency.
In particular, antibody dominance caused—unlike variations in total antibody
concentration—rank changes in the simulated antibody binding profiles. In vitro,
rank changes were consistent across healthy and diseased mice thus serving to classify
mice by stage of immune response. Additionally, ranks of antibody binding profiles
of plasma samples from healthy volunteers obtained over the course of one month
clustered by volunteer. This indicates the need for serological methods to take into
account individual variability to detect disease-induced changes in antibody mixtures.
Furthermore, simulations showed that AAWS are highly noise-resistant: AAWS
could readily separate original signal intensities from noise over a large range of noise
amplitudes. In fact, AAWS were found to not only show high consistency across
sera incubated on the same batch, but, unlike antibody binding profiles, also across
batches. However, AAWS varied with the microarray manufacturer.
In conclusion, this work shows that serum antibody ensemble properties impact
the genesis of antibody binding profiles measured with random-sequence peptide
microarrays. This thesis indicates that a knowledge of both a polyclonal mixture’s
diversity and composition is essential for the interpretation of antibody binding
profiles with respect to both serological diagnostics and B-cell epitope mapping.
Specificity, and thus classifiability, of serum antibody binding profiles is a function of
both the investigated antibody mixtures and technological features.
Zusammenfassung
Menschliche und murine humorale Immunantworten gehen einher mit der Ver-
änderung der Zusammensetzung und der Konzentration von Serumantikörpern.
Signalintensitäts-basierte Antikörperbindungsprofile, gemessen mit Zufallspeptidmi-
kroarrays, versuchen diese Veränderungen zu detektieren, um sie für serologische
Diagnostik nutzbar zu machen.
Die auf Antikörper-Profiling basierende Diagnostik beruht auf der Annahme, dass
Antikörperbindungsprofile von kranken und gesunden Individuen sich systematisch
voneinander unterscheiden. Antikörper-Profiling muss sowohl die krankheitsindu-
zierte Veränderung der Antikörpermischung wiedergeben als auch der Variabilität
Antikörperprofilen gesunder Individuen Rechnung tragen.
Gegenstand dieser Arbeit ist die Analyse des Einflusses des Antikörperrepertoires
auf Antikörperbindungsprofile. Da die charakteristischen Komponenten polyklona-
ler Antikörpermischungen, wie Zusammensetzung und Konzentration, experimen-
tell überwiegend nicht quantifizierbar sind, wurde ein mathematisches Modell für
Antikörper-Peptidbindung aufgestellt.
Dieses Modell basiert auf dem Massenwirkungsgesetz und beinhaltet als Parame-
ter (i) Antikörper- und Peptidsequenzen sowie (ii) Antikörperkonzentrationen. Die
Bindungsaffinität simulierter monoklonaler Antikörper hängt nichtlinear von den
Aminosäurepositionen in den Peptidsequenzen ab. Das Modell wurde mathematisch
analysiert und in silico implementiert, um Antikörperbindungsprofile zu simulieren.
Mathematische Analyse und Simulationen ergaben, dass die Antikörperbindungspro-
file von Mischungen hochdiverser, zufällig generierter Antikörpersequenzen, welche
nicht durch wenige Antikörper konzentrationsdominiert sind – genannt ideale Mi-
schungen – linear ausschließlich mit Hilfe der Aminosäurezusammensetzung der
Peptidbibliothek vorhergesagt werden können. Das bedeutet, dass für eine gegebene
Peptidbibliothek alle idealen Mischungen unabhängig von ihrer Zusammensetzung
das gleiche Antikörperbindungsprofil erzielen. Dieser lineare Zusammenhang führte
zu der Formulierung eines linearen Regressionsmodells, aus welchem Aminosäure-
assoziierte Gewichte (AAWS) hervorgehen. AAWS sind fast perfekte Prädiktoren
von Profilen idealer Mischungen. Die AAWS geben den Anteil jeder Aminosäure zur
gemessenen bzw. simulierten Peptid-Signalintensität wieder. Sie stellen eine kom-
pakte, verlustfreie Abbildung von Antikörperbindungsprofilen idealer Mischungen
dar. Für niedrig-diverse Mischungen ist die Vorhersagekraft des Regressionsmodells
jedoch eingeschränkt.
Um die in vitro-Relevanz der mathematisch vorhergesagten Ensembleeigenschaften
von Antikörpermischungen zu überprüfen, wurden monoklonale Antikörper (niedrige
Antikörperdiversität) und Serumantikörper (hohe Antikörperdiversität) mit derselben
Peptidbibliothek inkubiert. Wie durch das Modell vorhergesagt war (i) die AAWS-
Vorhersagekraft signifikant höher für Antikörperbindungsprofile von Serum- als für
monoklonale Antikörper. (ii) Des Weiteren entsprachen sich die AAWS gesunder
Individuen (murin, human) und in einem geringeren Maße auch deren Antikörper-
bindungsprofile. In der Tat sind AAWS in gewissem Umfang von der spezifischen
Antikörperkomposition unabhängig. Das Konzept der idealen Mischung entspricht
bevorzugt Seren gesunder Individuen.
Simulierte Antikörperbindungsprofile von zufällig dominierten Antikörpermischun-
gen waren isotrop im Varianzraum verteilt. Folgerichtig konnten in Simulationen
nur solche Antikörperbindungsprofile dominierter Antikörpermischungen in Gruppen
aufgetrennt werden, deren Antikörperpeptidbindung sich innerhalb einer Gruppe äh-
nelte und sich von jeder anderen Gruppe unterschied. Die Intra-Gruppen-Konsistenz
der Antikörperpeptidbindung ist einer der Hauptprämissen serologischer Diagnostik.
Das mathematische Modell erfüllt diese nicht nur, sondern hebt prädiktiv Antikörper-
dominanz als einen Zustand hervor, der Intra-Gruppen-Konsistenz herbeizuführen
vermag.
Im Gegensatz zu Gesamtantikörperkonzentrationsschwankungen führte insbeson-
dere Antikörperdominanz zu Peptid-Rangveränderungen innerhalb der simulierten
Antikörperbindungsprofile. In vitro konnten konsistente Rangunterschiede festgestellt
werden, welche die Klassifizierung von Seren gesunder und parasiteninfizierter Mäuse
ermöglichten. Außerdem clusterten die Ränge der Antikörperbindungsprofile von Plas-
maproben, erhalten über einen Zeitraum von einem Monat von gesunden Menschen,
bezüglich des jeweiligen gesunden Individuums. Dies belegt, dass serologische Me-
thoden individuelle Variabilität in Betracht ziehen müssen, um krankheitsinduzierte
Veränderungen diagnostizieren zu können.
Weiterhin zeigten Simulationen, dass AAWS hochgradig rauschresistent sind.
AAWS konnten das simulierte Originalsignal vom verrauschten Signal über eine
große Bandbreite von Rauschamplituden trennen. Darüber hinaus waren AAWS
nicht nur serum-, sondern im Gegensatz zu Antikörperbindungsprofilen, auch pro-
duktionschargenunabhängig. Jedoch hingen die AAWS vom Mikroarray-Produzenten
ab.
Zusammenfassend zeigt diese Arbeit, dass Antikörper-Ensembleeigenschaften die
Genese von mit Zufallspeptidemikroarrays bestimmten Antikörperbindungsprofilen
beeinflussen. Kenntnisse über die Zusammensetzung einer polyklonalen Mischung
sind essentiell für die Interpretation von Antikörperbindungsprofilen in Bezug auf
serologische Diagnostik und Epitopkartierung. Die Spezifität und damit auch die
Klassifizierbarkeit von Antikörperbindungsprofilen ist sowohl eine Funktion der
untersuchten Antikörpermischung als auch technologischer Faktoren.
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1 Introduction
1.1 The mammalian immune system
The mammalian immune system1 is responsible for removing dead and non-functioning
cells [4, 5] as well as for clearing the body from xenobiotics and pathogens such as
bacteria, viruses, fungi and protozoa. A complex system of immune cells is distributed
throughout the body. In addition, several immune organs exist. In the primary organs,
bone marrow and thymus, immune cells are generated and mature, whereas in secondary
tissues, including spleen and lymph nodes, the processing of the immune response takes
place2.
The immune system relies on three pillars: (i) physico-chemico-mechanical immune
barriers [7], (ii) the innate immune system and (iii) the adaptive immune system3.
After pathogens have passed the physical immune barriers, they are first challenged
by the innate immune system. It comprises germline encoded immune mediators such
as cytokines and complement as well as immune cells (e.g. macrophages, granulocytes
and NK cells). The innate immune system causes local inflammation, which preludes the
active and rapid elimination of pathogens by either phagocytosis or cell lysis. Additionally,
the innate immune system stimulates the adaptive immune system, which induces both a
highly diverse and specific immune response, and immunological memory. Immunological
memory is defined as a concept, which enables the immune system to react more specific,
faster and with higher amplitude to already encountered pathogens [2].
Adaptive immunity essentially branches off in two arms. The cell-mediated immunity
relies on cytotoxic T lymphocytes (T cells) that are responsible for the elimination of
intracellular pathogens by either destroying them or by lysing infected cells. On the
contrary, the humoral immunity is mainly mediated by glycoproteins called antibodies
that are derived from B lymphocytes (B cells). Antibodies account for the major
defense against extracellular4 pathogens and their toxins. Antibody binding neutralizes
the targets, marks them for elimination (opsonization) and activates adequate effector
mechanisms. Effector mechanisms comprise among others activation of complement and
endocytosis by antigen presenting cells.
1In the following, I will focus mainly on the human and murine immune system the both of which are
similar in some respects but different in others [1]. Parts of this introduction are inspired by the
textbooks Immunobiology [2] and Cellular and molecular immunology [3].
2The existence of “tertiary” (or ectopic) lymphoid organs was also reported. They are characterized as
cellular accumulations arising during chronic inflammation by the process of lymphoid neogenesis [6].
3Newer studies draw a rather interconnected picture of innate and adaptive immune system in which
both parts critically depend on one another [8].
4The existence of intracellular antibody-mediated immunity has recently been suggested [9].
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1.2 Humoral immunity
1.2.1 Immune reaction and immune response
Following Thomas Pradeu, in this work an immune reaction is defined as the biochemical
interaction between an immune receptor and its ligand. An immune response is launched
only if its immunological effector mechanisms were activated [10].
1.2.2 Antigens and immunogenicity
An antigen is defined as any substance that can bind to a specific antibody [2]. The
antigen’s ability to induce an immune response in a competent host is known as im-
munogenicity. The term immunogenicity has no meaning outside the host context and
depends on the potentialities of the host being immunized such as its immunoglobulin
gene repertoire and various cellular regulatory mechanisms [11, 12].
1.2.3 Criteria for immunogenicity
Since the 1950s, a consensus has formed on the acceptance, and the adjustment of
Burnet’s seminal ideas [13–15] according to which the discrimination between “self” and
“non-self” is the criterion (SNC) for immunogenicity [16]: every element that distinctively
belongs to the organism (“self”) does not trigger an immune response, whereas every
foreign element (“non-self”) triggers an immune response [17]. Yet, several published
experimental data [5, 18–20] as well as conceptual articles [21, 22] have put the SNC into
question.
At least two other significant alternatives to the SNC have been proposed. (i) Polly
Matzinger formulated the danger theory, wherein the immune system does not react
to non-self but rather to any danger, be it exogenous or endogenous [19, 23]. (ii) The
continuity criterion, published by Thomas Pradeu and Edgardo D. Carosella, relies on
the immune system’s ability to discriminate pathogens based on significant molecular
differences. Thus, the immune system does not respond to non-self, but rather to abrupt
modifications of the antigenic patterns with which it is in contact [15].
1.3 The antibody molecule
1.3.1 The function of antibody molecules
The antigen recognition molecules of B cells are the immunoglobulins (Igs, Figure 1.1).
These proteins are produced by B cells in a vast variety, each B-cell clone producing an
Ig of a single kind. Membrane-bound Ig on the B-cell surface serves as the cell’s receptor
for antigen, and is known as the B-cell receptor (BCR). Igs of the same antigen affinity
are secreted as antibodies by antibody secreting cells (ASCs)—proliferating plasmablasts
and terminally differentiated plasma cells.
The antibody molecule has two distinct roles: (i) binding to molecules associated
with the immune response eliciting pathogen in a neutralizing fashion and (ii) recruiting
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additional cells (and molecules) to the site of inflammation in order to destroy opsonized
pathogens.
The twofold functionality of antibodies is also mirrored by the structural duality of
the antibody. One part of the antibody recognizes and binds to the antigen, whereas
the other one engages different effector functions. The antigen-binding region varies
extensively among antibody molecules and is thus named V(ariable) region (Section
1.3.3). The part of the antibody which engages effector functions does not vary in the
same way and is thus called the C(onstant) region. It is generated in five main forms,
which are specialized for activating different effector functions5.
The membrane-bound BCR does not have these effector functions, because the C
region remains inserted in the membrane of the B cell. Its function is as a receptor that
recognizes and binds antigen thereby transmitting signals, which elicit mechanisms such
as (T-cell mediated) B-cell activation, clonal expansion and the production of antibodies
[3].
1.3.2 The structure of antibody molecules
Figure 1.1: Schematic depiction of the IgG molecule. The antigen binding sites are formed by
juxtaposition of variable light chain (VL) and variable region heavy chain domains (VH). C:
constant region, CDR: complementarity determining region, Fab: fragment antigen binding, Fc:
fragment crystallizable, FR: framework, H: heavy chain, L: light chain, V: variable region. From
Wittenbrink (PhD thesis, [27]) who modified this Figure from Abbas and Lichtman [3].
Antibodies are roughly Y-shaped molecules consisting of three equal-sized portions
connected by disulfide bonds (Figure 1.1). The five main Ig classes (also called isotypes)
5The C region can affect the interaction of the V region with an antigen [24–26].
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IgA, IgD, IgE, IgM6, IgG are mainly distinguished by their C region. In the following,
the IgG molecule is described in more detail exemplifying the general structure of Igs
as it is the most abundant isotype (Section 1.6). Nevertheless, the general structural
features of all Ig isotypes are similar.
IgGs are large proteins of about 150 kDa consisting of two kinds of polypeptide chains.
The one with a molecular weight of 50 kDa is referred to as H chain and the other of
25 kDa is called L chain. Each IgG molecule consists of two heavy and two light chains.
The two H chains are linked together by disulfide bonds, and each H chain is linked to an
L chain by another disulfide bond. In any given Ig molecule, these chains are identical
enabling the Ig to bind simultaneously to two identical structures.
Light chains are subdivided into kappa (κ) and lambda (λ) chains. Each antibody has
either κ or λ light chains, never both together. The class, and thus the effector function
of an antibody is defined by the structure of its heavy chain. The distinctive function of
the several classes results from the properties conferred to them by the carboxyl terminal
part of the H chain, where it is not associated with a light chain.
1.3.3 Variability of antibody molecules
Each Ig chain consists of similar, although not identical about 100 amino acid long
sequences. Each of these repeats corresponds to a discrete, compactly folded region of
protein structure known as a protein domain. The light chain is made up of two of such Ig
domains, whereas the heavy chains of the IgG molecule consists of four of such domains.
The aminoterminal sequences of heavy and light chain vary markedly among antibodies.
The sequence variability is limited to the first 110 amino acids, corresponding to the
first domain, whereas the remaining domains are constant between Ig molecules of the
same isotype. The amino-terminal V domain of the heavy and light chains (VH and VL
respectively) together make up the V region of the molecule and confer on it the ability
to specifically bind antigen, whereas the C domain of the heavy and light chains (CH and
CL respectively) make up the C region of the heavy and light chains. In order to dissect
the function of the parts of the antibody, proteases have been used, cleaving the antibody
in distinct polypeptide sequences. Papain (a protease) cleaves the antibody into three
fragments. Two fragments are identical and contain the antigen-binding activity. These
are termed Fab7 fragments. The remaining fragment shows no antigen-binding activity
but is crystallizable, thus termed Fc fragment8. It represents the part of the antibody that
interacts with effector molecules and cells. The reasons for effector-functional differences
between H chain-isotypes lie mainly in the Fc fragment.
Each B-cell clone produces antibodies with a unique V region. The V region’s sequence
variability is concentrated in three hypervariable segments denoted as HV1, HV2, and
HV3. They are found in both the VH and VL regions.
The most variable part of the domain is the HV3 region. The less variable regions
between the hypervariable regions, which comprise the rest of the V domain are termed
6IgM is the only isotype common to all vertebrates [28].
7Fragment antigen binding.
8Fragment crystallizable.
4
1.4 Antibody reactivity
framework regions. Four of such regions exist in each V domain, termed FR1 to FR4.
When the VL and VH domains are paired in the antibody molecule, the hypervariable
regions from each domain are brought together, creating a single hypervariable site at the
top of each arm of the molecule. These are the sites mostly involved in antigen-binding.
The six hypervariable regions determine antigen affinity by forming a surface comple-
mentary to the antigen and are more commonly termed complementarity determining
regions (CDRs) denoted CDR1 to CDR3 (there are three CDRs from each of the heavy
and light chains).
1.4 Antibody reactivity
1.4.1 B-cell epitopes
B-cell epitopes are traditionally defined as antigenic molecules that are recognized by
individual antibody paratopes: the epitope is the molecular surface that makes physical
contact with the paratope [29, 30]. Greenspan and van Regenmortel suggest an operational
epitope definition according to which epitope and paratope are relational entities defined
by their mutual complementarity. An epitope is thus a function or an activity, as opposed
to a mere structure [12, 31, 32].
Epitopes are usually classified as either continuous (obsolete: linear) or discontinuous
(obsolete: conformational). Epitopes on the surface of proteins are mostly discontinuous
and conformation-dependent [33–35]. The label continuous epitope is given to any short,
linear peptide fragment of the antigen that binds to antibodies raised against the intact
protein. Because the peptide fragment usually does not retain the conformation present
in the folded protein and mostly represents only a portion of a more complex epitope,
it tends to react only weakly with anti-protein antibodies. Discontinuous epitopes are
made up of residues brought together by the folding of the polypeptide chain. Thus,
as a rule, antibodies to discontinuous epitopes will recognize the antigen only if the
protein molecule is intact, and its native conformation is preserved. There are exceptions,
however, and it has been estimated that about 10% of the monoclonal antibodies that
recognize discontinuous epitopes are also able to react with linear peptide fragments of
the protein [12].
It is now accepted that the entire surface of the protein harbors numerous overlapping
epitopes [34]. For example, insulin, a dimeric protein with 51 amino acids, has on its
surface at least 115 B-cell epitopes [12, 36].
1.4.2 Antibody-epitope interaction
The central paradigm of antigen-antibody recognition is that the three-dimensional
structure formed by the six CDRs recognizes and binds a complementary surface (epitope)
on the antigen (Sections 1.3.3 and 1.4.1, [37]9).
9However, Kunik and colleagues very recently showed that about 20% of the amino acid residues that
bind the antigen fall outside the CDRs [38].
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An antibody contains a variety of binding sites. Each antibody binding site defines a
paratope composed of the particular amino acids of that antibody that physically bind to
a specific epitope. Approximately 50 variable amino acids make up the potential binding
area of an antibody [32]. Typically, only about 15 of these 50 amino acids physically
contact a particular epitope. These 15 contact residues define the structural paratope.
Only approximately 5 of these amino acids dominate in terms of binding energy. In both
epitope and paratope, substitutions both in and away from the binding site can change
the spatial conformation of the binding region and affect the binding reaction [32, 39, 40].
The association of antibody and antigen is of non-covalent nature. The free energy
of interaction between an antibody and its antigen is a function of both enthalpy and
entropy. Non-bonded forces between the interacting molecules include hydrophobic,
hydrogen bonds, van der Waals and electrostatic interactions [41]. Charge neutralization
in the interface plays a prominent role as well [42].
CDRs were found to have a much greater frequency of tyrosine and tryptophan residues
than is usual on the surface of protein molecules [33, 43–45]. These aromatic side chains
can make large rotations with little entropic cost, and they contribute significantly to
the binding energy [12, 41]. Furthermore, crystallographic studies showed that binding
involved a certain amount of induced fit [12, 46]. Upon binding, residues are displaced
by several angstrom [47, 48].
Furthermore, two molecules that have nearly identical structures on the basis of
crystallography may not interact comparably with a given receptor because of differences
in molecular dynamics [49]: the crystallographic structure of antibody-antigen complex
captures merely one point in time. The contributions of the time dimension should
therefore be taken into account for a characterization of bimolecular interactions [31, 32].
Hence, Greenspan proposed a richer epitope description by taking into account (i) the
spatial coordinates of the contact atoms, (ii) the dynamics [time dimension] of the atoms
involved in contact with the paratope, (iii) the relative energetic contributions of atoms
or amino acids to the interaction or to the discrimination between cognate epitopes and
other epitopes as well as (iv) the context in which the binding takes place [31, 50].
1.4.3 Affinity and avidity
The affinity between a ligand (such as an antibody) and a protein (such as an antigen)
(Equation 1.1), defining the strength of a ligand-protein bond, is commonly expressed by
the dissociation constant Kd (Equation 1.2).
Ab + Ag⇌ AbAg (1.1)
Kd =
[AbAg]
[Ab] [Ag] =
1
Ka
(1.2)
In the specific case of antibodies binding to antigen, usually the affinity constant, defined
at chemical equilibrium, Ka, is used (Equation 1.2). It is the inverted dissociation
constant and determines the binding strength of an antibody with a given antigen. The
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higher the affinity of the antibody for its antigen, the less antibody is required to eliminate
the antigen in a physiological immune response, as antibodies with higher affinity will
bind at lower antigen concentrations.
Ka is also the ratio of the kinetic on- and off-rate constants, which quantify the rates
at which a free antibody and free antigen combine (through collisional encounters) to
form a binary antibody-antigen complex and at which a binary antibody-antigen complex
dissociates to the free antibody and free antigen, respectively.
Ka =
on-rate, Kon
off-rate, Koff
(1.3)
In addition to affinity, the notion of avidity is crucial for describing the strength of
antibody-antigen binding. Avidity is defined as the combined strength of multiple bond
interactions. IgM is said to have low affinity but high avidity because it has 10 weak
binding sites due to its pentameric structure as opposed to the 2 stronger (higher affinity)
binding sites of IgG, IgE and IgD.
Enzyme-linked immunosorbent assay (ELISA)10 enables the determination of the
dissociation constant (Kd) of antigen-antibody equilibria in solution [51].
For measuring affinity, surface plasmon resonance (SPR) is a well-established label-free
technique that is frequently used not only to detect affinity of protein-protein, protein-
ligand or DNA-DNA interactions, but also for retrieving kinetic information, such as Kon
and Koff , on antibody-antigen binding by following the SPR signal in real time [52, 53].
1.4.4 Polyspecificity of antibodies and completeness of the antibody
repertoire
Antibodies, just like other proteins, are not monospecific [54]: they are proteins, which
bind with varying affinity to a multitude of structures [55–58]. While antibodies are
able to bind multiple antigens with comparable high affinity [54, 59–62], this does not
necessarily mean the bound antigens are structurally close [47]. The search for the single
correct antigen for a given antibody is thus rendered meaningless by the polyspecificity
of antibodies [63]—the range of shared specificities is the key observation [64].
The number of B cells (not distinct B-cell clones) present at any one time is estimated
to be 108–109 in mice and 1012 in humans [65]. This number is much lower than the
number of all possible antigens. Polyspecificity [63] of antibody molecules may thus
ensure the completeness of the antibody repertoire [66–69] describing its ability to react
to all possible antigens.
10ELISA is a technique that essentially requires any ligating reagent that can be immobilized on the
solid phase along with a detection reagent that will bind specifically. An enzyme is used to generate a
signal that can be quantified. ELISA is also a common means for determining antibody titers. An
antibody titer is a measurement of how much antibody an organism has produced that recognizes a
particular antigen, expressed as the greatest dilution that still gives a positive result [2].
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1.4.5 Humoral specificity and current definitions of specificity
The so called specificity of antibodies is a hallmark of antibody reactivity. It is often
described as a selective reaction tailored to a specific cause: clearing of dead cells,
pathogens, etc. [70].
A general definition of specificity reflecting its relative nature has been given by Neil
S. Greenspan [50]: “Monovalent affinity can be defined as a ∆G (change in free energy)
value pertaining to a particular receptor-ligand interaction and specificity can be defined
by ∆∆G values that characterize two or more receptor-ligand interactions.” Thus, the
definition of specificity depends on a frame of reference: the local environment of the
studied species has to be given11 as well as the chemical species to which the studied
species is compared to [50].
Greenspan’s definition is in its nature consistent with that of van Regenmortel who
states that “[...] a perfect fit between epitope and paratope is not a meaningful concept.
The degree of specificity of an interaction cannot be linked directly to the size of the
antibody affinity constant, and it is generally more meaningful to compare specific
interactions in terms of their discrimination potential. The same antibody may thus be
called specific or nonspecific, depending on what the investigator is trying to achieve”
[12].
Specificity is primarily discussed with respect to monoclonal antibodies [72, 73]. Also,
concepts such as cross-reactivity are mostly looked at from a monoclonal antibody’s point
of view [74–76], whereas, in fact, monoclonal specificity does not per se explain humoral
specificity. Indeed, despite antibody polyspecificity (Section 1.4.4), the population of
serum antibodies shows a high degree of specificity towards the eliciting antigen [59].
Serum specificity provides the very basis for the clearing of pathogenic agents from the
body. Talmage suggested that “in a mixture of a large number of different globulin
molecules, the dominant reactivity will be that common to the largest number of molecules
present” [77]. The exquisite specificity of an immune serum could therefore be regarded
as an ensemble phenomenon of serum antibodies [59, 71, 78].
1.5 The shaping of the B-cell receptor repertoire
Virtually any substance can be the target of a humoral immune response due to the
antibody repertoire’s high diversity. The response to even a simple antigen bearing a
single antigenic determinant is diverse, comprising many different antibodies, each with
a subtly different and unique antigen affinity (Section 1.4.4). The number of different
antibodies available at any one time to an individual depends on the number of B cells in
an individual as well as to various other factors such as health status, number of antigen
encounters in life etc. The diversity of the BCR repertoire is generated by four main
processes.
11„Solute-solvent interactions, molecular crowding and confinement not directly related to the details of
the intermolecular interface can play crucial roles in determining both intrinsic affinity and differential
intrinsic affinity.“ ([71])
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1.5.1 Somatic recombination of Ig genes: a mechanism creating threefold
diversity
Gene rearrangement takes place during development of B cells in the bone marrow
combining two or three gene segments to form a complete V region exon. The gene
rearrangement is also referred to as somatic recombination. Three separate loci encode
the two Ig light chains (Igκ, Igλ) and the Ig heavy chain. Each light chain locus is
composed of three different clusters of gene segments, referred to as variable (V), constant
(C) and joining (J) gene segments. The IgH locus bears an additional cluster of diversity
(D) gene segments. Somatic recombination thus generates diversity in two ways: first,
there are multiple types of copies of each gene segment and different combinations of gene
segments can be used in different rearrangement events. This combinatorial diversity
is responsible for a substantial portion of the diversity of the heavy and light chain V
regions. Second, junctional diversity is introduced at the joints of the different gene
segments as a result of addition and subtraction of nucleotides by the recombination
process. A third source of diversity originates from combinatorial events, arising from
the many different combinations of heavy- and light chain V region pairings forming the
antigen-binding site in the Ig molecule. These three mechanisms give rise to a potential
diversity of about 1012–1013 different BCRs in humans and 109 in mice [79]. They take
place during the initial development of B cells in the primary lymphoid organs.
The human and mice species generate their BCR diversity in a similar fashion [80].
Prior to the antigenic challenge, these species produce a primary repertoire through
the recombination of multiple germline genes [81–83]. However, even though human
and mouse antibodies are similar with respect to their diversification strategies, they
differ in the extent to which κ and λ light chains are present in their variable light chain
repertoires. While the Igκ-V germline genes are dominating the response in mice (95%
or more), they comprise only 60% in humans [84].
1.5.2 Somatic hypermutation—a fourth process increasing the diversity of
the BCR repertoire
Somatic hypermutation (SHM) introduces point mutations into rearranged V regions of
activated B cells, creating further diversity that can be selected for enhanced antigen
binding. SHM takes place in the germinal centers (GCs) [85] in the peripheral lymphoid
organs after functional Ig genes have been assembled. It introduces point mutations at
a rate of 10−3bp−1generation−1 giving rise to mutated BCRs on the surfaces of B cells
[81, 86, 87]. In mice and humans, SHM occurs only when B cells respond to antigen
along with signals from activated T cells (T-cell dependent B-cell activation) [88]. The
Ig C region and other genes are mostly not affected, whereas the rearranged VH and
VL genes are mutated even if they are non-productive and are not expressed. The base
changes are distributed throughout the V region, but are not entirely random due to
the existence of certain mutational hotspots [89, 90]. Some of the mutant Ig molecules
bind antigen better than the original BCR and B cells expressing them are preferentially
selected to mature into antibody-secreting plasma cells or memory B cells. This gives
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rise to a phenomenon called affinity maturation12.
1.5.3 B-cell receptor repertoire analyses
The BCR repertoire is highly variable and of broad chemical diversity and high selectivity
(Sections 1.4.2 and 1.5). However, it is still unclear which fraction of the potential
repertoire is expressed in an individual at any point in time and how similar repertoires
are between individuals who have lived in similar environments [77, 92, 93].
Recently, genome deep-sequencing13 technologies allowed the exploration of the BCR
repertoire due to the recent development of techniques and the exponential reduction
in cost of sequencing [94]. The process of obtaining the BCR repertoire starts with the
B-cell isolation from the relevant biological sample. Subsequently recombined sequence
regions are isolated and sequenced on parallel sequencing machines [95, 96]. According
to output sequences, clones are quantified. The use of RNA is among others a source of
bias. There are different quantities of mRNA in different cells: active B cells and ASCs
produce much higher amounts of mRNA compared with resting B cells.
Weinstein and colleagues sequenced the IgM-BCR repertoire of healthy zebrafish. They
discovered that (i) the abundance distributions of both the VDJ repertoire and antibody
heavy-chain diversity were similar between individuals, (ii) that VDJ usage is not uniform,
(iii) and that individuals can have highly correlated VDJ repertoires [97, 98]. Similar
characteristics were also found within the IgM repertoire of human blood cord cells
[99]. Furthermore, Weinstein and colleagues used their data to estimate the number of
different B-cell clones to be between 1200 and 3500 per fish [93]. For the human system,
Glanville and colleagues determined the total diversity of IgM BCRs of peripheral blood
mononuclear cells to be at least 3.5× 1010 per individual [100]. A similar number was
reported by Arnaout and colleagues [101].
1.6 Serum antibodies
The serum is a component of the blood, containing neither blood cells nor clotting
factors14. However, it contains all the electrolytes, antibodies, antigens, hormones, and
any exogenous substances (e.g. drugs and microorganisms) [102].
Serum antibodies constitute the antibody repertoire (AR)—the ensemble of secreted
antibodies found in the blood at any one time [103, 104]. ASCs can synthesize and
secrete several thousand antibody molecules per second [105, 106]. The antibody levels
in the serum and other body fluids are maintained by a relatively small population of
ASCs making up only about 0.1% to 1.0% of the cells of secondary lymphoid organs and
the bone marrow [107–110]. The half-life of antibody molecules in serum is less than 3
weeks [111]. The maintenance of serum antibody levels requires therefore continuous
secretion of antibodies [112].
12The concept of affinity maturation remains a matter of discussion [70, 88, 91].
13Also called next generation sequencing, immunosequencing or repertoire sequencing [94].
14Serum is equivalent to plasma after removal of clotting factors.
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1.6.1 Antibody isotypes in serum
The serum of human immunocompetent donors mainly contain antibodies of the IgG,
IgA, and IgM classes [2]. IgD and IgE are present in serum at only low concentrations,
together accounting for less than 1% of total serum Ig. Accounting for about 85% of total
serum antibody levels in humans, antibodies of the IgG subclasses are most abundant.
IgA abundance amounts to 7%–15% of serum antibodies. Most IgA is secreted as a dimer
within mucosal fluids [113]. Roughly 5% of serum antibody is IgM, mainly in pentameric
form [112, 114, 115].
IgM and IgG antibodies are already present in serum of newborns before they have
contacted any pathogens. IgG levels in fetal serum are comparable to IgG levels of the
mother [112]. A fraction of these antibodies is produced by ASCs, which developed from
B-1 lymphocytes (Section 1.6.2, [116]).
1.6.2 Antibody secreting cells
Serum antibodies are derived from different types of ASCs, reflecting the dual role of B
cells in both innate and adaptive immunity.
The innate part is carried out by ASCs of the B-1 lineage which express antibodies that
bind often to microbial structures shared by a variety of pathogens throughout the life of
the individual [117–119]. Antibodies secreted by B-1 cells are usually of the IgM, IgA, or
IgG3 subclass. B-1-derived ASCs, producing “natural antibodies”, are already prenatally
active. B-1 cells are present in low numbers in the lymph nodes and spleen (in the
marginal zone [120]) and are instead found predominantly in the peritoneal and pleural
cavities [112, 121]. B-1 lymphocytes differ from other B lymphocyte subsets in that they
arise early in ontogeny, they use a distinctive and limited set of gene rearrangements
to make their receptors and they are self-renewing in the periphery. They cannot be
boosted: after repeated exposure to the same antigen, they elicit similar, or decreased,
responses with each exposure. B-1 B cells, in the mouse, can be further subdivided into
B-1a (CD5+) and B-1b (CD5−) subtypes. Unlike B-1a B cells, the B-1b subtype can be
generated from precursors in the adult bone marrow [122].
In response to antigen, ASCs also develop from B-2 lymphocytes, in an adaptive
humoral immune reaction that peaks at about 1 to 2 weeks after antigenic challenge
[112, 123]. When naïve B cells traffic through secondary lymphoid tissues and encounter
foreign antigen, they can differentiate into multiple fates depending on the type, strength
and timing of signals received within the lymphoid microenvironment. Both T-cell-
independent (TI) and T-cell-dependent (TD) antigens induce naïve B cells to become
short-lived antibody-secreting plasmablasts that localize to extrafollicular regions of
lymphoid tissues [124, 125]. TD antigens also induce naïve B cells to seed GCs in
lymphoid follicles. Within GCs, B cells undergo SHM, isotype switching and affinity-
based selection, which is thought to result in the generation of long-lived memory and
PCs [70, 91, 126–130]. Long-lived memory B cells and PCs then migrate from the
GC to distinct sites, such as the splenic red pulp, medullary cords of lymph nodes or
mucosal-associated lymphoid tissues of the gut for PCs, or splenic marginal zone or
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tonsillar epithelium for memory B cells [124, 131]. Alternatively, the cells can egress from
their tissue of origin, enter the circulation and take up residence in distal sites (e.g. the
bone marrow), so called niches, where they receive survival cues from neighboring cells.
During inflammatory or autoimmune responses, PCs can also home to inflamed tissues
[132–134].
Of outstanding interest is a study by Bachmann and colleagues who set out to enumerate
the number of specific ASCs after immunization with the vesicular stomatitis virus (VSV).
VSV is thus an example of a pathogen for which a single epitope is immunodominant.
Bachmann and colleagues show that after a certain time a relatively small part of the
ASC repertoire is enough to uphold protective antibody titers against VSV: during the
acute phase (day 8) of the immune response, more than 50% of all IgG2a-producing ASCs
were specific for VSV. In a later phase (days 21 or 50), 10 to 20 times fewer VSV-specific
ASCs were present, corresponding to a frequency of approximately 1:104 spleen cells
[135]. During the memory phase of the anti-VSV response usually 104 ASCs/mouse are
engaged to maintain a high level of memory IgG against the neutralizing determinant on
VSV suggesting a neutralizing anti-viral protective memory-ASC repertoire of 102 to 104
different VSV-affinities [135].
1.6.3 Antibody repertoire analyses
The recent BCR repertoire sequencing approaches (Section 1.5.3) only draw a fragmentary
picture of the shape of the AR. In fact, it is unknown how the structure of the BCR
repertoire [93, 97, 98] compares to that of the AR. The exclusive sequencing of ASCs,
which would give a better picture of the AR, is rendered difficult due to their widespread
localization throughout the body (Section 1.6.2). A deeper understanding of the AR is of
considerable importance as it represents the very foundation of serodiagnostic approaches
(Section 1.8) and many B-cell epitope approaches (Section 1.7.3). Brissac and colleagues
estimated the number of different IgM specificities present at any one time in murine
blood to be of the order to 104 [103].
1.7 Studying antibody-peptide binding
1.7.1 Structural and thermodynamic affinity mapping of antibody-antigen
interfaces
The most accurate experimental method for the determination of the structure of antigen-
antibody complexes is X-ray crystallography [136]. Since the first X-ray crystallographic
structure determinations, sequences of immunoglobulin light and heavy chain variable
regions have accumulated at an ever increasing rate. Nevertheless, protein crystallography
is limited by two main factors: the time required to collect, process, and refine an X-ray
data set and the intractability of certain proteins to crystallographic analysis. Currently,
the only experimental alternative to X-ray techniques is nuclear magnetic resonance
(NMR) which has its own particular shortcomings [137].
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Functional analyses of antibody-antigen interaction complement structural analyses in
that they describe antibody-antigen interaction by the kinetic rate constants, equilibrium
constants (Section 1.4.3), and thermodynamic binding parameters of the complex (Equa-
tions 1.4 and 1.5) [26, 138]. The change in enthalpy ∆H and entropy ∆S in combination
allow for the calculation of the change in free enthalpy (or Gibbs energy) ∆G, which in
turn allows for the determination of the equilibrium association constant Ka.
∆G = ∆H − T∆S (1.4)
∆G = −RT log (Ka) (1.5)
The binding enthalpy primarily reflects the strength of the interactions of the ligand
with the target protein (e.g. van der Waals, hydrogen bonds, etc.) relative to those
existing with the solvent. The entropy change, on the other hand, mainly reflects two
contributions: changes in solvation entropy and changes in conformational entropy. Upon
binding, desolvation occurs, water is released and a gain in solvent entropy is observed.
This gain is particularly notable for hydrophobic groups [139]. Because the enthalpic
and entropic components are related to structural parameters, they can be used (i) as a
guide to molecular (drug) design, (ii) as a way to validate structure-based computational
predictions of binding energetics (iii) to develop rigorous structure-energy correlations
[139]. Calorimetric instrumentation that can be used to directly determine binding
enthalpies has become increasingly available over the last two decades [43, 140, 141].
Isothermic titration calorimetry (ITC) is a quantitative technique that can directly
measure the binding affinity (Ka), enthalpy changes (∆H), and binding stoichiometry
(n) of the interaction between two or more molecules in solution. From these initial
measurements the Gibbs energy (∆G) and entropy changes (∆S) can be determined
using Equations 1.4 and 1.5 [142]. ITC does not rely on the presence of chromophores or
fluorophores (label-free) nor does it require an enzymatic assay [143].
1.7.2 Modeling antibody-peptide binding
Presently, mathematical modeling approaches complement experimental methods of
antibody-antigen characterization in at least two interdependent regards: (i) mathematical
modeling functions as a generator of hypotheses for experimental studies. (ii) Modeling
approaches aim to generalize experimental findings, since a complete characterization of
a given antibody-ligand pair would be both money and time consuming.
String modeling
To mathematically simulate binding of antibodies to antigen, bit strings are often used to
represent antibodies as well as antigens [68, 144–147]. Antibody and antigen sequences
are only composed of two “amino acids”, 0 and 1. The patterns of the bits represent the
shapes of molecules and determine their ability to bind with other molecules [144]. In
the bit string universe conceived by Farmer and colleagues, molecular binding takes place
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when the antibody bit string and the antigen bit string “match” each other. A match
occurs when the antigen and antibody have complementary binary patterns [145].
Bit string models are often not only used to study antibody-antigen binding per
se. Instead they serve as a means to address broader questions concerning evolution,
adaptation and pattern recognition of immune systems [147]. Lancet and colleagues used
bit strings to predict sizes of various receptor repertoires [146].
Bit string approaches were also explored in vitro: Fellouse and colleagues [148] obtained
functional antibodies from a library of antigen-binding sites generated by a binary code
restricted to tyrosine and serine. An antibody raised against human vascular endothelial
growth factor recognized the antigen with high affinity and high specificity in cell-based
assays.
Molecular modeling
There have been many attempts to design models of antibody combining sites to overcome
the experimental limitations (Section 1.7.1). The availability of accurate and reliable
modeling frameworks would allow the prediction of the effects of site-directed mutagenesis
experiments and enable the intelligent application thereof as well as larger modifications
to the combining site (CDR replacement, introduction of catalytic activity, and metal
binding sites) and, eventually, tailoring of combining sites to new antigens by means of
antibody-antigen docking simulations [137, 149]. Moreover, antibody structures can be
used to guide rational efforts to enhance stability [150, 151] or to humanize sequences to
minimize immunological response [152, 153].
The Protein Data Bank (PDB) [154] currently contains the structures of around 1000
immunoglobulins and enables the creation of good models for the majority of antibody
structures via homology modeling [155–157]. However, due to the high variability of the
CDRs, these regions are predicted far less accurately [155]. This is unfortunate, since
they are the principal contributors to antibody-antigen binding along with the relative
orientation of the antibody light and heavy chains [158]. The accurate prediction of the
conformations of CDRs is vital for the understanding of antibody-antigen complexes
and has increased in importance with the rise of therapeutic antibodies in healthcare
[159, 160]. Despite the high sequence diversity of CDR regions, five of the six CDRs
(L1, L2, L3, H1 and H2) are thought to have a set of limited structural conformations
(canonical structures) [161]. Reasonably accurate predictions can be made for these five
non-CDR-H3 regions using a set of sequence based canonical rules [162, 163]. More
recently, the canonical structures have been updated and it was shown that non-CDR-H3
regions are largely predictable (≈ 85%) using sequence, gene source and framework
regions [164, 165].
Recently, online web servers for high-resolution molecular homology modeling, based
on antibody sequence data, such as Web Antibody Modeling [166], Prediction of Im-
munoglobulin Structure [167], as well as Rosetta Antibody became available: not only
are these web-based solutions directed at yielding highly accurate predictions of antibody
binding sites, but also to rendering in silico antibody-antigen docking experiments15
15Docking is a computational technique that samples conformations of small molecules in protein binding
14
1.7 Studying antibody-peptide binding
possible [155].
Quantitative structure modeling
Quantitative structure-activity relationship (QSAR) models are regression models used in
the chemical and biological sciences and engineering. QSAR models relate measurements
of a set of “predictor” variables to the behavior of the “response” variable. The predictor
variables consist of the properties of chemicals whereas the response variables represent
the chemicals’ activity. The analysis of QSARs is performed to model ligand-binding site
interactions, thus being of use in the analysis of molecular recognition [12].
Proteochemometrics is derived from chemometrics16 and is related to QSAR. In
proteochemometrics, simultaneous modifications of all interacting molecules are applied,
whereas in QSAR only the interacting ligand is modified. In proteochemometrics,
descriptions of both proteins and the interacting ligands are correlated to experimentally
measured interaction data by applying multivariate data analysis [73]. Mandrika and
colleagues used a proteochemometric approach to analyze the amino acids and amino acid
physico-chemical properties that are involved in antibody recognition of peptide antigens.
To this end, they used a study system comprising a diverse single chain antibody library
derived from the murine monoclonal antibody anti-p24 (HIV-1) CB4-1. The library was
manufactured by SPOT synthesis [40]. The binding pattern obtained was correlated to
physico-chemical descriptors (z-scales) of antibody and peptide amino acids using partial
least-squares projections to latent structures (Section 3.7). The authors claim that with
this approach, the physico-chemical properties of each interacting amino acid residue of
both the peptides and the antibodies being essential for the antigen-antibody recognition
could be retrieved from the model [73].
1.7.3 Predicting antibody-peptide binding
The ability to predict B-cell epitopes for a given protein is a precursor to new vaccine
design and diagnostics [30]17 (Section 1.7.1).
Epitope prediction is often done by immunizing the host with the antigen in question
followed by profiling the resulting serum-antibody response [172–175] with a wide array
of methods some of which are shortly outlined in this section.
Although it is believed that the majority of B-cell epitopes are discontinuous epitopes
[34] (Section 1.4.1), the experimental determination of epitopes has focused primarily on
sites. It uses scoring functions to assess which of these conformations best complement the protein
binding site [168]. Warren and colleagues conclude in their survey of docking programs that “all
of the docking programs were able to generate ligand conformations similar to crystallographically
determined protein/ligand complex structures for at least one of the targets”. However, “no single
program performed well for all of the targets. For prediction of compound affinity, none of the docking
programs or scoring functions made a useful prediction of ligand binding affinity” [168].
16Chemometrics is the science of extracting information from chemical systems by data-driven means
[169].
17Recently, the development of peptide-based vaccines, relying on advances in the prediction of linear
epitopes, has been suggested to be severely limited by a narrow reductionist view of vaccine design,
ignoring that the majority of epitopes is discontinuous [30, 34, 170–172].
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the identification of continuous B-cell epitopes [176, 177].
Apart from X-ray crystallography, which represents a structural approach to epitope
mapping [33, 45, 178, 179] (Section 1.7.1), one important experimental technique to map
epitopes is the use of phage-display libraries [180]. By selecting phages from a library for
their ability to bind antibodies specific for a known antigen, linear peptide sequences
that cross-react with these antibodies, commonly referred to as mimotopes [181], can be
discovered [182].
Another approach to epitope mapping of continuous epitopes is the screening libraries
of short synthetic peptides that span the entire target antigen [173, 183–186]. Overlapping
peptides for mapping sequential epitopes cannot only be synthesized on pins, but also
on a cellulose membrane support [187] and microarrays [188–190] (Section 1.8.1). Other
technologies for B-cell epitope mapping include fragmentation methods, competition
methods and antigen modification methods (site-directed mutagenesis) [178].
In addition to molecular modeling (Section 1.7.2) and experimental epitope mapping
approaches, several computational methods for prediction of continuous B-cell epitopes
have been published in recent years.
Propensity scale methods assign a propensity value (scores) to each amino acid which
measures the tendency of an amino acid to be part of a B-cell epitope (as compared
to the background)—an approach similar to the used z-scales in proteochemometric
modeling [191] (Section 1.7.2). These methods rely on the observed correlations between
specific physico-chemical properties of amino acids and the antigenic determinants in
protein sequences to identify the location of the linear B-cell epitopes in the query protein
sequence. The propensity scores are used as a basis for predicting whether a given amino
acid sequence residue is likely to be part of a linear B-cell epitope. The first propensity
scale method for predicting linear B-cell epitopes was introduced by Hopp and Woods
[192] and utilized the Levitt hydrophilicity scale [193]. The Levitt scale is based on
the assumption that antigenic determinants of protein sequences correspond typically
to sequence windows that contain a large number of charged and polar residues and
lack large hydrophilic residues18. Subsequently, several other propensity scales based
on hydrophilicity [194], flexibility [195], turns [196] and accessibility [197] have been
proposed for predicting linear B-cell epitopes. Approaches combining different scales
were also published [198–200].
Recently, Blythe and Flower [172] have performed an assessment of 484 amino acid
propensity scales to examine the correlation between propensity scale-based profiles and
the location of linear B-cell epitopes in a data set of 50 proteins. Their study found that
even the best combinations of amino acid propensities yielded B-cell epitope predictions
that were only marginally better than random [177].
Due to the poor results yielded by propensity scales alone, several authors have
explored methods for improving the predictive performance of propensity scale methods
by combining them with machine learning methods such as Hidden Markov models or
support vector machines [201, 202]. However, the combination of scales with several
18A study published by Lollier and colleagues [174] suggests that hydrophilicity of amino acid residues
may not play a primary role per se in epitope definition.
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machine learning algorithms showed little improvement over single scale-based methods
[30, 182].
The increasing number of experimentally characterized linear amino acid sequences
of B-cell epitopes [203] led several authors to explore approaches using exclusively
machine learning based methods for predicting linear B-cell epitopes [204–206]. All these
approaches showed prediction accuracies between 70% and 80%. However, benchmark
studies show that the predictive performance of machine learning methods is also rather
poor [30].
Prediction of conformational epitopes has gained traction over the recent years due to
an increasing amount of sequence and structure data which is being stored in various
databases making it possible to use machine learning approaches for prediction. A
detailed overview over recent developments is given in a review from EL-Manzalawy and
Honavar [177].
In conclusion, even though publications involving epitope prediction approaches are mul-
tiplying owing to steadily increasing computational power and databases, the predictive
performance of current methods is far from ideal [172, 182]. Furthermore, immunogenicity
of proteins is poorly understood [207], and it remains an open question whether B-cell
epitopes could after all be deciphered as intrinsic features of proteins [30, 177].
1.8 Serological diagnostics with antibody profiling
The discovery of humoral antitoxic antibodies in the early 1890s exerted a profound
influence upon the future development of both immunologic practice and thought [208].
The demonstration of the presence of specific agents in the serum of immunized animals
opened the way for the development of such serologic tests as agglutination, the precipitin
reaction, and complement fixation [208]. More recently, techniques such as ELISA joined
the ranks of serological methods serving to diagnose diseases such as HIV and Hepatitis
C [208]. Specific antibody-antigen recognition is therefore the basis for the widespread
use of antibodies for molecular identification in research and in the clinic [38, 208].
As the AR (Section 1.2) is subject to constant change—both with respect to respective
antibody concentrations and overall antibody composition [135]—due to continuous
antigen encounter and the establishment of immunological memory [3], its investigation
provides the possibility to gather information about both past and on-going immune
responses, and ultimately about the immune state of the body [209]. Antibodies are
rather easily detectable and amplify the immune response [210].
Due to the AR’s high diversity, high-throughput immunoblot [211, 212], SEREX [213],
phage display [180, 214–216] and microarray technologies using as probe molecules among
others glycans [217, 218], aptamers [219–221], peptides (Figure 1.2) and proteins (Section
1.8.1) have been used for large-scale profiling of serum antibody binding.
Such antibody profiling data were used for disease classification by exploiting dif-
ferences of antibody-peptide binding patterns (Table 1.1) as well as for characterizing
antibody binding patterns in general [222]. Ultimately all these approaches harness the
antibodyome’s [223] specificity potential to diagnose diseases in a minimally invasive way
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based on the premise that the AR reflects an individual’s health status [210].
Thus, the underlying data-analytic assumption of serodiagnostic approaches is that
disease-induced antibodies dominate antibody-ligand binding (ligand: glycans, aptamers,
proteins, peptides etc.) in a consistent fashion across infected individuals: only consistent
antibody binding patterns allow the discrimination of healthy and diseased individuals.
1.8.1 Antibody profiling with peptide microarrays
The use of high-throughput-screening methods made it obvious that antibody binding
patterns, that is, signal intensities (Section 1.8.1) of multiple peptides, are rather the more
important observation of antibody profiling studies and not necessarily single signals.
Patterns show a higher discriminatory power regarding the separation of healthy and
diseased groups [188, 224]. In this regard, especially random-sequence peptide array
approaches have emerged as a tool of choice for antibody profiling. In the following, I
will present the production and functioning of peptide19 microarrays, one of the major
platforms for antibody profiling [223].
Production of peptide microarrays
A microarray is a gridded presentation of molecules across a planar surface. Each molecule
occupies a pre-defined position on the grid, denoted as a spot, which encodes its identity
[225]. Microarray surface types include chemically derivatized planar glass or silicon
chips, flow cytometric microbead assays, arrays in plastic microwells, nitrocellulose on
chips and three-dimensional gels [226].
The production of peptide microarrays involves the covalent linkage of peptides to
the microarray surface. To enable this linkage, slides are chemically treated [227] with
compounds such as aldehyde-containing silane reagents. The aldehydes react readily
with primary amines on the proteins to form a Schiff’s base linkage [228]. To fabricate
peptide microarrays, printing robots deliver nanoliter volumes of peptide samples to the
slides. Printing approaches include contact- as well as non-contact printing [228, 229].
The disadvantages of glass or silicon chips lie in the batch-to-batch variability associated
with attachment chemistry [226].
Signal detection of antibody-peptide binding
For detecting antibody-peptide binding, label-free approaches such as SPR (Section
1.4.3) and labeled-probe approaches exist. The latter include labeling by a chromogen, a
fluorophore or a radioactive isotope. Fluorescence detection can be by direct labeling of
monoclonal antibodies which then bind to the spotted peptides or by indirect approaches
via secondary antibody detection, where an isotype-specific antibody is fluorescently
labeled [230] to bind to, for instance, serum antibodies (Figure 1.2). The resulting
fluorescence signal intensity is measured with a scanning device (e.g. laser scanner, Figure
1.2). The fluorescence is proportional to the amount of bound antigen [231, 232].
19For improved readability, I will use the term peptide for both proteins and peptides.
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Figure 1.2: Overview over the workflow of antibody profiling with random-sequence peptide
arrays. (A) Incubation of a random-sequence peptide array with primary antibody (monoclonal
or serum antibodies), of which the binding is detected with a fluorescently-labeled secondary
antibody. (B) The incubated peptide array is scanned yielding an image in which the spot
intensities (here in red) are proportional to antibody binding to the peptide spots. (C) The signal
intensity read-out (also termed “antibody binding profile” or “signal intensity profile”) yields a
signal intensity distribution (here log-transformed), which is used for downstream analyses such
as serological diagnostics (Section 1.8) or B-cell epitope mapping (Section 1.7.3). The presented
workflow is adopted by the majority of antibody profiling studies (Table 1.1).
State of the art of antibody profiling with peptide microarrays
Antibody profiling studies with peptide microarray differ widely with respect to method-
ology and objectives. Among those shown in Table 1.1, two types of approaches can be
discerned.
Type 1 Peptide microarray approaches which, presuming humoral specificity, interpret
measured signal intensities in absolute terms: in addition to binding patterns,
much attention is given to absolute measured peptide signal intensities, which are
interpreted as a reflection of the peptides’ function (eliciting antigen) in the studied
disease. These approaches, therefore, mostly use disease-dedicated peptide libraries
to find potential disease-antigens20. Articles of the survey (Table 1.1) belonging to
this category are Hueber et al. [234], Robinson et al. [235] and [236], Gaseitsiwe et
al. [237] and Merbl et al. [224].
Type 2 Peptide microarray approaches which, presuming humoral specificity, interpret
measured signal intensities in relative terms: peptide signal intensities are ana-
lyzed as consequences of antibody polyspecificity [63] (Section 1.4). The relative
differences in binding patterns between the healthy and the diseased case represent
the main finding. The fact that polyspecificity of antibodies renders the nature
of the eliciting antigen(s) unimportant makes random-sequence peptide arrays,
which are primarily used in this type of approach, a relatively cheap, unbiased,
non-pathogen-restricted, and user-friendly tool for serological diagnostics [189, 238].
Articles of the survey (Table 1.1) belonging to this category are Legutki et al. [189],
Reddy et al. [239] and Bongartz et al. [188].
20This assumption is problematic due to antibody polyspecificity (Section 1.4.4). See also Kroening and
colleagues for further evidence against this hypothesis [233].
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Table 1.1: Literature survey of studies using antibody profiling for serological diagnostics. Legend of abbreviations, which are not listed in the List
of Abbreviations. AAA: autoantigen microarray, AA: autoantigen, AD: Alzheimer disease, BCResp, B-cell response, EAE: Experimental autoimmune
encephalomyelitis, FC: Fold change, FL: Fluorescence, FP: False positive, H: Human, HB: Heligmosomoides bakeri, HC: Healthy control, IR: Immune
response, LDA: Linear discriminant analysis, M: Mouse, NA: not available, NRP: non-random peptides, P: proteins, PA: peptide array, RM: regression
model, R: Rat, RA: Rheumatoid arthritis, RPA: random peptide array, SAM/PAM: Significance (Prediction) analysis of microarrays, SI profile:
signal intensity profile, SP: Spots, SVM: Support vector machine, TB: Tuberculosis.
Study Array platform Sample processing Data processing
Ref. Objective Results Number of pep-
tides
Ig-
Isotype-
detection
Sample type Sample
dilu-
tion
Signal defini-
tion
Normal-
ization
Bioinformat-
ical methods
used
[234] Ident. of dis-
tinct serum SI
profiles in pa-
tients with RA.
Classification
of different RA
patient groups
with AA is
possible.
225 NRP
and Pr from
the synovial
proteome.
IgM,
IgG
H (27 RA pa-
tients, 11 HC).
1:150 Median of the
FL of the repli-
cated SP.
Scaling to a
positive con-
trol (IgM).
SAM and
PAM.
[235] Measurement
of serum SI
profiles with
structurally
diverse AA.
Description of
AAA technol-
ogy.
196 distinct pu-
tative AA on
1152-feature ar-
rays.
IgM/IgG H (50 sam-
ples of SLE
patients).
1:150 Median of the
background-
subtracted FL
of replicated
SP.
Scaling to a
positive con-
trol (IgG).
Simple SI
analysis.
[236] Measurement
of EAE-
autoAb re-
sponses.
AAA-identified
EAE targets
functioned
to treating
established
EAE. Reduc-
tion of epitope
spreading of
autoreative
BCResp.
2304-feature
myelin pro-
teome arrays
containing
≤ 232 distinct
antigens.
IgM,
IgG
M/R (Number:
NA).
1:150 Median of the
background-
subtracted FL
of replicated
SP.
Scaling to a
positive con-
trol (IgG).
SAM.
[189] Profiling of the
IR with RPA.
Sets of peptides
discriminated
healthy and
influenza-
infected M
groups as well
as H individu-
als.
10000 20-mers IgM,
IgG1,
IgG2a,
IgG3
M (Serum
samples, num-
ber: NA), (H,
Serum samples,
number: NA).
1:500 Average of trip-
licates of me-
dian SI per SP.
Each array
was normal-
ized to the
50th per-
centile. SIs
of less than
0.01 were set
to 0.01.
PCA.
Continued on next page
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Table 1.1 – Continued from previous page
Ref. Objective Results Number of pep-
tides
Ig-
Isotype-
detection
Sample type Sample
dilu-
tion
Signal defini-
tion
Normal-
ization
Bioinformat-
ical methods
used
[239] Measurement
of HC and
case serum
SI profiles
with unnatural
molecules.
Identification
of two can-
didate IgG
biomarkers for
AD.
Two copies of
4608 octameric
(AA are non-
naturally
occuring) pep-
toids and
control SP.
IgG H (Serum
samples (22
HC, 22AD), M,
Serum samples:
HC: NA, EAE-
induced (via
MOG injec-
tion) C57BL/6
M: 30
15
µg/ml
Local back-
ground sub-
tracted median
SP SI (40000 >
SI > 10000)
were used
for further
analysis.
None FC analysis.
[188] Discrimination
of RPA serum
SI profiles with
few peptides.
Classification
of different M
strains and
HB-infection
with high accu-
racy and small
peptide sets.
249 differ-
ent random-
sequence
14-mers.
IgM M, Serum sam-
ples: 15 HC
(C57BL/6),
28 (HC, case,
BALB/c).
1:10 Elimination of
FP SIs.
None PCA, LDA,
P-SVM.
[237] Serum Ab-
based target
identification
of TB anti-
gens using
high-content
PA.
Successful
classification
of HC and TB
patients.
7776 peptide
SP.
IgG,
IgA
H (Serum sam-
ples: 35 HC, 34
TB).
1:100 Elimination of
FP SIs.
Use of linear
RM to re-
move effects
of slide, sub-
array, block
and FP.
SAM, PAM.
[224] Measurement
of serum SI
profiles of
healthy and
metastatic in-
bred C57BL/6
M.
Classification
of healthy and
cancerous M.
327 AA. IgM,
IgG
M (Serum
samples: HCs
and 2 groups of
20 M injected
with different
lung cancer
lines).
1:500 Mean log inten-
sity measures
of at least 4
replicate SP.
Division of
each array by
its median
SI.
Wilcoxon
Rank-sum
test, SVM.
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1 Introduction
Standardization of experimental and bioinformatical approaches to antibody
profiling with peptide microarrays
As observed in the literature survey (Table 1.1), both experimental handling (dilution
of sera, microarray platform, chosen peptides, etc.) and the data preprocessing is
rather non-standardized across studies, which is in contrast to cDNA microarray studies
[240–244].
The more recent emergence of peptide arrays as an experimental method for antibody
profiling as well as the different nature of data that represent antibody-peptide binding
profiles may be the cause for experimental and bioinformatical heterogeneity across
studies.
Bioinformatic methods from gene array analysis cannot be readily transferred to the
analysis of antibody-peptide binding, because in nucleic acid microarray technologies,
binding is essentially only between two types of molecules of complementary sequence.
With peptide microarrays used for antibody profiling, signal intensity profiles are contin-
uously distributed and binding is not restricted to a single complementary molecule21.
Due to antibody polyspecificity (Section 1.4.4), multiple antibodies can bind to the same
peptide on the array and a single antibody may also bind to multiple peptides on the
array: an issue almost non-existent in gene expression arrays [238, 245, 246].
As suggested by the non-exhaustive survey of peptide array studies (Table 1.1),
approaches to antibody profiling are largely phenomenological. However, standardization
of experimental and bioinformatical protocols can only be done faithfully if the genesis
of antibody binding profiles is understood [238]. Publications focusing on the theoretical
study of antibody profiles are, as far as I know, almost non-existent [245]. Consequently,
publications [247–251] focusing on the standardization of peptide array approaches are
of uncertain theoretical foundation.
Therefore, this thesis sets out to study antibody-peptide binding with a
mathematical model. The advantage of this theoretical approach is that the
effect on antibody binding profiles of experimentally mostly inaccessible pa-
rameters such as antibody composition and diversity can be readily studied.
1.8.2 Characterization of the murine parasite Heligmosomoides bakeri
In the following, I will characterize the murine parasite Heligmosomoides bakeri (HB),
since antibody-peptide reactivity data involving samples of mice attained by an HB-
infection are presented in the Results section (Chapters 5–8).
HB typically causes long-lasting infections in mice and in this respect has been a
laboratory model of chronic intestinal nematode infections [252–254]. HB is a natural
enteric nematode parasite of murine rodents that enters the gastrointestinal tract at larval
stage L3 then penetrates the epithelial cell barrier of the small intestine to mature within
the submucosa to an L4 stage. Approximately 8–10 days after infection, the parasite
21It has recently been shown that antibody-binding to random-sequence peptide arrays is largely driven
by the variable region of the antibody: competition with 10-fold excess Fc protein showed no effect on
the measured antibody binding profiles [210].
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exits the intestinal mucosa to populate the intestinal lumen and establishes a chronic
infection as a sexually mature adult producing viable eggs that are secreted through the
feces [254–256].
While target antigens for some helminth infects are known [257]—immunogenic antigens
of HB are largely unknown—in particular it is not known whether the antigens that
induce protective antibodies are derived from the same or different stages of the HB life
cycle [258].
Works by Wojciechowski [258], McCoy [256] and colleagues showed that both polyclonal
and affinity-matured IgG antibodies play an essential role in protective immunity to HB
expulsion (IgM, IgE, and IgA do not play a significant role in resistance). Polyclonal IgG
antibodies, present in naïve mice and produced following HB-infection, functioned to
limit egg production by adult parasites. Comparatively, affinity-matured parasite-specific
IgG antibodies that developed only after multiple infections were required to prevent
adult worm development.
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2 Objectives
Antibody profiling with random-sequence peptide arrays holds great promises for serolog-
ical diagnostics [188, 189, 245] as it represents a versatile method for the discrimination
of either healthy from diseased individuals or individuals at different disease stages.
Serological diagnostics based on antibody profiling rest primarily on the assumption that
antibody profiles of diseased and healthy individuals differ consistently from one another.
The challenge for antibody profiling is therefore twofold: reflecting the change in the
antibody mixture induced by the disease while taking into account the variability of
antibody profiles of healthy individuals. To my knowledge, the antibody repertoire’s
impact on antibody binding profiles has not been extensively investigated. Since the
characterizing components of antibody repertoires, such as composition and concentration,
are difficult to study in vitro, an aim of this thesis is to provide a mathematical model
for antibody-peptide binding.
The study of both the genesis and specificity of antibody binding profiles
with a mathematical model and the subsequent validation of the model’s
predictions by in vitro antibody-peptide reactivity data is the major objective
of this thesis.
This work has the following specific aims:
Description of a mathematical model for antibody-peptide binding. This model
is based on the law of mass action incorporating as parameters (i) antibody and peptide
sequences and (ii) antibody concentrations.
Mathematical analysis of the proposed model and implementation of a frame-
work for simulating antibody-peptide reactivity data. The mathematical analysis
will center on studying the impact of both antibody composition and diversity on signal
intensity. Furthermore, the simulation framework allows for the study of the impact of
parameters such as peptide length and peptide library size, which are somewhat elusive
to analytical analysis. It also provides the opportunity to investigate external parameters
such as noise.
Test of the predictions generated by both the mathematical model and the
simulation framework with in vitro antibody-peptide reactivity data. In order
to quantify the generality of the predictions, the studied data sets include various peptide
libraries, both human and murine serum samples and monoclonal antibodies.
Discussion of the results obtained with the mathematical model, the simula-
tion framework and the in vitro data in light of their significance for serological
diagnostics and B-cell epitope mapping.

3 Methods
This Methods chapter is divided into two parts. The first part constitutes the description
of the experimental methods (Sections 3.1–3.5) none of which were performed by me.
Their knowledge is nevertheless important for the understanding of this work’s results.
For a more extensive description of experimental methods, please refer to Lück (PhD
thesis, [259]). The second part describes the computational methods used in this thesis
(Sections 3.6–3.9).
3.1 Peptide microarrays used for incubation with serum or
plasma samples
In this work, different peptide microarrays with varying peptide libraries, produced by
both contact and non-contact printing technique have been used for the analysis of
antibody-peptide binding. Detailed information on peptide libraries and their amino acid
composition is provided in the Tables 3.1 and 3.2.
(i) Each peptide spot on a given microarray is assumed to have an equal density of
functional groups. (ii) The amino acid sequence of all analyzed peptides is known.
3.1.1 JPT microarrays
Non-contact printed random-sequence peptide microarrays
Non-contact printed peptide microarray slided obtained from JPT Peptide Technologies
GmbH (Berlin, Germany) covered five identical sub-arrays each including 255 random-
sequence1 14-mers and 45 EAE (experimental autoimmune encephalomyelitis) antigen
peptides (Figure 3.1). In this work, only the antibody binding to the 255 random peptides
was analyzed. Their sequence was designed with a random generator, which did not
allow three or more consecutive repeats of an amino acid. This library will hereafter be
referred to as J25514-mer.
Each sub-array comprises TAMRA-derived peptides as internal fluorescence control,
and mouse-IgM, mouse-IgG, human-IgM, human-IgG, human IgE as secondary antibody
controls.
Contact printed random-sequence peptide microarrays
JPT contact-printed microarrays were made of three identical sub-arrays in two different
formats. Format 1 constitutes sub-arrays of 7056 spots, which include the analyzed
1Henceforth, “random” will stand for “random-sequence”.
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15-mer random peptide library of 3352 peptides and a non-analyzed non-random 15-mer
sub-library (STY-library) containing S, T or Y as the 8th amino acid of each peptide. In
addition, human IgM, IgG, IgA and IgE (according to the batch also mouse IgM and
IgG) as secondary antibody controls and empty spots were found on arrays of format 1.
Analyzed peptide libraries originating from this fabrication will be called J335215-mer.
Format 2 includes sub-arrays on which 13-mers and 15-mers are displayed. These
arrays counted 9600 spots comprising the analyzed 15-mer random peptide library of
either 3418 (J341815-mer) or 3626 (J362615-mer) peptides2, an analyzed 13-mer 3 library J230413-mer, a
non-analyzed STY-library containing S, T or Y as the 8th amino acid of a peptide. In
addition, human IgM and IgG as secondary antibody controls4 and empty spots were
found on arrays of format 2. Cysteine was not constitutive of any of the peptides in
either of the two formats (Table 3.2).
Peptides, produced by spot synthesis5 [40], are linked to the arrays in an N-terminal
fashion. The spot diameter is about 100 µm with an approximate density of functional
groups of 15 fmol/mm2.
3.1.2 Pepscan microarrays
Peptide microarrays obtained from Pepscan (Zuidersluisweg, 28243 RC Lelystad, The
Netherlands) are made of three identical sub-arrays each of which shows a total of 1024
spots. Spots include the analyzed library of random 15-mers and shorter peptides, empty
spots and human IgM and IgG secondary antibody controls. Cysteine is not constitutive
of any of the peptides (Table 3.2). The first four lines of spots of each sub-array were
removed prior to the analysis of antibody-peptide reactivity leading to an analyzed
number of 942 15-mers (P 94215-mer).
According to the data sheet provided by Pepscan, peptide microarrays were spotted onto
microarrays with a proprietary surface chemistry, based on a co-polymer of acrylic acid
and polyethylene glycol moieties. This surface features a thin (50–100 nm) hydrophilic
environment. The peptides were generated by solid-phase synthesis and covalently coupled
with a low-charge coupling chemistry.
The microarrays were spotted using a split-pin microarray spotter in a controlled
environment. The spot distance (center-to-center) is 560 µm with an approximate density
of functional groups 50 fmol/µm2.
3.2 Incubation of peptide microarrays
Peptide arrays were either manually incubated (Section 3.2.1) or in an automated fashion
(Section 3.2.2).
2The differing number of analyzed random 15-mers is due to different batches (Table 3.1).
3The 13-mer sequences are not random since the 7th position is as a rule S, T or Y.
4The secondary antibody controls may or may not be present depending on the batch.
5For both JPT (contact and non-contact printed) and Pepscan arrays, details related to array manufac-
turing are scarce.
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Batch number Analyzed random peptide library Experimental study
879, 901 J25514-mer Mouse study (MS)
840 J25514-mer Monoclonal antibodies
1189 J230413-mer, J341815-mer Glioma 08 study
1233 J335215-mer Glioma 09 study
1190 J230413-mer, J341815-mer Slovenian healthy study (SHS)
1133 J230413-mer, J341815-mer NephroFIT study
1027 J230413-mer, J362615-mer NOD study (NS)
0151 P 94215-mer NephroFIT-Pepscan study
0153 P 94215-mer NephrOT study
Table 3.1: Analyzed random peptide libraries are shown with both the associated microarray
batch number and experimental study. As to the Mouse study (Section 3.1.2), the repeats used to
characterize technological variability were incubated on batch 901, whereas incubations analyzing
biological variability were performed on batch 879 (Section 3.5.8). Batch production is a technique
used in manufacturing, in which the object in question is created stage by stage over a series of
workstations (http://en.wikipedia.org/wiki/Batch_production).
After either type of incubation, antibody-peptide binding signals were recorded with
a microarray scanner (GenePix 4000B or GenePix 4200AL, Molecular Devices GmbH,
Ismaning, Germany) at 532 or 635 nm (10 µm resolution, 5% laser power, 400 photomul-
tiplier excitation) unless mentioned otherwise. Microarray images were stored in a 16-bit
TIFF-format.
3.2.1 Manual incubation
The microarrays were briefly immersed in 100% v/v ethanol, washed three times with
T-PBS (phosphate buffered saline containing 0.05% w/v Tween20), three times with
deionized water and dried by centrifugation. Since the microarray surfaces had been
pre-treated to minimize unspecific binding of the target antibodies, no blocking step was
required prior to incubation. All incubations were performed using a five-well adhesive
incubation chamber (Multiwell GeneFrameTM, ABgene Germany, Hamburg, Germany)
with a total assay volume of 45 µl per well. Serum was diluted 1:10 in T-PBS. After
incubation for 4 h at room temperature, the microarrays were washed three times with
T-PBS and three times with deionized water. Secondary antibodies were diluted in
T-PBS (20 µg/ml, 300 µl) and incubated for 1 h at room temperature. The microarrays
were washed three times with T-PBS, three times with deionized water, rinsed with
running deionized water and dried by centrifugation. Water, ethanol and PBS were
filtered.
3.2.2 Automated incubation
Automated incubations were performed using the Tecan HS 4800 hybridization station
(Tecan, Mannedorf, Switzerland). Microarrays were washed with T-PBS (washing buffer)
29
3 Methods
Amino acids Frequencies of amino acids in analyzed peptide libraries [%]
J230413-mer J
255
14-mer P
942
15-mer J
3352
15-mer J
3418
15-mer J
3626
15-mer
A 5.0 5.4 5.3 5.2 5.1 5.1
C 0 1.5 0 0 0 0
D 4.6 7.1 5.3 5.3 5.3 5.3
E 4.8 6.0 5.6 5.3 5.3 5.2
F 4.8 4.4 5.3 5.4 5.3 5.2
G 5.3 5.2 5.4 5.3 5.3 5.2
H 4.9 4.0 5.1 5.2 5.2 5.3
I 5.0 3.8 5.2 5.4 5.4 5.5
K 5.1 7.3 5.2 5.4 5.4 5.2
L 5.0 5.2 5.2 5.3 5.2 5.6
M 5.0 2.4 5.3 5.4 5.4 5.2
N 4.8 5.6 5.2 5.3 5.2 5.1
P 5.0 5.1 5.3 5.2 5.2 5.1
Q 4.7 5.0 5.3 5.2 5.2 5.1
R 4.8 6.7 5.1 5.2 5.2 5.3
S 7.2 6.5 5.1 5.1 5.2 5.4
T 9.8 6.2 5.2 5.3 5.3 5.2
V 4.5 5.0 5.1 5.2 5.2 5.1
W 4.7 3.1 5.3 5.2 5.2 5.0
Y 4.8 4.6 5.5 5.2 5.3 5.9
Table 3.2: Frequencies of peptide amino acids by analyzed peptide library. Frequencies may
not add up to 100% due to rounding effects. J/P xy denotes the array manufacturer (JPT [J ],
Pepscan [P ]), the analyzed number of peptides x and their length y. Except for J25514-mer, cysteine
(C) is absent from all analyzed peptide libraries. For further information on the itemized peptide
libraries, please refer to Section 3.1.
and blocking buffer (PBS, 1% BSA) and blocked for 30 min at 30◦C. After three further
washing steps with T-PBS, samples were injected, followed by an array incubation for
2–3 h at 30◦C with constant agitation. Thereafter, microarrays were washed four times
with T-PBS followed by the injection of the secondary antibody, which was incubated
for 1 h at 30◦C (contant agitation). Finally, microarrays were washed three times with
T-PBS, twice with 0.01x SSC buffer and were rinsed with running deionized water for 3
min.
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3.3 Signal detection and determination of raw signal intensities
3.3.1 Signal detection
Signal intensities were quantified with either the GeneSpotter6 (MicroDiscovery GmbH,
Berlin, Germany) or GenePix Pro 6.0 (Molecular Devices GmbH, Ismaning, Germany)
software by taking the median pixel intensity of a circular region around the center of
each spot [259].
3.3.2 Determination of raw signal intensities
The median signal intensities of each sub-array were averaged to yield one signal intensity
value per peptide per array. This averaging procedure was not performed for the J25514-mer
library, since on every sub-array a different mouse serum was applied.
3.4 Preprocessing of in vitro antibody-peptide reactivity data
3.4.1 Preprocessing of antibody-peptide reactivity data prior to signal
intensity profile analysis
Fluorescence signal intensities were not normalized unless stated otherwise. If normalized,
signal intensities were transformed as detailed in Section 3.4.2.
3.4.2 Preprocessing of antibody-peptide reactivity data prior to AAWS
analysis
Measured raw signal intensities were log-transformed (log(I)). Subsequently, the signal
arising from the polyclonal secondary antibody was removed according to the linear
model:
log(I) = β0 + β1 log(ISecondaryAntibody) + ϵ. (3.1)
By partial least squares regression (PLSR)-based computation (Section 3.7) of the
intercepts, β0 and β1, log(I) was replaced with the resulting PLSR-computed, mean-
centered and scaled-to-unit variance residuals ϵ prior to determination of AAWS. The
signal of the secondary antibody (ISecondaryAntibody) was obtained by incubating an array
instead of serum/plasma with blocking buffer (PBS, 1% BSA, “blank”, Section 3.5).
3.5 Experimental studies
In the following, experimental methods are grouped by experimental study. The peptide
library type and batch number for a given experimental study can be found in Section
3.1 and Tables 3.1 and 3.2. Signal detection was performed, if not stated otherwise, as
described in Section 3.3.
6Only the antibody-peptide reactivity data of the mouse study was analyzed with GeneSpotter. All
other studies were performed with GenePix Pro 6.0.
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Technological variability of signal intensity profiles was assessed for each experimental
study with repeated measurements (repeats) of healthy control sera. The correlation
of repeats was found to be generally above rPearson = 0.85. However, technological
variability across studies is high: the Pearson correlation coefficients of blank7 signal
intensity profiles between studies was found to be mostly in the range of 0.20 < r < 0.40
(both for JPT and Pepscan, data not shown): the variability across batches is high [259].
The dependence of the secondary detection antibody on serum signal intensity profiles
was found to be low: the correlation between blank and serum signal intensity profiles
was generally in the range of 0.10 < rPearson < 0.30. In contrast, the impact of the
secondary-detection antibody on profiles of monoclonal antibodies was found to be large
(Figure S.4).
Plasma as well as serum samples were used to measure antibody binding profiles.
Reports indicate that “fresh serum, fresh plasma, frozen serum and frozen plasma from
the same volunteer showed almost no discernible differences” in antibody binding profiles
[210].
In each section, the person who performed the experiment is named8.
3.5.1 Slovenian healthy study (SHS)
The Slovenian healthy study (SHS) is a baseline study in which 16 healthy human
individuals have donated blood at three different time points. The results of this baseline
study (peptide array results excluded) were recently published [260].
Incubations, plasma IgM quantification and signal detection were performed by Bodo
Steckel.
Slovenian healthy study: Plasma samples
Peripheral blood samples were drawn from 16 healthy individuals after obtaining their
signed informed consents. The selected experimental group was age and gender equili-
brated. BMI was calculated for each individual enrolled. The inclusion criterion was
age (20–60 years). The exclusion criteria were the following: acute or chronic diseases,
pregnancy, smoking and taking oral contraception or other drugs. Every volunteer was
screened for the viral and bacterial infection markers of blood-transmittable diseases
(Syphilis, HIV, Hepatitis B/C). Blood samples from fasting morning participants were
collected between 7 am and 9 am, on three separate days within a period of one month
[260].
7blank: incubation of only PBS buffer with the secondary detection antibody.
8This Methods section is not exhaustive with respect to experimental materials and methods. Only the
necessary information needed to understand the experiments as well as to understand the Results
and Discussion section is presented in this section. In addition, as mentioned in Section 1.8.2 (page
22), except for the Mouse study (Section 3.5.8), only results (Chapters 4–8) regarding signal intensity
profiles of healthy individuals of each experimental study are reported to remain within this work’s
scope. For completeness reasons, however, sample numbers of non-healthy individuals are listed for
each experimental study.
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Slovenian healthy study: Quantification of plasma IgM
Serum IgM was quantified using the human IgM quantification sets (Bethyl Labs). EIA
(Enzyme Immunoassay) plates included standard, blank and positive control samples
(serum pool). Briefly, Corning 96-well EIA plates (Sigma Aldrich) were coated for 1 h
with anti-human IgM diluted 1:100 in coating buffer (carbonate-bicarbonate, pH=8) and
blocked for 30 min in blocking buffer (TBS, 1% BSA, pH 8). Samples were pre-diluted
1:600 (IgM) in sample diluent (TBS, 1% BSA, 0.05% Tween20, pH 8), serially two-fold
diluted across columns and incubated for 3 h. HRP (horseradish peroxidase)-coupled
anti-human IgM was diluted 1:5000 in sample diluent and incubated for 2 h. ABTS
substrate was incubated for 5 min, and absorbance was measured at 405 nm.
Slovenian healthy study: Serum antibody binding assays
Sera were 1:10 diluted in blocking buffer and incubated automatically on individual
microarrays as detailed in Section 3.2.2. Additionally, one microarray was, instead of
serum, incubated with blocking buffer (PBS, 1% BSA) (negative control, blank) and two
repeated incubations were performed to characterize technological variability. Serum IgM
antibody binding was detected with goat-anti-human IgM-Alexa Fluor 647 secondary
antibody (20 µg/ml).
3.5.2 Glioma 09 study
Incubations, serum IgM quantification and signal detection were performed by both
Juliane Lück and Bodo Steckel. All samples originate from the lab of Christian Schichor
(Ludwig-Maximilians-Universität, Munich, Germany). For the study’s background, please
refer to Lück (PhD thesis) [259].
Glioma 09: Serum samples
Serum samples from primary astrocytoma patients (Table 3.3) were collected prior to
any radiotherapy, multimodal treatment (excluding cortisone intake) and surgical tumor
resection. Patients were classified into low malignant histological tumor subtypes (LM :
WHO grade I and II) and high malignant histological tumor subtypes (HM : WHO
grade III and IV) were included (Table 3.3). The histological grade was confirmed by
histopathological analysis. Patients with tumor recurrence or progression, and patients
with non-Glioma benign lesions were excluded from the study. Blinded samples (diagnosis
not known to the Systems Immunology research group) were also included in this study.
Glioma 09: Quantification of serum IgM
Serum quantification was done as for the SHS (Section 3.5.1) with the exception that
sera were diluted 1:500.
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Experimentator Healthy LM HM Serum pool Blinded
Juliane Lück 17 (17) 7 (7) 31 (31) 4 (4) 0 (0)
Bodo Steckel 1 (0) 7 (6) 2 (1) 0 (0) 9 (9)
Total 18 (17) 14 (13) 33 (32) 4 (4) 9 (9)
Table 3.3: Glioma 09 study: Incubated samples analyzed in the Glioma 09 study. Brackets
indicate sample numbers without repeats. Juliane Lück used serum pool samples of healthy human
individuals as repeats to control for technological variability. The repeats, performed by Bodo
Steckel, served mainly for comparing whether signal intensities depend on the experimentator.
This was found to be not the case (data not shown).
Glioma 09: Serum antibody binding assays
Incubations were performed automatically using the Tecan HS 4800 hybridization station.
Serum was applied in a concentration of 80 µg/ml, diluted in PBS/BSA. IgM-antibody
binding was detected using anti-human IgM-Alexa Fluor 647. Isotype-specific secondary
antibodies were applied in a concentration of 20 µg/ml. Additionally, one microarray
was, instead of serum, incubated with blocking buffer (PBS, 1% BSA) (negative control,
blank) and repeated incubations were performed to characterize technological variability
(Table 3.3).
3.5.3 Glioma 08 study
The two major differences between the Glioma 08 and the Glioma 09 studies are: (i)
fewer samples were used in the Glioma 08 study, (ii) serum samples were diluted 1:10 in
the Glioma 08 study whereas for the Glioma 09 study the IgM concentration of incubated
samples was set to 0.08 mg/ml.
Incubations and signal detection were performed by Juliane Lück. All samples originate
from the lab of Christian Schichor (Ludwig-Maximilians-Universität, Munich, Germany).
Glioma 08: Serum samples
In the Glioma 08 study, healthy controls (n = 17), low malignant histological tumor
subtypes (LM : WHO grade I and II, n = 8) and high malignant histological tumor
subtypes (HM : WHO grade III and IV, n = 24) were included.
Glioma 08: Quantification of serum IgM
Please refer to Section 3.5.2 as methods were analogous.
Glioma 08: Serum antibody binding assays
In total, 49 distinct sera (32 patient sera and 17 healthy control sera) were diluted 1:10
in blocking buffer and were manually incubated (Section 3.2.1) on individual peptide
microarrays. Additionally, one microarray was, instead of serum, incubated with blocking
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buffer (PBS, 1% BSA) (negative control, blank) and two repeated incubations of a
healthy control serum were performed to characterize technological variability. Serum
IgM antibody binding was detected with goat-anti-human IgM-Alexa Fluor 647 secondary
antibody (20 µg/ml).
3.5.4 NephroFIT study
This study was originally designed to study whether sera from kidney transplanted
patients who rejected the graft could be separated by antibody binding profile from
those who did not reject. Blood samples were collected thirty days after transplantation.
Patients were then monitored for the period of one year in order to follow their rejection
behavior. The goal was to detect differentiating patterns with regard to those patients
that rejected the transplant and with regard to those who did not reject.
Serum incubations and signal detection were performed by Bodo Steckel. Serum samples
were obtained from Nina Babel, Thomas Schachtner and Petra Reinke (Department of
Nephrology, Charité, Berlin, Germany).
NephroFIT: Serum samples
Blood samples were collected thirty days after transplantation. Patients were monitored
for the period of one year in order to follow their rejection behavior. For this purpose,
they were divided into two groups: “Rejection” (n = 15), and “No rejection” (n = 14).
NephroFIT: Antibody binding assays
The serum-array incubations were performed automatically using the Tecan HS 4800
hybridization station (Section 3.2.2) with serum, which was diluted 1:10 in PBS/BSA
(blocking buffer). Additionally, one microarray was, instead of serum, incubated with
blocking buffer (PBS, 1% BSA) (negative control, blank) and two repeated incubations
with healthy control sera were performed to characterize technological variability. IgM-
antibody binding was detected using goat anti-human IgM-Alexa Fluor 647. This
secondary antibody was applied in a concentration of 20 mg/ml.
3.5.5 NephroFIT-Pepscan study
In contrast to the NephroFIT study, this study was carried out with peptide arrays
from Pepscan and has fewer samples. For further background on platform differences
between JPT and Pepscan microarrays, please refer to Section 3.1. Incubations and
signal detection was performed by Juliane Lück. Serum samples were obtained from
Nina Babel, Thomas Schachtner and Petra Reinke (Department of Nephrology, Charité,
Berlin, Germany).
NephroFIT-Pepscan: Serum samples
Blood samples were collected thirty days after transplantation. People were then followed
for the period of one year in order to follow their rejection behavior. For this purpose,
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they were divided into two groups: “Rejection” (n = 13), and “No rejection” (n = 13).
NephroFIT-Pepscan: Antibody binding assays
The serum-array incubations were performed manually (Section 3.2.1) with serum, which
was diluted 1:10 dilution in PBS (1% BSA). Additionally, one microarray was, instead
of serum, incubated with blocking buffer (PBS, 1% BSA) (negative control, blank)
and two repeated incubations with healthy control sera were performed to characterize
technological variability. IgM-antibody binding was detected using goat anti-human
IgM-Alexa Fluor 647. This secondary antibody was applied in a concentration of 20
µg/ml.
3.5.6 NephrOT study
Briefly, this study was to study whether differences in rejection behavior of kidney
transplant recipients can also be detected by antibody profiling. Studied rejection
behaviors are tabled in Section 3.5.6.
Incubations, plasma IgM quantification and signal detection were performed by Juliane
Lück, Rafael Burtet and Andrea Maranhao.
NephrOT: Plasma samples
Plasma samples were obtained from two different centers of the Operational tolerance
multicenter study: Rio Grande do Sul (PUC-RS) and of the clinics hospital of medicine
school of São Paulo University (HCFMUSP).
Characterization of studied groups:
• Group OT (operational tolerance): Individuals with long term stable transplant
(> 1 year of transplantation), without use of immunosuppressive drugs or at least 1
year. Number of samples: 5.
• Group CR (chronic rejection): Individuals with chronic rejection long time after
transplantation (> 1 year of transplantation) (diagnosed by biopsy using histopatho-
logic criteria for the classification of the transplanted kidney [261, 262]). Number
of samples: 8.
• Group ST (stables): Individuals with long term stable transplant (> 1 year of
transplantation) treated with standard doses of immunosuppressants. Number of
samples: 8.
• Group HE (healthy): Healthy donor for kidney transplantation. Number of samples:
9.
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NephrOT: Quantification of plasma IgM
Plasma IgM was quantified using the human IgM quantification set (Bethyl Labs). EIA
plates included standard, blank and positive control samples (human reference serum,
Lonza). All blood plasma samples and the standard were assayed in duplicate. Briefly,
corning 96-well EIA plates (Sigma Aldrich) were coated for 1 h with anti-human IgM
diluted 1:100 in coating buffer (carbonate-bicarbonate, pH=8) and blocked for 30 min in
blocking buffer. (TBS, 1% BSA, pH 8). Samples were pre-diluted 1:300 in sample diluent
(TBS, 1% BSA, 0.05% Tween20, pH 8), serially two-fold diluted across columns and
incubated overnight at 4◦C. HRP-coupled anti-human IgM was diluted 1:5000 in sample
diluent and incubated for 1 h. TMB substrate was incubated for 1 min, the reaction was
stopped with 0.18 M sulfuric acid, and absorbance was measured at 450 nm.
NephrOT: Antibody binding assays
The plasma-array incubations were performed automatically using the Tecan HS 4800
hybridization station (Section 3.2.2).
Plasma samples were diluted 1:10 in blocking buffer. IgM-antibody binding was
detected using anti-human IgM-Alexa Fluor 647. Secondary antibodies were applied in a
concentration of 20 µg/ml. Additionally, one microarray was, instead of serum, incubated
with blocking buffer (PBS, 1% BSA) (negative control, blank) and 6 repeated incubations
of a healthy control serum were performed to characterize technological variability.
NephrOT: Signal detection
Microarrays were scanned with the Genepix4200AL microarray scanner. The PMT
(Photomultiplier Tube) gain was set to 350, the laser power to 20%9 and the resolution
to 10 µm.
3.5.7 NOD study (NS)
Christin Schläwicke performed incubations involving samples of healthy C57BL/6 mice
and healthy NOD (non-obese diabetic) mice.
NOD study: Serum samples
Serum was taken from female 5 healthy C57BL/6 and 5 NOD (non-obese diabetic, still
healthy), mice. Mice were provided by the Disease Genetics Group (AG Penha-Gonçalves),
Instituo Gulbenkian de Ciência, Oeiras, Portugal.
NOD study: Serum antibody binding assays
Serum samples (1:10 diluted in blocking buffer) were manually incubated (Section 3.2.1).
Additionally, one microarray was, instead of serum, incubated with blocking buffer (PBS,
9PMT gain and laser power were set to different values than for all other studies (Section 3.3) and are
therefore reported here.
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1% BSA) (negative control, blank). Serum IgM antibody binding was detected with
goat-anti-mouse IgM Alexa Fluor 546 secondary antibody (20 µg/ml).
3.5.8 Mouse study (MS)
Serum samples from 15 BALB/c mice bred under specific pathogen-free (SPF) conditions
were collected. These mice were infected with Heligmosomoides bakeri HB (Figure 3.1)
Further serum samples were collected at 10 dpi (days post infection; 15 samples), at 14
dpi (13 samples) and at 18 dpi (15 samples) totaling 58 serum samples (Figure 3.1). The
goal of this study was to discriminate the binding patterns of samples obtained from
different time points after infection. For an immunological background on murine HB
infections, please refer to Section 1.8.2.
In addition to sera from BALB/c mice, also 15 sera from distinct healthy C57BL/6
SPF-mice were analyzed.
Incubations, serum IgM quantification and signal detection were performed by Juliane
Lück.
Mouse study: Mice
Male BALB/c mice were bred and maintained under specific pathogen-free (SPF) condi-
tions by the Department of Molecular Parasitology, Humboldt University Berlin (Sebastian
Rausch). Infection of mice with HB was carried out by oral gavage with 200 L3 stage
larvae in distilled water (Figure 3.1).
C57BL/6 mice were bred and maintained under specific pathogen-free (SPF) condi-
tions and were provided by the lab of Marc Ehlers (former Research Group “Tolerance
und Autoimmunity”, DRFZ, Berlin, Germany) and by the lab of Simon Fillatreau
(“Immunregulation”, DRFZ, Berlin, Germany).
Mouse study: Serum samples
Mice of both groups (healthy C57BL/6 [n = 15] and BALB/c mice [n = 58]), Section
3.5.8) were narcotized and bled either by cardiac or retro-orbital puncture at the age of 8
weeks.
As to BALB/c mice, blood samples were collected from healthy SPF-BALB/c mice
(n = 15), which were subsequently infected with HB. Blood samples were collected at
three time points post infection (dpi): at 10 dpi (n = 15), 14 dpi (n = 13) and 18 dpi
(n = 15).
The blood was allowed to clot at room temperature, centrifuged and the supernatant
was stored at −20◦C.
Mouse study: Quantification of serum IgM
Serum IgM quantification was performed as described for the NephrOT study (Section
3.5.6) with the exception that sera were prediluted 1:500. The IgM concentration was
only measured—due to technical complications—for 32 samples (HE : 12, AP: 15, CP: 5).
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Figure 3.1: General experimental setup. (A) Heligmosomoides bakeri (HB)-infection of mice
was carried out by oral gavage with 200 L3 stage larvae in distilled water. Sera were prepared
from blood samples collected prior to infection (HE), during acute infection (AP) or early chronic
infection (CP). (B) Sera were probed on peptide microarrays and afterwards bound serum
antibodies were detected with fluorescence- labeled anti-mouse IgM. (C) Microarray slides covered
five identical sub-arrays, each including 300 peptide (255 random-sequence peptides [J25514-mer] and
45 EAE-peptides) spots and four replicates of six internal controls. Only the 255 random-sequence
peptides were analyzed in this study. This Figure was conceived by Nicole Wittenbrink.
Mouse study: Antibody binding assays
Sera were manually incubated as detailed in Section 3.2.1. Each sub-array was incubated
with a different serum. This is in contrast to all other studies (Section 3.3.2). Additionally,
one sub-array was, instead of serum, incubated with blocking buffer (PBS, 1% BSA,
negative control, blank). Furthermore, three arrays of a different batch but analogous
design were incubated with the same serum of a healthy mouse in order to characterize
technological variability. Serum antibody binding was detected with polyclonal goat
anti-mouse IgM-Alexa Fluor 546.
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3.5.9 Monoclonal antibodies
The 13 human monoclonal antibodies were kindly provided by the group of Hedda
Wardemann (Max Planck Institute for Infection Biology, Berlin, Germany). Ten different
Ig gene sequences of IgG+ memory B cells from 2 healthy human donors, PN and VB,
(PN115, PN138, PN16, PN89, VB1, VB142, VB161, VB176, VB18, VB4) [76] and three
further ones from 3 other human donors ED38 [263], eiJB40 and mGO53 [74] were
expressed as detailed in Tiller and colleagues [264].
Monoclonal antibodies were manually incubated analogously to sera from the Mouse
study (Section 3.5.8) with a concentration of 10 mg/ml on sub-arrays displaying the
J25514-mer library (Section 3.1.1).
3.6 Simulation of antibody-peptide reactivity data
3.6.1 Simulation of signal intensities
Peptides (p⃗ i) and antibody binding sites (⃗ak) were modeled as strings. Binding strengths
between antibodies and the various amino acid residues of a peptide, referred to as
assigned AAWS h⃗, were sampled from the uniform distribution on the closed interval
[0, 1]. A binding site on an antibody a⃗k was simulated in a similar fashion with a random
number from the closed interval [−1, 1] (i.i.d.) for every sequential position and scaled
such that (⃗ak)Ta⃗k = 1. The binding association between peptide p⃗ i and antibody a⃗k was
calculated by yi,k = (⃗ak)Tp⃗ i (Section 4.2).
Based on the interpretation of the binding association as being negatively linearly
proportional to the standard Gibbs free energy change of reaction, ∆rG◦, the binding
affinity Ki,k, the thermodynamic equilibrium association constant for antibody k binding
peptide i, is defined as shown in Equation 3.2.
Ki,k = exp

−∆rG
◦
RT

= exp

β0 + β1yi,k
RT

(3.2)
Similar to a bit string model approach published by Rosenwald and colleagues [265],
the calculation of Ki,k assumes additivity in free energy of binding10, an assumption
that is supported by experimental results [266, 267]. The measured signal intensity is
assumed to be proportional to the ratio of bound-to-total surface of the peptide spot,
Si. An expression for this quantity, based on the law of mass action, can be obtained
from classical Langmuir adsorption theory [268] resulting in the following Equation with
R = 8.314472, T = 273.15 + 25, β0 = 0 and β1 = RT .
Si =
nAb
k=1[Ab]kKi,k
1 +nAbk=1[Ab]kKi,k , (3.3)
where [Ab]k is the concentration of antibody k with
nAb
k=1[Ab]k = [Ab]Total. The total
10This thermodynamic insight was contributed by the author of this thesis.
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antibody concentration [Ab]Total is set to 1 unless mentioned otherwise11. Equation 4.1
has been conceived by Henning Redestig, Johannes Schuchhardt and Michal Or-Guil and
was first published in Greiff and colleagues [104].
At last, signal intensities were normalized (log-transformed, mean-centered, and scaled
to unit variance) if not stated otherwise.
3.6.2 Introduction of Gaussian noise into simulated signal intensities
If Gaussian noise (N (μ, σ)) was introduced into simulated signal intensities, the noise
term—an i.i.d. generated vector of the length of the antibody sequence—was multiplica-
tively introduced before logarithmic transformation of the data.
3.6.3 Simulation of correlated antibody repertoires
Correlated antibody repertoires were simulated as shown in Figure 3.2. Briefly, correlated
antibody repertoires were simulated by adding Gaussian noise
#                                             „N (μ = 0, σ = x(j))i (i ∈
{1, 2, . . . , 104}) to an antibody sequence a. Repeating this 104 times with the same
antibody sequence a yields a set of 104 sequences, {ainoise}i∈{1,2,...,104}, wherein the set’s
internal correlation structure depends on the amount of Gaussian noise added to an
antibody sequence (Table 3.4). The amount of noise added to an antibody sequence is
a function of x(j), where x(j) ∈ [0, 10], j ∈ {1, 2, . . . , 10}. All antibody sequences were
normalized to (ainoise)Tainoise = 1 after Gaussian noise was added.
Median correlation coefficient (r) 1.00 1.00 0.86 0.61 0.27 0.14 0.08 0.05 0.00 0.00
Gaussian noise (N (μ = 0, σ = x)) 0.00 0.01 0.10 0.20 0.40 0.60 0.80 1.00 5.00 10.00
Table 3.4: Assessment of the dependence of the median correlation of correlated antibody
repertoires on the level of Gaussian noise introduced into antibody sequences (Figure 3.2).
With increasing Gaussian noise, the degree of decorrelation of generated antibody repertoires
increases. The medians of the median pairwise Pearson correlation coefficients of the 40 generated
repertoires (Section 6.5, Figure 6.11) are tabled (1st row) in function of Gaussian noise (2nd row).
No dependence on antibody strength was found (data not shown).
Decorrelation describes an increase in the standard deviation (σ = x(j)) of the added
Gaussian noise accompanied with a decrease in pairwise Pearson correlation between
antibody sequences of a given repertoire (Table 3.4).
3.7 Partial least squares regression
3.7.1 Estimation of AAWS with PLSR
Let S be a vector, which itemizes the measured or simulated signal intensities and X the
amino acid composition matrix (AACM) where xi,q is number of amino acid residues of
11The importance of a constant total antibody concentration for the simulation of signal intensities was
contributed by the author of this thesis.
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Figure 3.2: Flowchart of the generation of correlated antibody repertoires. For further informa-
tion, see main text (Section 3.6.3).
type q in peptide p i (Equation 4.8).
The response variable S and the matrix of predictor variables X cannot be correlated
directly with each other due to non-congruent dimensionality. Thus, a to be determined
vector w, which relates the predictor matrix X to the both log-transformed and scaled
(μ = 0, σ = 1) response variable S, is needed. If S is of dimension m × 1 and X of
dimension m × n, then, according to Equation 4.8, w must be of dimension n × 1. If the
variance of the residual vector  in Equation 4.8 is small, one would expect the regression
coefficients composing w to vary sensitively with any changes in S, thus displaying the
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importance of every amino acid for signal intensity generation.
In theory, w⃗ can be estimated by ordinary least squares regression (OLR), i.e. ˆ⃗w =
(XTX)−1XTS⃗, however, unless the peptide library was designed for this purpose, XTX
may not be invertible and OLR fails. In this case, it is still possible to obtain a robust
estimate of w⃗ by means of Partial Least Squares Regression [191, 269, 270].
PLSR is used to find the fundamental relations between two matrices (or one vector
[S⃗] and one matrix [X]). It is a latent variable approach to modeling the covariance
structures in these two spaces. A PLSR model tries to find the multidimensional direction
in the X-space that explains the maximum (multidimensional) variance direction in the
S⃗-space. PLSR is particularly suited when the matrix of predictors has more variables
than observations, and when there is collinearity in X. An introduction to PLSR can be
found in Wold and colleagues [270]. More extensive mathematical foundations, especially
regarding the latent variables, are presented in the Appendix (Section A.1).
All calculations involving PLSR were carried out with the pls R package (Version
2.10) [271, 272].
3.7.2 PLSR model diagnostics
In order to assess the quality of the built PLSR model, Q2 was used as a measure for
assessing the predictive performance. The predictive performance is defined as:
Q2 = 1−
(SˆLeft out − SLeft out)2
S2Left out
. (3.4)
The vector S⃗Left out is the left-out test data set, the signal intensity of which is predicted
( ˆ⃗SLeft out) from the remaining training data set. The left-out test data represented
randomly chosen 10% of the total data set. The predictive performance was assessed for
a varying number of latent components (Section A.1). The number of latent components
which minimized the cross-validated prediction error, that is, which maximized the
predictive performance (Q2), was chosen.
3.8 Unsupervised and supervised machine learning methods
3.8.1 Principal component analysis
Principal component analysis (PCA) is an unsupervised12 technique in pattern recognition.
It transforms the input data set in such way that it may be represented by a reduced
number of “effective features”, yet retains most of the intrinsic information content of the
original data. Simply truncating a vector x⃗ would result in a mean-square error equal to
the sum of the variances of the elements eliminated from x⃗. PCA, however, provides a
linear invertible transformation of the data space. This yields a truncation of x⃗, which
is optimal in mean-square-error sense; PCA projects the data onto a new coordinate
system such that the greatest variance by any projection of the data lies on the first
12Unsupervised methods are mostly used for pattern recognition and dimension reduction purposes [273].
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coordinate (called the first principal component), the second greatest variance on the
second coordinate, and so forth. PCA is not optimized for class separability [273, 274].
Principal component analysis was done with the pca-function of the pcaMethods R
package (Version 1.32) [272, 275].
3.8.2 Support vector machines
Support vector machines are binary13 learning machines, which are mostly used in
pattern-classification problems. They are categorized as large margin classifiers. Given
a training sample, the support vector machine constructs a hyperplane as the decision
surface maximizing the margin of separation between positive and negative examples.
A notion that is central to the development of the SVM learning algorithm is the
inner-product kernel between a “support vector” x⃗i and a vector x⃗ drawn from the input
data space. The support vectors consist of a small subset of data points extracted by the
learning algorithm from the training sample [273, 274, 277].
The optimization problem is normally solved in its dual form with the classification
rule being:
f(x) = sgn

m
i=1
αiyik(x⃗i, x⃗) + b

,
where m is the number of training samples, b is the bias, ai are the Lagrange multipliers,
yi ∈ {−1, 1} is the label vector and k(x⃗, x⃗i) is the kernel function. Those vectors for
which the Lagrange multipliers αi are non-zero are called support vectors. They are
either found on the classification margin or within the margin.
P-SVM
Support vector machine analysis was carried out with an R implementation of the
Potential Support Vector Machine (P-SVM) [278], which facilitates linear classification
of high-dimensional data with a built-in feature selection. The classification performance
was measured using nested leave-one-out cross-validation (LOOCV), where feature
selection and hyperparameter selection were performed in the inner cross-validation loop
independently of the test sample of the outer cross-validation loop. The inner loop
was used to determine the combination of parameters that gives the best classification
performance: the cost parameter c was varied from 1 to 17 in 5 equally spaced steps and
the regularization parameter ε was chosen as 2i with i = −3,−2, . . . , 3, 4. In order to
obtain compact models that only use a small set of features, all parameter combinations
in the inner cross-validation loop for which more than three models exceeded an upper
limit of six selected features were rejected. The goal criterion of classification performance
was balanced accuracy (BACC, Equation 3.7). A flowchart of the used algorithm is given
in Figure 3.3.
For determining whether selected peptides were unique in their classification accuracy,
unique peptides—determined across folds by subproblem (Table S.1)—were removed
13Multi-class support vector machine approaches also exist [276].
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from the respective subproblem’s data set. Afterwards, the cross-validation procedure
was carried out for the remaining peptides as described above (Figure 3.3).
All P-SVM computations were done with the psvm R package14 (Version 0.06).
P-SVM: Definition of balanced accuracy, specificity and sensitivity
Sensitivity = number of true positivesnumber of true positives+ number of false negatives (3.5)
Specificity = number of true negativesnumber of true negatives+ number of false positives (3.6)
Balanced accuracy (BACC) = 12 × (Sensitivity+ Specificity) (3.7)
P-SVM: Permutation testing
Since, throughout this thesis, the number of peptides (features) is high compared to the
number of samples, correlations between features and the target may occur by chance.
In order to quantify such random effects, permutation testing was performed: for 1000
independent random shuffles of the label vector LOOCV15 was performed. Then, the
proportion of outcomes in which the balanced accuracy was at least as good as for
the original unshuffled label vector is an unbiased estimate of the true p-value, i. e. the
probability to achieve a balanced accuracy at least as good as the observed one under
the null hypothesis that labels and input data are independent.
3.9 Statistical analysis
3.9.1 Correlation coefficients
Association between variables was assessed by Pearson correlation (rPearson) unless stated
otherwise, in which case the Spearman-rank correlation (rSpearman) coefficient was used.
The Pearson correlation coefficient is a measure of the correlation (linear dependence)
between two variables X and Y , rPearson, rSpearman ∈ [−1, 1].
Pearson’s correlation coefficient between two variables (X,Y ) is defined as the covari-
ance of the two variables divided by the product of their standard deviations:
rPearson =
n
i=1(Xi − X¯)(Yi − Y¯ )n
i=1(Xi − X¯)2
n
i=1(Yi − Y¯ )2
.
14This package has not yet been published.
15Permutation testing was performed using the best precomputed parameter combinations (ε, c) de-
termined by P-SVM nested cross-validation for the non-shuffled data set. This was done to limit
computational load.
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Figure 3.3: Flowchart of the P-SVM algorithm. For further information, see main text (Section
3.8.2).
Correlation coefficients equaling to 1 or −1 correspond to data points lying exactly on a
line.
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In contrast to the Pearson-correlation coefficient, the Spearmen correlation coefficient
is a non-parametric measure of statistical dependence between two variables. It is defined
as the Pearson correlation coefficient between the ranked variables. For a sample of size
n, Xi, Yi are converted to ranks xi, yi, and rSpearman is computed from these:
rSpearman =

i(xi − x¯)(yi − y¯)
i(xi − x¯)2

i(yi − y¯)2
.
The Spearman correlation coefficient assesses how well the relationship between two
variables can be described using a monotonic function. If there are no repeated data
values, a perfect Spearman correlation of +1 or −1 occurs when each of the variables is
a perfect monotone function of the other. Tied values are assigned a rank equal to the
average of their positions in the ascending order of the values [279, 280].
3.9.2 Hierarchical clustering
For hierarchical clustering of signal intensity profiles or AAWS, correlation coefficients of
the data type in question were Pearson/Spearman-correlated in a pairwise fashion thus
yielding a correlation matrix. The dimension of this matrix is equal to the number of
pairwise-correlated samples. These coefficients were then transformed into Euclidean
distances by the dist()16 function in R thus returning a distance matrix. The “complete-
linkage” clustering algorithm performed by the R function hclust()17 proceeds by
initially assigning each object to a cluster. It then proceeds iteratively, at each stage
joining the two most similar clusters, continuing until there is just a single cluster. At
each stage distances between clusters are recomputed by the Lance-Williams dissimilarity
update formula [281]. When joining a new object (signal intensity profile or AAWS) to an
existing node, the distance of this new object from the node is the largest distance found
from the new object to all objects contained within that node. This method provides
the greatest separation of clusters when compared to other types of clustering such as
“single-linkage” or “average-linkage clustering” [282]. Hierarchical clustering creates a
dendrogram, which is passed on to the heatmap.2()18 R function creating a heatmap of
the clustered correlation matrix.
Heatmaps are false color images with an added dendrogram. Ordering of the rows and
columns is imposed by the restrictions of the dendrogram. In this thesis, a histogram
displaying the distribution of Pearson/Spearman correlation coefficients is shown in the
upper left corner of the heatmap.
3.9.3 Significance testing
The two-sided, non-paired Wilcoxon rank-sum test was used to test—if not mentioned
otherwise—the difference between two samples of independent observations. P-values
were regarded as significant when p < 0.05.
16stats R package, Version 2.12.1, [272].
17stats R package, Version 2.12.1, [272].
18gplots R package, Version 2.10.1, [272, 283].
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4 A minimal model of antibody-peptide
binding: mathematical analysis and
simulations
Parts of this Chapter were recently published [104].
4.1 Preliminary definitions
Definition 4.1.1. An antibody repertoire is the set of all unique antibody strings1 a⃗k
in a given entity. An antibody repertoire is thus defined as Aj = {a⃗k|k ∈ N≥1}. The
cardinality of the antibody repertoire Aj (#Aj) is denoted as nAbAj .
Definition 4.1.2. An antibody mixture is the entirety of antibody strings in a given entity
and defined as an indexed family AMj = (⃗aj)j∈J . The set of antibody concentrations
in an antibody mixture is Cj = {[Ab]k|k ∈ N≥1}, where [Ab]k is the concentration of
antibody a⃗k. The sum of all antibody concentrations [Ab]k in a given mixture is the
total antibody concentration k[Ab]k = [Ab]Total.
4.2 A minimal model of antibody-peptide binding
In the following, a model that simulates binding between peptides and antibodies is
presented. In this model, the binding affinity of simulated monoclonal antibodies depends
non-linearly on amino acid positions in the peptide sequences (Equation 4.1). The
proposed model is similar to bit string models [68, 284–286] in that it uses vectors as
representations of peptides and antibodies.
The peptide string is represented by unique real numbers taken from a vector of
assigned amino acid-associated weights (AAWS), denoted h⃗, the twenty components of
which were drawn from a uniform distribution on the closed interval [0, 1]. A peptide p⃗i
of l amino acids is thus represented by a vector of l numbers drawn from h⃗.
Definition 4.2.1. A peptide p⃗ i is defined as an oriented string of amino acids pik ∈ AA,
where AA is the alphabet amino acids are drawn from. An assortment of peptides forming
an indexed family P is called a peptide library P = (p⃗ j)j∈J .
An antibody binding site is represented by a vector a⃗k of length l. The binding strength
of each position is given by a number between −1 and 1 that is drawn randomly from a
1Hereafter, the terms “string” and “sequence” will be used interchangeably.
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uniform distribution (i.i.d.) and is scaled such that (⃗ak)Ta⃗k = 1. The binding association
between peptide p⃗ i and antibody a⃗k is computed as the dot product of the two vectors,
yi,k = (⃗ak)Tp⃗ i. Thus, the binding association yi,k depends explicitly on an amino acid’s
position in a given peptide sequence.
Antibody and peptide sequences were modeled such that, unilaterally, positive values
in the antibody sequence increase the binding association yi,k, whereas negative values in
the antibody sequence cause a decrease of yi,k. If both assigned AAWS h⃗ and components
of antibody sequences could assume negative contributions to binding, then, in contrast to
biochemical intuition, negative values at a given position i of both peptide and antibody
binding site would yield a positive contribution to signal intensity and, therefore, would
not be different from double positive entries.
Based on the law of mass action and classical Langmuir adsorption theory [268], an
expression for the peptide signal intensity yielded by a given antibody mixture is
Si =
nAb
k=1[Ab]kKi,k
1 +nAbk=1[Ab]kKi,k = si1 + si . (4.1)
The thermodynamic equilibrium association constant for antibody k binding to peptide
i is defined as Ki,k = exp

−∆rG◦RT

with ∆rG◦ = − (β0 + β1yi,k). For further details
on parameter values, please consult Section 3.6. Equation 4.1 has been conceived by
Henning Redestig, Johannes Schuchhardt and Michal Or-Guil and was first published in
Greiff and colleagues [104].
Definition 4.2.2. A signal intensity profile (S⃗) is defined as a vector of signal intensities
(Sj) for an arbitrary antibody mixture AMk and a given peptide library P . Sj is the
signal intensity of peptide p⃗ j . The terms signal intensity profile or antibody binding
profile are used interchangeably to denote S⃗.
Simulated signal intensity profiles were normalized (log-transformed, mean-centered,
and scaled to unit variance) if not stated otherwise.
Non-normalized simulated signal intensity profiles of monoclonal antibodies (nAb = 1)
show a lognormal shape (Figure 6.3), whereas those of highly diverse antibody mixtures
(nAb = 10000) have a Gaussian shape (Figure 6.2).
4.3 Mathematical and in silico analysis of the minimal model
of antibody-peptide binding
4.3.1 Randomly generated, highly diverse antibody mixtures render the
signal intensity profile exclusively dependent on peptide amino acid
composition
In the following, the described minimal model (Section 4.2) is mathematically analyzed2
with respect to the impact of antibody diversity on peptide signal intensity (Si). It is
2The mathematical analysis in Section 4.3.1 was performed by Johannes Schuchhardt and Michal
Or-Guil.
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assumed, without loss of generality, that [Ab]Total = 1 and all antibodies have equal
concentration ([Ab]k = 1/nAb). Setting β0 = 0 and β1 = RT , si gives:
si =
1
nAb
nAb
k=1
exp (yk) (4.2)
si =
1
nAb
nAb
k=1
exp

(⃗ak)Tp⃗ i

(4.3)
si =
1
nAb
nAb
k=1
exp

l
z=1
akzp
i
z

(4.4)
For this Section’s mathematical analysis only, the binding strength at each position of
an antibody binding site is given by a number that is drawn randomly from a Gaussian
distribution. The change from uniform (Section 4.2) to Gaussian distribution greatly
simplifies the following derivation.
According to the central limit theorem (CLT) and assuming a mixture for which the
number of different randomly generated antibodies tends to infinity (nAb → ∞), one
can proceed with the mean of the lognormal distribution (exp(µz+σ
2
z/2)) for each peptide
position z, where µz = µ× piz and σz = σ × piz (µ and σ being the mean and standard
deviation used to generate the antibody sequences).
si =
l
z=1
exp (µz + σ2z/2) (4.5)
si = exp

l
z=1
µz + σ2z/2

(4.6)
For the special case, where a⃗k are modeled with N (0, 1), µz = 0 and σ2z = σ2 × (piz)2 =
⟨(akz)2⟩ − ⟨akz⟩2

× (piz)2 = (1− 0)× (piz)2. Thus, si simplifies to:
si = exp

l
z=1
(piz)2
2

(4.7)
Therefore, for highly diverse and randomly generated antibody mixtures simulated signal
intensities (Si) depend exclusively on peptide amino acid composition (Equation 4.7).
The order of the amino acids in a peptide sequence p⃗ i is rendered unimportant for the
signal intensity Si.
4.3.2 Building a regression model based exclusively on peptide amino acid
composition to predict signal intensity profiles
Equation 4.7 indicates that the signal intensity (Si) simulated with highly diverse and
identically and independently distributed (i.i.d.) antibody sequences is independent of
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any specific antibody composition as long as antibody diversity is high. In particular,
the signal intensity solely depends on peptide amino acids (piz). The simplest ansatz to
model the sole dependence of signal intensity profiles S⃗ (#P × 1) on peptide amino acid
composition would be the following linear regression model.
S⃗ = Xw⃗ + ε⃗, (4.8)
where X (#P ×#AA) is the amino acid composition matrix, w⃗ (#AA× 1) the amino
acid-associated weights (AAWS), and ε⃗ (#P × 1) the residuals capturing the part of S⃗
which cannot be explained by the amino acid composition alone. The X matrix is formed
by counting the occurrences of each of the elements of the used amino acid alphabet (AA)
in each peptide which results in a matrix with #P rows and #AA columns. Importantly,
X does not contain any information about the position of an amino acid in a given
peptide sequence. The AAWS vector w⃗ indicates the contribution of every amino acid to
the measured signal intensity. Equation 4.8 has been conceived by Henning Redestig,
Johannes Schuchhardt and Michal Or-Guil and was first published in Greiff and colleagues
[104].
Once the vector w⃗ has been estimated, the regression model is used to predict measured
signal intensities based solely on the peptides’ amino acid composition. The regression
model’s predictive performance (Q2) is determined by 10-fold cross-validation (Section
3.7.2). The predictive performance equals 1 for perfect predictions (⃗ϵ→ 0) and is close
to zero for poor predictions.
AAWS and residuals are estimated by partial least squares regression (PLSR, Sections
3.7 and A.1). Prior to any PLSR, signal intensity vectors S⃗ are log-transformed, centered
to zero and set to unit variance.
4.3.3 Simulations show that the peptide amino acid composition-based
prediction of signal intensity profiles improves with increasing
antibody diversity
In order to test the above statistical ansatz (Equation 4.8), first, signal intensities for 100
antibodies (nAb = 100) binding to a peptide library of 255 14-mers were simulated. The
peptide library used in the simulation determines the amino acid composition matrix
Xsim. Simulated intensities S⃗sim (Figure 4.1A) and respective weights w⃗sim (Figure 4.1B)
were estimated using the linear regression model ˆ⃗Ssim = Xsimw⃗sim. The prediction of
simulated signal intensities yielded a predictive performance (Q2) of 0.53, and the Pearson
correlation between assigned h⃗ and estimated AAWS w⃗sim was found to be r = 0.90
(Figure 4.1B), which indicates a very good recovery of h⃗.
Second, signal intensity profiles were simulated with different numbers of antibody
variants. The results of the simulation framework are in accord with the mathematical
analysis in that predictive performance nears perfection (Q2 → 1) with a growing
antibody diversity (nAb ≥ 10000 antibodies, Figure 4.2A)3. Correspondingly, (i) the
3This simulation result (Figure 4.2) is independent of the distribution (Gaussian, uniform) used for
generating antibody sequences as long as the used values are small. In fact, not only components of
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pairwise correlation of computed AAWS (w⃗isim), (ii) the correlation of estimated AAWS
with assigned AAWS h⃗ as well as (iii) the pairwise correlation of signal intensity profiles
(S⃗sim) near perfection (r = 1) with growing antibody diversity (Figures 4.2B–D)4. Of note,
the correlation of estimated AAWS with assigned AAWS is already high for mixtures of
low antibody diversity (nAb = 16) and low predictive performance (Figures 4.2A and
4.2C).
Thus, there exist antibody mixtures which yield predictive performance values near
perfection. Their signal intensity profiles depend almost exclusively on assigned AAWS h⃗.
These mixtures are hereafter called unbiased. They are defined by the following properties:
(i) the number of different antibody sequences (nAb) tends to infinity (nAb →∞) and (ii)
antibody sequences are generated in a random (i.i.d.) fashion. Section 4.3.4 shows that
property (i) can be generalized by not only requiring the overall antibody diversity to be
high but also demanding that the diversity of antibodies tends to infinity (nAb[Ab]k →∞)
for any antibody concentration [Ab]k ∈ Cj . Section 4.3.4 shows that a violation of this
property may decrease the regression model’s predictive performance.
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Figure 4.1: Simulated signal intensities and assigned amino acid-associated weights are recovered
by an amino acid composition-based regression model. (A) Normalized simulated signal intensities
(S⃗sim) obtained by amino acid position-dependent simulation of the binding of 100 antibodies
to a random peptide library of 255 14-mers were predicted using the regression model given
by Equation 4.8. This regression model takes into account only the amino acid composition of
the simulated peptide sequences (Xsim). Predictive performance: Q2 = 0.53. Simulated signal
intensities were computed using Equation 4.1. (B) Equation 4.8 was used to estimate (w⃗sim),
which are shown against the assigned AAWS (⃗h). Pearson correlation coefficient: r = 0.90.
antibody sequences but also those of assigned AAWS have to be small (≈ −1 ≤ aki , hi ≤ 1) so that
predictive performance increases with increasing antibody diversity (Figure 4.2A).
4Changing the peptide library for each simulation run, but leaving assigned AAWS constant, does not
significantly change Figure 4.2C.
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Figure 4.2: Simulations show that the predictive performance of antibody binding profiles
improves with increasing antibody diversity. Antibody binding profiles (S⃗sim) were simulated for
antibody mixtures of 1 to 16384 different antibodies. (A) The predictive performance increases
with increasing number of antibody variants (nAb), (B) as does the correlation (r) between all
pairs of estimated AAWS (w⃗isim), (C) between estimated AAWS and assigned AAWS (⃗h) and
(D) between all pairs of the corresponding normalized signal intensity profiles (S⃗isim). In (A–D),
a random peptide library with associated AACM (Xsim) of 255 14-mers and assigned AAWS
(⃗h) were generated once and were kept constant across all simulation runs. For every mixture of
nAb-different antibodies, 100 simulations with newly generated random antibody mixtures were
run. Antibody binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim)
were determined using Equation 4.8.
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4.3.4 Antibody dominance decreases the linear predictability of simulated
signal intensity profiles
In the following, the effect of the selective increase in concentration of a subset of an
antibody mixture (hereafter termed dominant antibodies) on predictive performance is
studied. Based on the above results (Figure 4.2), one would expect that such a relative
increase in antibody concentration has a decreasing effect on predictive performance.
Antibody dominance would turn an unbiased mixture into a biased one.
In fact, simulations indicate that the reduction of predictive performance (Figure 4.3A)
as well as the distancing of the signal intensity profiles from that of unbiased mixtures
(Figure 4.3F) only occurs for those biased mixtures in which a small number of dominant
antibodies is found in absolute terms (5–10 dominant antibodies). Indeed, for 1000
dominant antibodies in a biased mixture of 10000 antibodies, the predictive performance
nears 1 (Figure 4.3A and D).
Of note, using Spearman correlation coefficients yields analogous results to those shown
in Figure 4.3F: dominant antibodies induce rank changes which distance signal intensity
profiles of biased from those of unbiased mixtures. Ranks of signal intensity profiles are
determined by assigning the rank 1 to the peptide with the highest signal intensity, the
rank 2 to the peptide with the second highest signal intensity and so forth.
Therefore, the fruitfulness of the term “antibody-dominated mixture”—implying a less
than perfect predictive performance and lower recovery of assigned AAWS h⃗ (Figure
4.3C)—depends as much on the number of dominant antibodies as on their actual increase
in concentration. Antibody dominance is, therefore, absent in a highly diverse randomly
generated antibody mixture if for all different antibody concentrations [Ab]k ∈ Cj the
diversity of antibodies tends to infinity (nAb[Ab]k → ∞). This negative definition of
antibody dominance is consistent with property (iii) of unbiased mixtures (Section 4.3.3,
page 53).
Furthermore, Figure 4.3D5 shows that simulated monoclonal antibodies exist which
show quite high predictive performance values with almost perfect recovery of assigned
AAWS (Figure 4.3E). These simulated monoclonal antibodies are studied in Section 7.2.
4.3.5 The signal of unbiased mixtures enables the isolation of the signal of
simulated dominant antibodies in biased mixtures
The link between unbiased and biased mixtures are the dominant antibodies. One could
therefore ask whether, given the signal of an unbiased mixture, the signal of the biasing
dominant antibodies can be isolated from any biased mixture’s signal.
Let S⃗U be the signal intensity profile of an unbiased mixture AMk of nAb,U antibodies.
Let S⃗U-D be the signal intensity profile of a biased mixture AMj of nAb,U-D antibodies
dominated by nAb,D antibodies. The antibody repertoires of AMk and AMj are not
required to match (Ak ̸= Aj). Let S⃗D be the signal intensity profile of the nAb,D dominant
5Slight variations of predictive performance values by concentration (Figure 4.3D) are due to the R
implementation of PLSR.
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Figure 4.3: Simulations show that the predictive performance of biased mixtures changes in
function of both the number and concentration of dominant antibodies. Simulations were done
with a total of 10000 antibodies. Subsets of cardinalities 1–1000 were increased in concentration
within the range of 1 (no increase) to 10000 (10000-fold increase of dominant antibodies with
respect to the rest). (A) For all abundances of dominant antibodies, predictive performance (Q2)
is decreased with increasing antibody concentration. However, the degree to which predictive
performance (Q2) is decreased, depends on the number of dominant antibodies increased in
concentration. (B) The correlation (r) between all pairs of estimated AAWS (w⃗isim) is shown as is
(C) the recovery of assigned AAWS (⃗h) by estimated AAWS (w⃗sim). (D) Predictive performance
(Q2) values as well as (E) the recovery of assigned AAWS of dominant antibodies used to bias
mixtures of Figures (A–C) are shown. (F) The Pearson correlation of normalized signal intensities
obtained with dominant antibodies alone (D–E) and normalized signal intensities obtained of
dominant antibodies in a biased mixture (A–C) is shown. Using Spearman correlation yields
equivalent results. In (A–F), for every simulation run (50 per boxplot), the peptide library of
255 14-mers with the associated AACM (Xsim) and the assigned AAWS h⃗ were kept constant.
Simulated antibodies, but not the dominant ones, were changed for each simulation run. Antibody
binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim) were determined
using Equation 4.8.
antibodies. S⃗U, S⃗U-D and S⃗D are assumed to be simulated with the same peptide library.
Also, it is assumed that nAb,U, nAb,U-D ≫ nAb,D.
According to Equation 4.1, Si,U =
si,U
1 + si,U
, and sU = − Si,U
Si,U − 1 , Si,U ̸= 1.
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Si,D = si,D1+si,D and si,D = −
Si,D
Si,D − 1 , Si,D ̸= 1.
Then, Si,D can be expressed as follows:
Si,D ≈
Si,U-D−Si,U
(Si,U-D−1)(Si,U−1)
1 + Si,U-D−Si,U(Si,U-D−1)(Si,U−1)
(4.9)
For an extended version of the derivation, please refer to the Appendix (Section A.8.3)
Applying Equation 4.9 to the simulations performed for Figure 4.3 shows that the
quality of the isolation of the signal of the dominant antibodies increases with increasing
concentration of dominant antibodies but worsens with an increasing number of dominant
antibodies (Figure 4.4)6.
Thus, as predicted by theory, a negative correlation between the predictive performance
of a biased mixture (Figure 4.3A) and the isolation quality of the signal of the dominant
antibodies that are in that biased mixture (Figure 4.4) exists. The higher the predictive
performance of a biased mixture, the lower is the quality of signal isolation since an
increasing predictive performance signifies a decreasing antibody dominance (Section
4.3.4).
In cases of lower concentrations of dominant antibodies, the isolation quality depends
on the antibody composition of the given biased mixture as evidenced by the high
variation7 in correlation coefficients (Figure 4.4).
4.4 Summary
• A mathematical model of antibody-peptide binding was formulated (Section 4.2).
Therein, a special case of simulated antibody mixtures, termed unbiased (Section
4.3.3), was found. Unbiased mixtures yield antibody binding profiles which are
completely determined by assigned AAWS h⃗: the unbiased mixture’s antibody
composition becomes unimportant for peptide signal intensity (Figure 4.2D) as
antibody diversity tends to infinity. This was shown both by mathematical analysis
(Section 4.3, Equation 4.7) and simulations (Section 4.3.2, Figure 4.2).
• A regression model linking amino acid composition and signal intensity profiles
was formulated (Section 4.3.2). It yields estimated AAWS (w⃗), which display
the importance of every amino acid for signal intensity generation. For unbiased
mixtures, the regression model’s residuals tend to zero (Figure 4.2A). In this case,
estimated AAWS are near perfect predictors of antibody binding profiles (Q2 → 1)
and recover assigned AAWS (⃗h) (Figure 4.2C).
• The fruitfulness of the term “antibody-dominated mixture”—implying both a less
than perfect predictive performance (Q2) as well as recovery of assigned AAWS
caused by a concentration increase of several antibodies in the mixture—depends
6If Si,U-D = Si,U, then Si,D = 0⃗,∀i ∈ {1, . . . ,#P}.
7Some of the variation may also be due to numerical reasons.
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Figure 4.4: The quality of the isolation of the signal of the dominant antibodies (S⃗D) from the
antibody binding profile of a biased mixture (S⃗U-D) increases with an increasing concentration of
dominant antibodies but decreases with an increasing number of dominant antibodies. For lower
antibody concentrations, the isolation quality depends on the unbiased mixture (S⃗U) as evidenced
by the high variation in correlation coefficients. Pearson correlation coefficients between the
signal of dominant antibodies isolated from the profile of the biased mixture and the simulated
(original) signal intensities of the dominant antibodies are shown. Antibody binding profiles were
simulated as in Figure 4.3 except that a normalization of profiles was not performed. Signal
intensity profiles of dominant antibodies were isolated using Equation 4.9.
as much on the number of dominant antibodies as on their actual increase in
concentration (Section 4.3.4, Figure 4.3A–C). Dominant antibodies distance profiles
of biased antibody mixtures from those of unbiased ones by induction of rank
changes (Figure 4.3F).
• Given the signal of the unbiased mixture, mathematical analysis indicates that the
signal of the dominant antibodies can be, to a certain extent, isolated from the
signal of any biased mixture (Section 4.3.5). Complementary simulations show that
the quality of the isolation is dependent on both the number and the concentration
of dominant antibodies: it is essentially negatively proportional to the biased
mixture’s predictive performance (Figures 4.3 and 4.4).
• Further mathematical derivations in the Appendix (Section A.8) show that (i) the
simulation of signal intensities is not bijective. Input data such as antibody diversity
(nAb) cannot be restored from the signal intensity (output) space (Section A.8.1,
Footnote 22 page 131). (ii) The signal intensity subspace of unbiased mixtures is
considerably reduced compared to that of biased mixtures (Section A.8.2, Equation
S.7). This reduction depends both on peptide sequence length and the cardinality
of the amino acid alphabet (#AA).
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5 A minimal model of antibody-peptide
binding: in vitro validation of
mathematical predictions
Parts of this Chapter were recently published [104].
5.1 The predictive performance differs between monoclonal
and serum-antibody binding profiles
In order to test in vitro the in silico prediction that the regression model’s (Equation 4.8)
(i) predictive performance, the pairwise correlation of both (ii) signal intensity profiles
and (iii) AAWS increase with increasing antibody diversity (Figure 4.2), the predictive
performance of 58 BALB/c mouse serum samples (antibody diversity nAb ≫ 1, Mouse
study, Section 3.5.8) was compared with that of 13 human monoclonal IgG antibodies
(antibody diversity nAb = 1, Section 3.5.9). Both, monoclonal and serum antibodies were
incubated on microarrays with the peptide library J25514-mer (Table 3.1)1. Indeed, serum
antibodies showed both a significantly higher predictive performance (median Q2 = 0.39)
(Figure 5.1A, p < 0.001) and significantly higher pairwise correlations between AAWS
(Figure 5.1B, p < 0.001) than monoclonal antibodies (median Q2 = 0), which confirms
the predictions of the mathematical model (Section 4.3, Figure 4.2). The median pairwise
Pearson correlation2 of normalized monoclonal antibody binding profiles was found to be
r = 0.40, whereas that of BALB/c sera was determined to be r = 0.75 (Figure 5.4).
5.2 Predictive performance decreases in the course of an
HB-infection
In order to quantify the influence of immune response stage during the infection with the
murine parasite Heligmosomoides bakeri (HB, Nematoda) on predictive performance, the
mouse serum samples were divided into three groups: healthy, (HE), acute phase (AP,
10 and 14 dpi) and early chronic phase (CP, 18 dpi) (Section 3.5.8, Figure 3.1) [287].
In the course of the immune response, the predictive performance (Figure 5.2A) and
1Predictive performance values before and after secondary-antibody correction of both monoclonal and
serum incubations can be found in Figure S.4.
2The impact of the secondary detection antibody on monoclonal signal intensity was shown to be large
(Figure S.4). This is in contrast to the secondary detection antibody’s impact on signal intensity
profiles of serum antibodies (Section 3.5, page 32, Figure S.4).
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Figure 5.1: Predictive performance values and pairwise correlation of AAWS are higher for
serum IgM than for monoclonal antibodies. (A) Predictive performance values were calculated for
human monoclonal IgG (mAb, Section 3.5.9) and serum IgM antibody (Sera IgM) binding profiles
(BALB/c mice, Mouse study, Section 3.5.8). (B) The pairwise Pearson correlation (r) of the
corresponding AAWS w⃗j is shown. Sample numbers for the respective groups are: mAb, 13; sera
IgM, 58. Differences between monoclonal and serum IgM antibodies in predictive performance
(Q2) and pairwise correlation (r) of AAWS are significant (p < 0.001). Antibody binding profiles
were measured with the J25514-mer library. Corresponding AAWS (w⃗j) were determined using
Equation 4.8.
pairwise correlation of AAWS decrease significantly (Figure 5.2B) as does the pairwise
correlation of non-normalized IgM signal intensity profiles (Table 5.1). The decrease in
pairwise correlation of signal intensity profiles is due to biological (Table 5.1) and not
technological variability (Table 5.2): the intra-group median correlation of HE IgM signal
intensity profiles (r = 0.83; P < 0.001) is inferior to intra- and inter-array correlation of
HE sera (Tables 5.2 and 5.1)
5.3 Stages of murine immune response differ in their amino
acid-associated weights and signal intensity profiles
In order to test whether the AAWS determined for all 58 BALB/c mouse serum samples
differ systematically by stage of immune response (HE, AP, CP), principal component
analysis (PCA, Section 3.8.1) was used. Together, the first two principal components
yield a strong separation of healthy (HE) and diseased mice (AP, CP). Also, AP and
CP samples separate (Figure 5.3). Thus, during an immune response against HB, AAWS
change in a systematic way.
Likewise, (i) the corresponding IgM signal intensity profiles of sera of the different
stages of immune response as well as (ii) their ranks can be separated by PCA (Figures
S.2 and S.3).
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Figure 5.2: Predictive performance and pairwise correlation of AAWS decrease for serum IgM
antibodies in the course of the HB-infection. (A) Predictive performance values (Q2) were
computed from serum IgM antibody binding profiles across three stages of immune response:
healthy (HE), acute (AP), early chronic (CP). (B) The pairwise correlation (r) of the corresponding
AAWS w⃗j is shown. Numbers of BALB/c mouse serum samples: 15 samples from HE mice; after
infection with HB: 15 samples at 10 dpi and 13 samples at 14 dpi (AP), and 15 samples at 18
dpi (CP) totaling 58 BALB/c mouse serum samples. Differences in predictive performance (Q2)
between HE and both AP and CP mice are significant (p < 0.01), as are differences in pairwise
correlation (r) between all three stages of immune response (p < 0.001). Antibody binding
profiles were measured with the J25514-mer library. Corresponding AAWS (w⃗j) were computed using
Equation 4.8.
In order to characterize stages of immune response further, nested leave-one-out cross-
validation (LOOCV) using P-SVM was employed [278] (Section 3.8.2). P-SVM was
applied to the IgM signal intensity profiles of the three subproblems (HE–AP, HE–CP,
AP–CP). Balanced accuracies (BACC, Section 3.8.2, Equation 3.7) range from 80.0%
to 100% (Table 5.3). Notably, in order to obtain compact models only a small set of
peptides was used and all parameter combinations in the inner cross-validation loop for
which more than three models exceeded an upper limit of six selected peptides were
rejected (Section 3.8.2). The validation of the significance of the P-SVM classification
results was performed with permutation testing (Section 3.8.2). All three subproblems
led to p < 0.05 (Table 5.3).
Additionally, PSVM-nested cross-validation was applied to the ranks of IgM profiles.
BACCs are comparable to those found for signal intensities (83.3%–96.5%, Table 5.3).
For the subproblem HE–CP, ranks perform better than signal intensities (Table 5.3). All
three subproblems yield p < 0.01 (Table 5.3).
The successful classification of subproblems shows that the changes in binding patterns
induced by the immune response against HB are consistent across individuals of a group
(HE, AP, CP).
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Median intra-group
correlation coefficient (r)
Median inter-group
correlation coefficient (r)
HE 0.83
AP 0.79
CP 0.69
HE–AP 0.75
HE–CP 0.71
AP–CP 0.72
Table 5.1: Biological variability of random-sequence peptide array probing increases with pro-
gression of HB-infection. To evaluate changes in serum IgM profiles during an HB-infection
(BALB/c mice, Mouse study, Section 3.5.8), the biological variability of non-normalized IgM signal
intensity profiles within and among three groups of sera was investigated: pre-infection sera (HE),
acute infection sera (AP) and early chronic infection sera (CP) (Figure 3.1A). Median intra-group
correlation is highest for HE. Progression of infection is associated with a loss of correlation within
the groups of AP and CP. Median intra-group correlation was determined by the median of
pairwise non-redundant correlation coefficients between all serum samples of one group (p < 0.001
for all individual Pearson correlation coefficients). Inter-group correlation was calculated by taking
the median of the correlation coefficients between sub-arrays of microarray pairs (p < 0.001 for all
individual Pearson correlation coefficients). Differences between intra-group Pearson correlation
coefficients are significant (p < 0.001). Sample numbers for the respective groups are: HE, 15;
AP, 28; CP, 15.
Median intra-array
correlation coefficient (r)
Median inter-array correlation
coefficient (r)
901-18 0.96
901-19 0.94
901-20 0.93
901-18–901-19 0.90a
901-18–901-20 0.91
901-19–901-20 0.88
aTechnological variability was also assessed for all other experimental studies with repeated measurements
of healthy control sera. It was found to be generally above rPearson = 0.85 (Section 3.5).
Table 5.2: Assessment of the technological variability of random-sequence peptide array probing
with the J25514-mer library. To establish the technological variability of the experimental setup of
the Mouse study (Section 3.5.8), 3× 5 sub-array panels with the same serum obtained from an
uninfected (HE) BALB/c mouse were probed to evaluate inter- and intra-array correlation of
non-normalized IgM signal intensity profiles. For intra-array correlation, pairwise non-redundant
correlation coefficients between the five sub-array panels of each array were calculated and the
median was determined (Pearson r > 0.92; p < 0.001). Inter-array correlation, calculated by
taking the median of the correlation coefficients between sub-arrays of microarray pairs, was
found to be lower than intra-array correlation (Pearson r > 0.87; p < 0.001). Row names denote
the array identifiers.
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Figure 5.3: Stages of immune response differ in their AAWS. Principal component analysis was
applied to the 255× 58 signal intensity matrix (255 analyzed peptide signal intensities of library
J25514-mer times 58 BALB/c samples of the Mouse study, Section 3.5.8). The loadings of the first
4 principal components are shown. The first two principal components (PC1, PC2) separate
HE and diseased (AP, CP) mice whereas the second and the third principal component (PC2,
PC3) tend to separate AP and CP samples. Four components (PC1–PC4) explain 96.2% of the
variance in the data. Sample numbers for the respective groups are: HE, 15; AP, 28; CP, 15.
This significant consistency may not be with respect to the entire IgM profile or ranks
but certainly with regard to the small percentage of the library used by P-SVM. In fact,
removing the highly discriminatory peptides by subproblem from the data set (Section
3.8.2), considerably reduces the BACC of the subproblems HE–CP and AP–CP both
for IgM signal intensity profiles and their ranks (Table S.1). Only the selected peptides
for the subproblem HE–AP were not unique in their ability to classify IgM profiles and
ranks by stage of immune response with high accuracy (Table S.1).
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IgM signal intensity profiles
Subproblem BACC [%] Sensitivity [%] Specificity [%] Significance
(p-value)
HE–AP 100 100 100 0
HE–CP 80.0 66.7 93.3 0.04
AP–CP 84.4 86.7 82.1 0
Ranks
Subproblem BACC [%] Sensitivity [%] Specificity [%] Significance
(p-value)
HE–AP 96.5 92.9 100 0
HE–CP 83.3 73.3 93.3 0.006
AP–CP 89.8 86.6 92.9 0
Table 5.3: Assessment of the P-SVM balanced classification accuracy (BACC) for both IgM
signal intensity profiles and their ranks of subproblems of the Mouse study (BALB/c, Section
3.5.8, Figure 3.1). Signal intensity profiles were determined with the J25514-mer library. All BACCs
are higher than 83%. Determined BACCs were found to be significant (p < 0.05). Sample
numbers for the respective groups are: HE, 15; AP, 28; CP, 15.
5.4 Assessment of predictive performance values and pairwise
correlation of estimated AAWS and signal intensity profiles
by experimental study
In order to broaden the perspective beyond the Mouse study described in the previous
Sections, predictive performance values (Q2, Figure 5.4A), estimated AAWS (w⃗, Figure
5.4B) and signal intensity profiles of healthy individuals3 (S⃗, Figure 5.4C) were assessed
for all experimental studies described in Methods (Section 3.5): median predictive
performance values, analyzed by study, range from Q2 = 0.01 (NephroFIT study, human,
15-mers) to Q2 = 0.46 (NOD study, NOD mice), median pairwise Pearson correlation
of AAWS ranges from r = 0.63 (NephroFIT study, human, 13-mers) to r = 0.99 (NOD
study, NOD mice, 13-mers) and median pairwise Pearson correlation of signal intensity
profiles from r = 0.48 (NephroFIT study, human, 13-mers) to r = 0.95 (NOD study,
C57BL/6, 13-mers) (Figure 5.4)4.
Taken together, (i) murine samples show higher predictive performance values than
human samples (also on 15-mer libraries), (ii) on JPT arrays 13-mers yield consistently
higher Q2-values than 15-mers, (iii) and with respect to 15-mers, Pepscan arrays show
higher Q2-values than JPT arrays. (iv) However, independent of the manufacturer (JPT,
Pepscan), pairwise Pearson correlation of AAWS by study is relatively high across all
3For both the NephroFIT and the NephroFIT-Pepscan study, “No rejection” individuals were assessed
in this Figure, because no more than two samples of healthy controls were incubated in these studies.
“No rejection”-AAWS are highly correlated to AAWS of healthy controls (data not shown).
4Ranges of correlation coefficients with respect to both AAWS (Figure 5.4B) and signal intensity profiles
(Figure 5.4C) were found to be similar for Spearman correlation.
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AAWS and signal intensity profiles by experimental study
studies with murine samples showing highest correlation. The same is true5 for signal
intensity profiles (Figure 5.4).
Please refer to Chapter 8 for a comparative analysis of AAWS across experimental
studies.
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Figure 5.4: Assessment of (A) predictive performance values (Q2), (B) pairwise Pearson-
correlation (r) of estimated AAWS (w⃗), as well as of (C) normalized IgM signal intensity profiles
(S⃗) of healthy individuals by experimental study (Section 3.5). (For both the NephroFIT and the
NephroFIT-Pepscan study, “No rejection” individuals were assessed in this Figure, because no
more than two samples of healthy controls were incubated in these studies). Generally, the median
Q2 is highest for murine samples and lower peptide lengths (13-mer versus 15-mer). Pepscan
arrays show highest Q2-values for arrays with 15-mers. AAWS of each sample were determined
with Equation 4.8. Differences in predictive performance values between 13- and 15-mers are
significant (p < 0.05). Average AAWS are named according to the convention: Experimental
study-(Array manufacturer/Mouse model)-Peptide length.
5The minimum median correlation of r = 0.48 of serum signal intensity profiles is higher (i) than that
of monoclonal antibodies (r = 0.40, Section 5.1) and (ii) blank–serum correlation (Section 3.5).
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5.5 Assessment of the correlation of average AAWS with both
propensity scales for epitope prediction and amino acid
physico-chemical properties
Because of the high pairwise correlation of healthy AAWS found throughout all experi-
mental studies6, they were averaged by experimental study (Figure 5.5). Average AAWS
differ mostly by species (human, mouse) and array platform (JPT, Pepscan) (Figure
5.5). Whereas for murine samples, aromatic amino acids as well as methionine (M) and
glutamic acid (E) are top positive contributors to signal intensity, top ranking amino
acids for human samples incubated on JPT arrays are methionine (M) and proline (P).
Average AAWS of human samples incubated on Pepscan arrays showed mainly lysine
(K), histidine (H), proline (P) and tryptophane (W) as positively contributing amino
acids. For a further characterization of the technological variability of AAWS, consult
Chapter 8.
AAWS represent a priority scale for peptide-antibody binding assigning to every amino
acid the importance of contribution to the measured (or simulated) signal intensity. In
addition, analogously to QSAR modeling, AAWS can a posteriori be conceived of as
a vector representing correlates of the respective amino acids’ physico-chemical (PC)
properties. Therefore, average AAWS (Figure 5.5) were Spearman correlated with the
z-scale developed by Sandberg and colleagues (Table 5.4, [191]). The z-scale aggregates
in matrix form 26 PC amino acid properties for each of the 20 examined amino acids
(Table 3.2). The NephrOT study shows the highest number of correlation coefficients
exceeding a Spearman correlation of 0.5 (Table 5.4).
In order to compare the average AAWS with other published amino acid scales for epi-
tope prediction, they were Spearman correlated with four propensity scales (Section 1.7.3)
published by Parker and colleagues [194] (hydrophilicity), Kolaskar and Tongaonkar [288]
(antigenicity), Chou and Fasman [289] (secondary structure) and by Emini and colleagues
[197] (accessibility). The correlation of average AAWS with the described propensity
scales was found to be generally poor except for AAWS originating from Pepscan arrays
(NephroFIT-Pepscan, NephrOT, Table 5.5). Correlating the four mentioned propensity
scales among each other leads to coefficients ranging between rSpearman = −0.56 and
rSpearman = 0.68.
5.6 Summary
• The regression model (Equation 4.8) shows higher median predictive performance
values for serum than for monoclonal antibodies (Section 5.1, Figure 5.1). Fur-
thermore, the pairwise correlation of serum signal intensity profiles and AAWS is
significantly higher than that of monoclonal antibodies (Section 5). Thus, in vitro
data are in agreement with the predictions of the mathematical model (Figure 4.2).
6Except for the Mouse study, there are mostly no significant differences between 15-mer-AAWS between
different diagnosis groups of human studies (data not shown). This may be primarily explained be
the low a priori predictive performance (Q2) of 15-mers (Figure 5.4A).
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Figure 5.5: Average AAWS of healthy individuals differ by species (human, mouse) and man-
ufacturer (JPT, Pepscan). AAWS of healthy individuals were determined with Equation 4.8
and averaged by experimental study. (For both the NephroFIT and the NephroFIT-Pepscan
study, “No rejection” individuals were assessed in this Figure because no more than two samples
of healthy controls were incubated in these studies). The difference between two weights (wi)
indicates the contribution to the difference in normalized signal intensity corresponding to an
amino acid substitution. Top ranking amino acids are: (A–G) (human samples, JPT arrays): M,
P; (H–I) (human samples, Pepscan arrays): K, H, P, W; (J–0) (murine samples, JPT (contact
and non-contact printed)): F, W Y, E, M. Average AAWS are named according to the convention:
Experimental study-(Array manufacturer/Mouse model)-Peptide length.
• Median predictive performance decreases significantly in the course of a murine
HB-infection (Section 5.2, Figure 5.2A) as does the pairwise correlation of both
estimated AAWS (Figure 5.2B) and signal intensities (Table 5.1).
• Stages of immune response do not only differ by AAWS (Figure 5.3) but also by
IgM signal intensity profiles (Figure S.2) and their ranks (Figure S.3): changes in
binding patterns induced by the immune response against HB are consistent across
mice.
• In addition, size-restricted sets of selected peptides showed uniformly high prediction
accuracies both for IgM profiles (Section 5.3, Table 5.3) and ranks (Table 5.3) of
sera of healthy and HB-infected mice. Removing the selected peptides from the data
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5 A minimal model of antibody-peptide binding: in vitro validation of mathematical
predictions
Experimental study Number of absolute
Spearman correlation
coefficients higher
than 0.5
Physico-chemical properties
SHS-13 3 vdW, POLAR, Stot
SHS-15 0
Glioma09-15 0
Glioma08-15 3 TL1, TL2, TL5
Glioma08-13 3 TL1, TL2, TL5
NephroFIT-JPT-15 0
NephroFIT-JPT-13 0
NephroFIT-Pepscan-15 2 TL5, TL6
NephrOT-15 8 TL1, TL2, TL4, TL5, TL6, TL7, logP, HDONR
NS-C57BL/6-13 4 TL1, NM1, ELUMO, HA
NS-C57BL/6-15 2 NM1, ELUMO
NS-NOD-15 4 NM1, NM7, NM12, ELUMO
NS-NOD-13 5 TL1, NM1, NM12, logP, ELUMO
MS-C57BL/6-14 0
MS-BALB/c-14 0
Table 5.4: Assessment of the Spearman correlation of average AAWS with amino acid physico-
chemical (PC) properties (z-scale, Sandberg et al. [191]). The z-scale aggregates in matrix form 26
physico-chemical amino acid properties (listed below) for each of the 20 (19) (Table 3.2) examined
amino acids. AAWS of the healthy individuals (or “No rejection” for NephroFIT-studies) of each
experimental study were determined with Equation 4.8, averaged and Spearman-correlated with
the z-scale. Only those PC properties are shown, which showed absolute Spearman-correlation
coefficients higher than 0.5. The maximum absolute Spearman correlation coefficient is r = 0.74
(NephrOT-15, TL5). Correlation coefficients above r = 0.5 are significant (p < 0.05). MW
(molecular weight), TLx (thin layer chromatography at various conditions), vdW (side chain van
der Waals volume), NMx (NMR-proton shift at pD = x), logP (10log (octanol/water) partition
coefficient), EHOMO (energy of highest occupied molecular orbital), ELUMO (energy of lowest
unoccupied molecular orbital), HOF (heat of formation), POLAR (α-polarizability), EN (absolute
electronegativity), HA (absolute hardness), Stot (total accessible molecular surface area), Spol
(polar accessible molecular surface area), Snp (non-polar accessible molecular surface area),
HDONR (number of hydrogen bond donors), HACCR (number of hydrogen bond acceptors),
Chpos (indicator of positive charge in side chain), Chneg (indicator of negative charge in side
chain). Average AAWS are named according to the convention: Experimental study-(Array
manufacturer/Mouse model)-Peptide length.
set, decreases classification accuracy (Table S.1) of two of the three investigated
subproblems. Thus, P-SVM-selected peptides are partly unique in their ability to
classify IgM profiles and ranks with high classification accuracy.
• Median predictive performance values are higher for murine than for human samples.
AAWS from 13-mer libraries show higher Q2-values than those of 15-mers. Pepscan
arrays show highest Q2-values for human samples with respect to 15-mers (Section
5.4, Figure 5.4A). The correlation among AAWS of a given study is high (Figure
5.4B) as is that of IgM signal intensity profiles (Figure 5.4C), although to a lesser
extent. Thus, the mathematical predictions (Figure 4.2)—pertaining to a certain
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5.6 Summary
Experimental study Chou et al. (Sec-
ondary structure,
[289])
Emini et al. (Ac-
cessibility, [197])
Kolaskar et al.
(Antigenicity,
[288])
Parker et al.
(Hydrophilicity,
[194])
r p r p r p r p
SHS-13 0.22 0.37 0.06 0.80 -0.44 0.06 0.33 0.16
SHS-15 0.05 0.82 0.10 0.68 -0.20 0.41 0.19 0.43
Glioma09-15 0.26 0.29 0.21 0.38 -0.45 0.05 0.40 0.09
Glioma08-15 0.23 0.35 0.39 0.10 -0.32 0.19 0.23 0.35
Glioma08-13 0.33 0.17 0.18 0.45 -0.60 0.01 0.14 0.56
NephroFIT-JPT-15 0.14 0.56 0.20 0.42 -0.56 0.01 0.37 0.12
NephroFIT-JPT-13 -0.03 0.91 -0.18 0.46 -0.22 0.36 -0.08 0.74
NephroFIT-Pepscan-15 0.56 0.01 0.52 0.02 -0.33 0.17 0.43 0.07
NephrOT-15 0.64 0 0.69 0 -0.41 0.08 0.49 0.03
NS-C57BL/6-13 0.05 0.84 -0.06 0.80 -0.15 0.54 -0.29 0.23
NS-C57BL/6-15 0.22 0.37 0.11 0.65 -0.47 0.04 0.07 0.77
NS-NOD-15 0.10 0.68 0.02 0.94 -0.41 0.08 0.00 1.00
NS-NOD-13 0.05 0.83 -0.11 0.66 -0.11 0.67 -0.27 0.26
MS-C57BL/6-14 -0.19 0.41 0.08 0.75 -0.16 0.51 -0.23 0.33
MS-BALB/c-14 0.02 0.94 0.19 0.43 -0.18 0.45 -0.13 0.60
Table 5.5: Assessment of the correlation of average AAWS with selected amino acid propensity
scales for epitope prediction. AAWS of the healthy individuals (or “No rejection” for NephroFIT-
studies) of each experimental study were determined with Equation 4.8, averaged and Spearman
correlated with the listed propensity scales. Pepscan-AAWS (NephroFIT-Pepscan and NephrOT)
show the highest number of significant correlation coefficients (pSpearman < 0.05). Average
AAWS are named according to the convention: Experimental study-(Array manufacturer/Mouse
model)-Peptide length. Propensity scales were obtained from http://tools.immuneepitope.
org/tools/bcell/.
independence of antibody mixture and measured signal intensity profile—are valid
for both human and murine serum antibodies.
• AAWS of healthy individuals were averaged by experimental study. Average AAWS
differ by species and array platform (mouse vs. human, Pepscan vs. JPT, Section
5.4, Figure 5.5).
• Average AAWS are poorly correlated with amino acid physico-chemical properties.
However, NephrOT-AAWS are the exception with 8 out of 26 absolute Spearman
correlation coefficients higher than 0.5 (Section 5.5, Table 5.4).
• Average AAWS of most experimental studies show poor correlations with widely
used propensity scales for epitope prediction. The exception are Pepscan-AAWS,
which show absolute Spearman correlation coefficients higher than 0.5 and have
the highest number of significant correlation coefficients (Section 5.5, Table 5.5).
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6 A minimal model of antibody-peptide
binding: analysis of the impact of model
parameters on signal intensity profiles
In the following, the influence of model parameters on simulated signal intensity profiles
and predictive performance values is assessed. If applicable, experimental data are used
to determine whether changes of parameters entail collinear results in silico and in vitro.
6.1 Simulations show that the impact of both peptide length
and library size on predictive performance and recovery of
assigned AAWS is minimal
For unbiased mixtures, simulations show that neither the peptide library size (50–5000
randomly generated peptides) nor the peptide length (5–25 amino acids) greatly impact
predictive performance values. Across all tested library sizes and peptide lengths, the
predictive performance remains above Q2 = 0.95 (Figure 6.1).
Nevertheless, increasing the peptide library size has a slightly positive effect on pre-
dictive performance whereas higher peptide lengths have a slightly decreasing effect on
predictive performance (Figure 6.1).
6.2 Assessing the impact of total antibody concentration on
signal intensity and predictive performance
In this Section 6.2, a constant relative concentration within antibody mixtures is assumed
in order to study the impact of total antibody concentration on peptide signal intensity.
Assuming, without loss of generality, (i) that for given assigned AAWS h⃗, the peptide
string p⃗ i is the null vector (p⃗ i = 0⃗) and (ii) that a given antibody mixture AM1 is
composed of a single antibody a⃗1 such that the total antibody concentration is equal to
the concentration of antibody a⃗1 ([Ab]Total = [Ab]1). Then, the signal intensity Si for
peptide p⃗ i computes as follows:
Si =
[Ab]1 ∗ exp(0)
1 + [Ab]1 ∗ exp(0) =
[Ab]1
1 + [Ab]1
= [Ab]Total1 + [Ab]Total
. (6.1)
Thus, the simulated signal intensity is a monotone increasing nonlinear function of the
total antibody concentration, with signal intensities either saturating (Si → 1) if the total
6 A minimal model of antibody-peptide binding: analysis of the impact of model
parameters on signal intensity profiles
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Figure 6.1: Simulations show that for unbiased mixtures (nAb=10000) the predictive perfor-
mance is decreased for lower peptide library sizes and higher peptide length. However, for
both tested parameters, predictive performance does not fall below Q2 = 0.95. (A) Predictive
performance (Q2) decreases slightly with increasing peptide length but increases (slightly) with
library size. (B) The same is true for the correlation (r) between all pairs of estimated AAWS
w⃗isim as well as (C) for the recovery of assigned AAWS h⃗. In (A–C), random peptide libraries
with associated AACMs (Xsim) of 50–5000 peptides with 5–25-mers and assigned AAWS (⃗h) were
simulated once and kept constant across all respective simulation runs. For each peptide library
size and each peptide length, 50 simulations with newly generated unbiased mixtures were run.
Antibody binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim) were
determined using Equation 4.8.
antibody concentration tends to infinity ([Ab]Total →∞) or tending to zero (Si → 0) if
the total antibody concentration tends to zero ([Ab]Total → 0) (Figures 6.2 and 6.3).
In fact, also a peptide library’s mean simulated signal intensity (#Pi=1 Ssim,i) is a
monotone increasing function of the total antibody concentration (Figure 6.4A). Therefore,
ranks of (mean) simulated signal intensities are not affected by a varying total antibody
concentration (Figure 6.4B). Ranks are total antibody concentration ([Ab]Total) invariant.
Correspondingly, a significant dependence of total antibody concentration on in vitro
mean signal intensity (⟨S⃗⟩) is found for all but one tested experimental study with
Pearson correlation coefficients between signal intensity and total IgM concentration
ranging from r = 0.26 (Mouse Study) to r = 0.80 (NephrOT study) (Figure 6.5 and
Table 6.1).
Varying the total antibody concentration does not alter the predictive performance of
simulated antibody binding profiles: across all tested values of [Ab]Total (0.01–10000),
the predictive performance is high for unbiased mixtures (Figure 6.6B) and low for
monoclonal antibodies (Figure 6.6A). The slight decrease of predictive performance
values with growing total antibody concentration is due to the saturation of signal
intensities (Figure 6.2).
Accordingly, in vitro measurements show no evidence for a significant dependence of
predictive performance on total antibody concentration (Table 6.1).
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6.3 Assessing the impact of total antibody concentration on the clustering of signal
intensity profiles
Figure 6.2: Gaussian kernel density estimates of signal intensities (nAb = 10000, unbiased
mixture) in function of varying total antibody concentrations ([Ab]Total = 0.01–[Ab]Total = 10000)
are shown. Colors are meant to improve readability. A random peptide library with associated
AACM (Xsim) of 1000 14-mers and assigned AAWS (⃗h) were generated once and were kept
constant across all simulation runs. Antibody binding profiles were computed using Equation 4.1.
Simulated signal intensities were not normalized.
6.3 Assessing the impact of total antibody concentration on
the clustering of signal intensity profiles
The total antibody concentration does not only influence signal intensity values (Figures
6.2 and 6.3), but also the Pearson correlation structure of signal intensities due to its
nonlinear contribution to signal intensity (Equations 4.1 and 6.1). Signal intensity profiles
simulated with three different ranges of total antibody concentration were found to cluster
by range both hierarchically (Figure 6.9) and variance-wise (Figure S.13). Additionally,
signal intensity profiles could be classified by P-SVM nested cross-validation. Balanced
accuracies range from 83.3% to 91.7% (Section A.7, Table S.3).
However, the clustering behavior differs with respect to the chosen method of correlation.
Building the Spearman correlation matrix of the above simulated signal intensities
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6 A minimal model of antibody-peptide binding: analysis of the impact of model
parameters on signal intensity profiles
Figure 6.3: Gaussian kernel density estimates of signal intensity distributions (nAb = 1) in
function of varying total antibody concentrations ([Ab]Total = 0.01–[Ab]Total = 10000) are shown.
Colors are meant to improve readability. A random peptide library (Xsim) with associated AACM
of 1000 14-mers and assigned AAWS (⃗h) were generated once and were kept constant across all
simulation runs. Simulations were done with one antibody (nAb = 1). Antibody binding profiles
were computed using Equation 4.1. No normalization was applied to antibody binding profiles.
The switching of density plots from positive skew for low [Ab]Total to negative skew for higher
[Ab]Total is explained by Equation 4.1.
yields the identity matrix, which is due to the monotonic influence of total antibody
concentration on signal intensity values (Figure 6.4) leaving ranks of signal intensities
invariant (Section 6.2). The Spearman correlation is the Pearson correlation of the ranks
of the input data (Section 3.9.1).
Thus, simulations suggest that monotonic changes in signal intensity profiles—induced
by total antibody concentration differences—can be detected by Pearson correlation
analysis. In addition, non-monotonic differences in signal intensity profiles such as
rank changes—induced by antibody dominance (Section 4.3.4, Figures 4.3 and 7.1)—are
detectable by Spearman correlation analysis.
Applying this knowledge to the Slovenian healthy study (SHS), the clustering of
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6.4 Assessing the impact of the assigned AAWS distribution on signal intensity and
predictive performance
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Figure 6.4: Mean simulated signal intensities vary in monotone increasing fashion with the total
antibody concentration. (A) Mean signal intensities, obtained by averaging over all peptide signal
intensities of a simulated peptide library (
#P
i=1 Ssim,i), as well as (B) their ranks are displayed
in function of total antibody concentrations. Colors are meant to improve readability. Total
antibody concentrations ([Ab]Total) were varied between [Ab]Total = 0.01 and [Ab]Total = 10000.
A random peptide library with associated AACM (Xsim) of 1000 14-mers and assigned AAWS
(⃗h) were generated once and were kept constant across all simulation runs. Simulations were
performed with unbiased mixtures (nAb = 10000). Antibody binding profiles were computed
using Equation 4.1. No normalization was applied to antibody binding profiles.
signal intensity profiles by healthy volunteer (Figures 6.8A–D) is suggested to be more
likely due to dominant antibodies with volunteer-specific binding behavior than to total
IgM concentration differences between healthy volunteers (Figure 6.7). In addition, the
clustering of ranks by volunteer indicates that the putative dominant antibodies do not
change over the sample collection period (1 month, Section 3.5.1).
6.4 Assessing the impact of the assigned AAWS distribution on
signal intensity and predictive performance
In order to study in silico the influence of the distribution of assigned AAWS on simulated
signal intensities and predictive performance, the components of assigned AAWS (⃗h)
were set to 0 except for one component which was set to 1. Resulting signal intensity
profiles for monoclonal antibodies (Figure 6.10A) and unbiased mixtures (Figure 6.10B)
are multimodal. This multimodality is explained by examining the monoclonal case
(Figure 6.10A); due to the chosen h⃗, most peptides (p⃗ i) will be equivalent to the null
vector yielding a signal intensity (Si) of 0.5. Therefore, for a total antibody concentration
([Ab]Total) of 1, the kernel density estimates of the signal intensity profiles peak at 0.5
(Figure 6.10A). The remaining peaks are explained by peptides possessing at least one
amino acid with a non-zero weight.
Of note, within the tested range of total antibody concentrations, predictive perfor-
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6 A minimal model of antibody-peptide binding: analysis of the impact of model
parameters on signal intensity profiles
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Figure 6.5: Assessment of the dependence of mean signal intensity on IgM concentration by
experimental study. Corresponding correlation coefficients are displayed in Table 6.1. Signal
intensities and IgM concentrations for the respective studies were measured as detailed in Section
3.5. The mean signal intensity was calculated by averaging over all non-normalized peptide
signal intensities of an analyzed peptide library (
#P
i=1 Si). Subplots are named according
to the convention: Experimental study-(Array manufacturer/Mouse model)-Peptide length.
Experimental studies displayed are those for which the serum or plasma was diluted 1:10 and
IgM concentration data were available (Section 3.5).
mance is not affected by a change in assigned AAWS h⃗ for neither unbiased mixtures nor
monoclonal antibodies (data not shown as Figures are analogous to Figure 6.6)
6.5 Violating the assumption of the random generation of
antibody sequences decreases predictive performance
Previously, antibody sequences were simulated in random, i.i.d.-fashion, such that they
were no more than randomly correlated (Section 4.2). In order to simulate correlated
antibody mixtures, increasing Gaussian noise (until σ = 10) was added to 40 different
antibody sequences (Section 3.6.3, Figure 3.2). Thereby, antibody mixtures of 10000
antibodies each were built. Figure 6.11 shows that the predictive performance as well as
the recovery of assigned AAWS h⃗ is low when the correlation between antibody sequences
is high (Table 3.4). This is similar to low-diversity antibody mixtures (Figures 4.2A and
C). With increasing noise amplitude—thereby increasing the decorrelation1 of simulated
antibody mixtures (Table 3.4)—predictive performance values and recovery of assigned
1The explanation of the term “decorrelation” is found in Section 3.6.3.
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6.5 Violating the assumption of the random generation of antibody sequences decreases
predictive performance
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Figure 6.6: Simulations show that the predictive performance is marginally impacted by a
varying total antibody concentration ([Ab]Total =0.01–10000) for both (A) monoclonal antibodies
(nAb = 1, rPearson = −0.20, rSpearman = −0.36) and (B) unbiased mixtures (nAb = 10000,
rPearson = −0.21, rSpearman = −0.98). Colors are meant to improve readability. A random peptide
library with associated AACM (Xsim) of 1000 14-mers and assigned AAWS (⃗h) were generated
once and were kept constant across all simulation runs.
+HDOWK\YROXQWHHULQGH[
,J
0
F
RQ
FH
QW
UD
WLR
Q
>P
J
P
O@







●
●
●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Figure 6.7: Slovenian healthy study: IgM concentrations show low intra but high inter-volunteer
differences with up to a tenfold differences between volunteers (e. g. V7 compared to V4). Number
of samples: 48, 3 samples for each of the 16 healthy volunteers (V*, Section 3.5.1).
AAWS h⃗ improve (Figure 6.11), eventually reaching values similar to those of unbiased
mixtures (Figures 4.2A and C).
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Experimental study Correlation: [IgM] vs. Mean SI
rPearson pPearson rSpearman pSpearman
Glioma08-13 0.77 0.00 0.71 0.00
Glioma08-15 0.73 0.00 0.71 0.00
NephrOT-15 0.80 0.00 0.65 0.00
SHS-13 0.50 0.00 0.60 0.00
SHS-15 0.56 0.00 0.60 0.00
MS-BALB/c-14 0.26 0.15 0.41 0.02
Correlation: [IgM] vs. Q2
Glioma08-13 -0.11 0.45 -0.16 0.28
Glioma08-15 0.08 0.56 -0.03 0.85
NephrOT-15 0.24 0.20 0.04 0.84
SHS-13 -0.12 0.43 -0.10 0.49
SHS-15 -0.07 0.63 -0.14 0.33
MS-BALB/c-14 -0.13 0.48 -0.08 0.67
Table 6.1: Correlation coefficients and corresponding p-values between IgM concentration ([IgM])
and both mean signal intensity (Mean SI) and predictive performance values (Q2) are tabled
by experimental study. The mean signal intensity (
#P
i=1 Si) was calculated by averaging over a
peptide library’s non-normalized signal intensity profile. Signal intensities and IgM concentrations
for the respective studies were measured as detailed in Section 3.5. Experimental studies are
named according to the convention: Experimental study-(Mouse model)-Peptide length.
Thus, the violation of the i.i.d.-assumption of antibody sequence generation negatively
impacts predictive performance. This impact differs with respect to monoclonal antibody
strength2. Therefore, not only an antibody mixture’s diversity but also its composition
have an impact on predictive performance: mixtures which are both highly diverse and
highly correlated (Figure 6.11A) yield predictive performance values similar to those
yielded by low-diversity random mixtures (Figure 4.2A).
6.6 Summary
• The predictive performance and recovery of assigned AAWS of unbiased mixtures
are robust against variations in peptide library size and peptide length. For the
tested ranges of both parameters, the median predictive performance remains well
above Q2 = 0.95. However, increased peptide length slightly decreases predictive
performance and higher peptide library sizes result in a slight increase of both
predictive performance and recovery of assigned AAWS (Section 6.1, Figure 6.1).
• A growing total antibody concentration leads to the saturation of simulated signal
intensities (S⃗ → 1⃗) whereas if total antibody concentrations tend to 0, simulated
signal intensities will tend to 0 (S⃗ → 0⃗, Section 6.2, Figures 6.2 and 6.3). In
2For further information on antibody strength, please refer to Section 7.2.
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6.8A: Heatmap of SI, 13-mers
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6.8B: Heatmap of SI, 15-mers
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6.8C: Heatmap of ranks, 13-mers
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6.8D: Heatmap of ranks, 15-mers
Figure 6.8: Slovenian healthy study: antibody binding profiles and their ranks cluster mostly by
healthy volunteer. The heatmaps (Section 3.9.2) of 13- and 15-mer IgM signal intensity profiles
(A and C) and their ranks (B and D) are shown. Heatmaps were built based on the Pearson
correlation matrix of non-normalized signal intensities and ranks. Hierarchical clustering recovers
(A) 11, (B) 10, (C) 11, (D) 10 out of 16 triplets, where “triplet” denotes the three samples obtained
from each healthy volunteer (Section 3.5.1). IgM signal intensity profiles were measured with
the peptide libraries of J230413-mer and J341815-mer peptides for 13- and 15-mers, respectively. Number of
serum samples: 48, 3 samples for each of the 16 healthy volunteers (V*).
agreement with simulation results (Figure 6.4), in vitro data show for most tested
experimental studies a significant dependence of mean signal intensity on total IgM
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Figure 6.9: Simulations show that total antibody concentration differences have an impact on
Pearson-based hierarchical clustering of antibody binding profiles of unbiased mixtures (nAb =
10000). Thirty different total antibody concentrations ([Ab]Total) were randomly drawn from
each of the three different Gaussian distributions N (0.5, 0.25), N (1, 0.25) and N (1.5, 0.25) [shown
in the column labels of the heatmap] termed “low” (green), “middle” (red), and “high” (blue)
[row labels], respectively, to simulate antibody binding profiles (Equation 4.1). Subsequently,
non-normalized signal intensity profiles (255 random 14-mers) were subjected to Pearson-based
hierarchical clustering (Section 3.9.2). Across all simulation runs, the unbiased mixture was held
constant. PCA of the simulated signal intensity profiles shows clustering as well (Figure S.13).
concentration (Figure 6.5, Table 6.1).
• Predictive performance values are marginally influenced by the tested range of total
antibody concentrations both in simulations (Section 6.2, Figure 6.6) and in vitro
(Table 6.1).
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Figure 6.10: Gaussian kernel density estimates of signal intensity profiles are dependent on
assigned AAWS. A simulated random peptide library with associated AACM (Xsim) of 1000
14-mers and assigned AAWS (⃗h = (0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1)T) were generated
once and were kept constant across all simulation runs. Simulations were done with (A) one
antibody (nAb = 1, [Ab]Total = 1) and (B) an unbiased mixture (nAb = 10000, [Ab]Total = 1).
Antibody binding profiles were computed using Equation 4.1.
• Due to its nonlinear and monotonic increasing impact on simulated signal intensities
(Section 6.2, Figure 6.4), the total antibody concentration has an influence on the
clustering of simulated signal intensity profiles in case of Pearson correlated signal
intensity profiles (Figures 6.9 and S.13, Table S.3). No influence on Spearman corre-
lation of simulated profiles was evident (Section 6.3). Consequently, experimentally
determined signal intensity profiles of samples from the Slovenian healthy study
are suggested to cluster rather due to relative antibody mixture differences (e.g.
different rank-altering antibody dominances, Figure 4.3) than due to differences in
total IgM concentrations (Figures 6.7 and 6.8).
• The distribution chosen for assigned AAWS h⃗ influences the modality of signal
intensity distributions (Section 6.4, Figure 6.10). However, the studied distribution
change has no impact on predictive performance.
• Simulations show that a violation of the i.i.d.-assumption of antibody sequence
generation decreases predictive performance and recovery of assigned AAWS (Sec-
tion 6.5, Figure 6.11). Both an antibody mixture’s diversity and composition have
an impact on predictive performance: mixtures which are both highly diverse and
highly correlated (Figure 6.11A) yield predictive performance values similar to
those yielded by low-diversity random mixtures (Figure 4.2A).
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Figure 6.11: Simulations show that highly correlated antibody mixtures yield low predictive
performance values. (A) The predictive performance (Q2) of antibody mixtures which are
correlated to varying degrees is shown. (B) The correlation of estimated AAWS (w⃗isim) with the
assigned AAWS h⃗ is shown. A random peptide library with associated AACM (Xsim) of 1000
14-mers and assigned AAWS (⃗h) were generated once and were kept constant across all simulation
runs. Antibody binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim)
were determined using Equation 4.8. The 20 “strongest” (highest ⟨yi,k⟩ = ⟨(ak)Tpi⟩) and “weakest”
monoclonal antibodies (lowest ⟨yi,k⟩ = ⟨(ak)Tpi⟩) of the 500 monoclonal antibodies used in Figure
7.1A were chosen for this simulation. Based on the chosen 40 antibodies, antibody mixtures of
10000 antibodies with varying degree of correlation were generated (Section 3.6.3, Figure 3.2,
Table 3.4). The Gaussian noise term used had the following parameters: N (µ = 0, σ = x) with x
ranging from 0 to 10.
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7.1 Signal intensity profiles as well as AAWS of simulated
monoclonal antibodies are isotropically distributed in the
variance space
Simulations show that signal intensity profiles as well as AAWS of 500 randomly generated
antibodies are isotropically distributed in the space spanned by the first two principal
components (Figures 7.1A and 7.1B). Thus, variance-wise, clustering of both simulated
signal intensities and AAWS of biased antibody mixtures is only possible if the biasing
dominant antibodies have similar binding properties with respect to the peptide library
studied (Figures 7.1C and 7.1D).
7.2 Simulated monoclonal antibodies can be separated into
two groups based on their performance to recover assigned
AAWS
Simulated monoclonal antibodies can be separated into two different groups according to
a criterion termed “antibody strength”. Strong antibodies are defined as yielding a mean
binding association (⟨yi,k⟩|k=const = ⟨(⃗ak)Tp⃗ i⟩ =

i

z a
k
zp
i
z) higher than 0.5. Otherwise,
antibodies are termed “weak”.
AAWS, but not signal intensity profiles, of weak and strong antibodies can be separated
by PCA (Figures 7.2A and B)1. Strong antibodies cluster in the variance space spanned
by PCA because they are—in contrast to weak antibodies—highly correlated to assigned
AAWS (Figure 7.2I). Sequences of strong antibodies show a higher number of positive
components, higher mean signal intensities2 and slightly higher predictive performance
values (Figures 7.2D, E and H).
Strong antibodies recover assigned AAWS h⃗ well because they have a high number of
positive components. In fact, both the number of positive components (Figure 7.2D) and
the components’ means (Figure 7.2E) are highly correlated to the recovery of assigned
AAWS h⃗ (Figure 7.2I, rPearson, Spearman > 0.84). The more the number of positive and
1Higher order principal components do not show any separation of signal intensities by antibody strength
either (data not shown).
2This observation is only possible if signal intensities were neither log-transformed nor set to zero mean
and unit variance.
7 A minimal model of antibody-peptide binding: monoclonal antibodies
A
PC 1
P
C
2
−0.10
−0.05
0.00
0.05
0.10
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
2122
23
24 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
4243
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
5960
61
2
63
64
65
66
67
68
69
70
71
72
73
74
75 76
7778
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115 116
117
118
119
120
121
122
123
24
125
126
7
128
129
130
131
132
133
134
135
136137
1 8
139
140
141
142
143
144
145
146
147
148
149
150
151
1521 3
154
15
156
57
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189190
191
192
193
194
195
196
197
198
199
200
201
202
03
204
205
206
207
208
209
210
211
212
213
2
215
216
217
218
219
220
221
222
223
224
225
226
227
228229
230
231
232233
234
235
236
237
238
239
240
241
242
243
244
245
246 247
48
249
250
251
252
253
254
255
256257
258
259260
261
262
263
264
265
2 6
267
268
269
270271
272 273
274
275
276
277
278
27980
281
282
283
284
285
286
287
288
289
290
2 1
292
293
2 4
295
296
29
298
299
300
301
302
303
304
305
306
307
308
309310
311 312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
3 9
330
331
332333
334
335336
337
338
339
340
341
342
343
34
345 46
47
348
349
350
351
352
353
354
355
356
357
358
359 360
361
362
363
364
365
366
367
368
3 9
370
371
372
373
374
375
3 6377
378
379
380
381
382
383
384
385
386
387 388
389
390
391 392
393
394
395
396
397
398
399
400
401
402
403
404405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429430
431
432
433
434 435
436
437
438439
4 0
44
442
43
444
445
446
447
448
449
450
451
452
45
454
455
456
457
458
459
460
461462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499 500
−0.10 −0.05 0.00 0.05 0.10
B
PC 1
P
C
2
−0.10
−0.05
0.00
0.05
0.10
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
3435
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
6364
65
66
67 68
69
70
71
72
73
74
7576
77
78
79
80
81
82
83
84
85
86
87
88
8990
91
92
93
94
9596
97
98
99
100
101
102
103
104 105
106
107
1 8
109
110
111112
113
11
115
116
117
118
119
120
121
122
123
12425
126
127
128
129
130
131
132
133
134
135
1 6
137
138
139
140
141
142
143
144
145
1 6
147148
149
150
151
152
153
154
155156
15
158
159
160
161
162
163
164
165166
167
168 169
170 171
172
173
174
175
17177
178
179
180
81
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
21
212 13
214
215
216
217
218
219
220
221
222
223
224
225
6
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
2 243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
25
5
260
261
262
263
64
265
266
267 268
269
270
271
272
273
274
27
276
277
278
79
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
96
297
298
299
300
30
302
303
304
305
306
307
308
309
10
31312 313
314
315
316
317
318
319
320
321
322
323
324
325
2
7
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
3 5
346
347
348
349
350351
52
353
354
355
356
357
358
359
36
361
362
363
364
365366
367
368
369
370
71
372
373
374
375
76
377
378
9
380
38382 383
384
385
386
387
388
389
390
391392
393
394
95
396
397
398
99
400
401
402
403 404
405
4 6
07
408
409
410
411
2
413
414
415 416
417
418
419
420
421
422
423
424
425426
427
428
429
4 0
431
43
433
434
4 5
436437
438
9
440
441
442
443
444
445
446
447
4 8
449
450
451
452
453
454
455
456
457
458
59
460
46
462
463
464
465
466
467
468
469
470
471
472
473 474
475
476
477
478
479
480
481482
483
4 4
485
486
487
488
48
490
491
92493494
495
496
4 7
498
499
500
−0.10 −0.05 0.00 0.05 0.10
C
PC 1
P
C
2
−0.2
−0.1
0.0
0.1
0.2
113
113 113113113113
113
113
197197 197197197
unbiasedunbiased
unbiasedunbiasedunbiasedunbiasedunbiased i sunbiased
unbiased
−0.190 −0.185 −0.180
D
PC 1
P
C
2
−0.2
−0.1
0.0
0.1
11313
113 113113
1 3
113113113
113
197197197197 197197
197197197
unbiasedunbiased
unbiasedunbiasedunbiased
unbiased
i
unbiased
−0.20 −0.19 −0.18 −0.17
Figure 7.1: Normalized simulated signal intensity profiles and AAWS of biased mixtures separate
in the space spanned by the first two principal components if dominant antibodies show similar
binding properties with respect to the peptide library used. (A) Normalized signal intensity profiles
and (B) AAWS of 500 random simulated monoclonal antibodies are shown in the two-dimensional
space spanned by the first two principal components (PC1, PC2). (C) Ten signal intensity profiles
of biased mixtures of 10000 antibodies in which one dominant antibody, labeled “113” or “197”, is
increased 1000-fold in concentration were simulated. The dominant antibodies were kept constant
across simulation runs, whereas the other 9999 antibodies were varied for each of the ten runs.
In addition, ten signal intensity profiles of an unbiased mixture of 10000 antibodies (labeled as
“unbiased”) were computed. The 30 (10+10+10) signal intensity profiles are shown in the space
spanned by first two principal components as are (D) their corresponding AAWS. The first two
principal components explain 21.2% (A), 62.7% (B) , 95.7% (C) and 99.7% (D) of the variance in
the data, respectively. In (A–D) a random peptide library with associated AACM (Xsim) of 255
14-mers and assigned AAWS (⃗h) were generated once and were kept constant across all simulation
runs. Antibody binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim)
were determined using Equation 4.8.
84
7.2 Simulated monoclonal antibodies can be separated into two groups based on their
performance to recover assigned AAWS
negative components is equilibrated in an antibody sequence (e.g. for l = 14: 7 negative
and 7 positive components) or the more the components’ means tend to zero, the more
likely it is that the recovery of assigned AAWS tends to zero (r → 0). In contrast, the
more antibody sequences are biased toward positive or negative components, or the
higher or lower the components’ means are, the more likely it is that the recovery of
assigned AAWS tends to 1 or −1, respectively.
$
3&
3
&

í
í



























































 



























 


















 




 








































 



































 

















 












 




 



 






 

































 















































 





























 










 









 




 





















































 
















































í í   
%
3&
3
&

í
í







 






















































 








 












































































































 























 





















































































 


















 




























 




















































 

















 







 






 

 












 

















 

 







 
 







 


í í   
&
FR
XQ
W







í í    
'
1
XP
EH
UR
IS
RV
LWL
YH
F
RP
SR
QH
QW
V
LQ
$
E
VH
TX
HQ
FH
V






●
●
●
●
●
●
●
●
VWURQJ
DQWLERG\
ZHDN
DQWLERG\
(
0
HD
Q
RI
F
RP
SR
QH
QW
V
RI
$
E
VH
TX
HQ
FH
V
í
í
í




●
VWURQJ
DQWLERG\
ZHDN
DQWLERG\
)
0
HD
Q
EL
QG
LQ
J
DV
VR
FL
DW
LR
Q
\
L
N	
í
í



●
●
VWURQJ
DQWLERG\
ZHDN
DQWLERG\
*
0
HD
Q
VL
JQ
DO
LQ
WH
QV
LW\






VWURQJ
DQWLERG\
ZHDN
DQWLERG\
+
3
UH
GL
FW
LY
H
SH
UIR
UP
DQ
FH
4
 	
í




 ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
VWURQJ
DQWLERG\
ZHDN
DQWLERG\
,
&
RU
UH
OD
WLR
Q
EH
WZ
HH
Q
K
DQ
G
Z
VL
PL
U	
í


VWURQJ
DQWLERG\
ZHDN
DQWLERG\
Figure 7.2: Strong antibodies show a better recovery of assigned AAWS h⃗ compared to weak an-
tibodies. (A) Normalized signal intensity profiles and (B) AAWS of the 500 simulated monoclonal
antibodies of Figure 7.1 are shown in the space spanned by the first two principal components
(PC1, PC2). Strong antibodies, shown in red, are defined as having a mean binding association
(⟨yi,k⟩) higher than 0.5. (C) A histogram of the 500 mean binding associations (⟨yi,k⟩) shows
that there are more weak (n = 403) than strong antibodies (n = 97). (D) Compared to weak
antibodies, strong antibodies have a higher number of positive components, (E) which results
in higher component means, (F) per definitionem higher mean binding associations, (G) higher
mean non-normalized signal intensities (
#P
i=1 Ssim,i), (H) slightly higher predictive performance
values (Q2), as well as (I) a better recovery of assigned AAWS h⃗. Differences between boxplots
are significant (p < 0.05).
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7 A minimal model of antibody-peptide binding: monoclonal antibodies
7.3 The criterion of antibody strength is robust against peptide
library changes but not against changes in assigned AAWS
The binding association yi,k (Equation 4.1) is determined by two variables: (i) antibody
and (ii) peptide sequence. It is therefore of interest to determine, whether the criterion
of antibody strength depends on the given peptide library.
Simulations show that—assigned AAWS being constant—a change of peptide library
alters marginally the subset of strong antibodies (Figure 7.3A). This is due to the random
generation of peptide libraries which results in a similar mean binding association per
antibody3 (⟨yi,k⟩).
In contrast, antibody strength is sensitive to varying assigned AAWS h⃗ (Figures 7.3B
and C): the number of strong antibodies found for a given peptide library is highly
correlated to the mean of the components of given assigned AAWS (r = 0.99). Thus,
assigned AAWS modulate the number of strong and weak antibodies found for a given
peptide library.
7.4 Assessment of the in vitro evidence for antibody strength
The assessment of antibody strength in vitro can only be done indirectly. This is so
because assigned AAWS of the used peptide libraries are not known a priori which renders
the assessment of the quality of their recovery, one of the primary defining features of
strong antibodies (Figure 7.2I), unattainable. Simulations (Figure 4.2) predict that the
higher the predictive performance of an antibody mixture (or a monoclonal antibody),
the better the recovery of assigned AAWS h⃗ should be.
Assuming that estimated AAWS (w⃗) of healthy BALB/c mice (Section 5.1) near
assigned AAWS h⃗ of the J25514-mer-library, simulations predict that the Pearson correlation
between estimated AAWS (w⃗) of monoclonal antibodies and estimated AAWS of healthy
BALB/c mice increases with increasing predictive performance of monoclonal antibodies4.
Indeed, predictive performance of monoclonal antibodies positively correlates (rPearson =
0.86, rSpearman = 0.89)5 with the correlation between AAWS of monoclonal antibodies
and AAWS of healthy BALB/c mice (Figures 7.4A and 7.4C).
However, mean raw signal intensities of monoclonal antibodies6 only Pearson/Spearman
correlate poorly with predictive performance (rPearson = 0.22, rSpearman = 0.32) or
the median correlation between estimated AAWS of monoclonal and BALB/c serum
antibodies (rPearson = 0.23, rSpearman = 0.45), which is in contrast to simulation results
3Antibody strength is only independent of the given peptide library, assuming assigned AAWS are kept
constant, up until a certain minimal library size (data not shown).
4Both monoclonal antibodies and sera of BALB/c mice were incubated on the J25514-mer library (Table
3.1).
5Both correlation coefficients are significant (p < 0.01).
6Normalization of monoclonal antibody binding profiles was not performed for the here described
correlation as it would have rendered the analysis pointless. The high impact of detection antibodies
on raw signal intensity profiles (Figure S.4), however, could have biased the performed correlation
analysis.
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Figure 7.3: The criterion of antibody strength, which divides simulated antibodies into weak and
strong antibodies, is robust against changing peptide libraries but sensitive to varying assigned
AAWS h⃗. The strength of the 500 monoclonal antibodies of Figure 7.1 was determined with
respect to a library of 255 14-mers of which either (A) the composition, (B) the assigned AAWS
(⃗h) or (C) both the composition and assigned AAWS (⃗h) were altered. For each case (A, B, C) 100
simulations were run. In (A–C) for each simulation run, the strong antibodies were determined,
compared for correspondence with the strong antibodies determined for the peptide library and
assigned AAWS used in Figure 7.1. Subsequently, the number of corresponding strong antibodies
was divided by the total number of strong antibodies of Figure 7.1 thus forming the ratio which
constitutes the y-axis. This ratio can, by definition, exceed 1.
(Figures 7.2G–I). Summarizing, in vitro results are in accord with simulation results in
that monoclonal antibodies which have higher predictive performance values are also
higher correlated to AAWS of highly diverse antibody mixtures. However, the in silico
concept of antibody strength is only partly supported by in vitro antibody-peptide
reactivity data.
Of note, the predictive performance of monoclonal antibodies correlates negatively with
the correlation between AAWS from monoclonal antibodies and AAWS from healthy
individuals from the SHS (rPearson = −0.48, rSpearman = −0.54)7. In addition, whereas
estimated AAWS of monoclonal antibodies “VB142” and “eiJB40” correlate highest with
AAWS of BALB/c sera (Figure 7.4A), estimated AAWS of the monoclonal antibody
“VB176” correlate highest with AAWS of human sera (Figure 7.4B).
7Both correlation coefficients are not significant 0.05 < pPearson, pSpearman < 0.10.
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Figure 7.4: Predictive performance of monoclonal antibodies correlates positively with the
median Pearson correlation between AAWS of monoclonal antibodies and AAWS of healthy
BALB/c mice. The Pearson correlation of estimated AAWS of 13 monoclonal antibodies with
both (A) 15 AAWS of sera of healthy BALB/c mice (MS) and (B) 48 AAWS of human samples
(SHS) are shown. (C, D) The median correlation coefficients of each boxplot in (A, B) were
determined and plotted in function of the predictive performance values of monoclonal antibodies
(C: rPearson = 0.86, rSpearman = 0.89, pPearson, Spearman < 0.01, D: rPearson = −0.48, rSpearman =
−0.54, 0.05 < pPearson, Spearman < 0.10). Antibody binding profiles of monoclonal antibodies and
sera were determined as detailed in Sections 3.5.1, 3.5.8 and 3.5.9.
7.5 Antibody strength impacts antibody binding profiles of
correlated antibody repertoires
Simulations show that the predictive performance of correlated antibody repertoires is
dependent on antibody strength (Figure 6.11). For antibody repertoires based on strong
antibodies, an increasing decorrelation (Table 3.4) leads to higher predictive performance
values of generated antibody repertoires nearing perfection for a noise amplitude of
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N (µ = 0, σ = 10). This is partly in contrast to the behavior of correlated antibody
repertoires of weak antibodies for which up to a certain noise amplitude, predictive
performance does not increase. However, for high noise amplitudes, (N (µ = 0, σ = 5)
and N (µ = 0, σ = 10)), predictive performance values of antibody repertoires generated
on the basis of weak antibodies are analogous to those based on strong antibodies. The
explanation for the difference in predictive performance values between weak and strong
antibodies for low and medium noise terms is similar to that for the weak antibodies’
poor recovery of assigned AAWS (Section 7.2). Weak antibody sequences are biased to
possessing negative components (Figure 7.2D). Adding Gaussian noise terms to these
antibody sequences results in a transient equilibration of positive and negative components
which was suggested (Section 7.2) to be the cause of a poor recovery of AAWS.
7.6 Summary
• Signal intensity profiles and AAWS of random simulated monoclonal antibodies are
isotropically distributed in the variance space. Therefore, clustering of simulated
signal intensity profiles and AAWS in the space spanned by PCA is dependent on
dominant antibodies which have similar binding patterns with respect to a given
peptide library (Section 7.1, Figure 7.1).
• Within the variance space spanned by PCA, AAWS of a subset of simulated
monoclonal antibodies—strong antibodies—cluster but not their corresponding
signal intensity profiles (Figure 7.2A and B).
• Strong antibodies—defined as showing a mean binding association (⟨yi,k⟩) higher
than 0.5— differ from weak antibodies by having a higher number of positive com-
ponents, higher non-normalized mean signal intensities, slightly higher predictive
performance values and an enhanced recovery of assigned AAWS h⃗ (Section 7.2,
Figure 7.2).
• The criterion of antibody strength is robust against peptide library changes but
sensitive to varying assigned AAWS (Section 7.3, Figure 7.3).
• The in silico concept of antibody strength is only partly supported by in vitro
antibody-peptide reactivity data (Section 7.4, Figures 7.4 and 7.2G–I).
• The predictive performance of monoclonal antibodies correlates positively with
the correlation between AAWS of monoclonal antibodies and AAWS of healthy
BALB/c mice (Section 7.4, Figures 7.4A and 7.4C). This in accord with predictions
made by the mathematical model (Figure 4.2).
• The correlation structure of AAWS of monoclonal antibodies with AAWS of healthy
BALB/c mice (Figures 7.4A and 7.4C) differs from that observed with AAWS of
human individuals (Figures 7.4B and 7.4D).
• Correlated antibody repertoires behave differently regarding predictive performance
depending on the antibody strength of the monoclonal antibody they were generated
from (Section 7.5, Figure 6.11).
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8 Technological analysis of
antibody-peptide reactivity data
Parts of this Chapter were recently published [104].
The predictive performance of AAWS estimated from in vitro measurements of sera
is not perfect (Section 5.2, Figure 5.1). This could at least be in part due to noise in
signal intensity measurements. In the following, it is attempted to study with the help
of simulations the influence of noise on predictive performance and recovery of assigned
AAWS in function of peptide library parameters (Sections 8.1 and 8.2). Only simulations
of unbiased mixtures are shown in this Chapter.
The formulation of the mathematical model of antibody-binding (Section 4.2) makes no
assumptions about the dependence of estimated AAWS on genetic background, species,
microarray batch and manufacturer. In this Chapter, the impact of these in vitro
parameters on AAWS estimation is assessed (Section 8.3).
8.1 Simulations show that the introduction of noise into signal
intensities decreases both the predictive performance and
the recovery of assigned AAWS
Introducing Gaussian noise into simulated signal intensities (Section 3.6.2, Figure 8.4) of
unbiased mixtures results, depending on the noise amplitude, in a decrease of predictive
performance and recovery of assigned AAWS h⃗ by estimated AAWS w⃗ (Figure 8.1). Of
note, even for noise amplitudes (N (µ = 0, σ = 0.03), Figure 8.1A) for which predictive
performance nears zero, the median Pearson correlation of assigned AAWS and estimated
AAWS is about r = 0.7 (Figure 8.1C).
Thus, even though Gaussian noise destroys the linear relationship between the assigned
AAWS (the AACM) and the signal intensity profile, both the recovery of assigned
AAWS by estimated AAWS (Figure 8.1C) and the recovery of original signal intensities1
(Sˆrecovered = Xw⃗, Figure 8.2) do not fall much below a median correlation coefficient of
0.5. Indeed, across all noise amplitudes, recovered signal intensities are higher correlated
to original signal intensities than to noise-altered ones (Figure 8.2).
This property of PLSR being able to separate, up to a certain point, noise from signal
is owed to its ability to migrate the noise terms into the higher components of the PLSR
model. This PLSR property is exemplified in Figure 8.3; the higher the noise amplitude
is increased, the less components are significantly predictive and therefore used by the
model.
1Original signal intensities: signal intensities prior to introduction of Gaussian noise.
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Figure 8.1: Simulations show that the predictive performance of antibody binding profiles of
unbiased mixtures (nAb = 10000) decreases with increasing introduction of Gaussian noise. (A)
Predictive performance (Q2) decreases with increasing noise, (B) as does the correlation (r)
between all pairs of estimated AAWS (w⃗isim), (C) and the correlation between assigned AAWS (⃗h)
and estimated ones (w⃗isim). In (A–C), a random peptide library with associated AACM (Xsim)
of 255 14-mers and assigned AAWS (⃗h) were generated once and were kept constant across all
simulation runs. For each noise amplitude, 50 simulations with a newly generated unbiased
mixture were run. Antibody binding profiles were computed using Equation 4.1. Corresponding
AAWS (w⃗isim) were determined using Equation 4.8. Gaussian noise was introduced into the signal
intensities: N (µ = 0, σ = x) with x ranging from 0 to 0.1.
8.1.1 Summary I
• Increasing the amplitude of Gaussian noise introduced into simulated signal inten-
sities (Figures 8.1 and 8.4) decreases the predictive performance (Q2), the pairwise
correlation of AAWS and recovery of assigned AAWS h⃗ (Section 8.1, Figure 8.1).
Even though high noise amplitudes reduce predictive performance to near zero
(Figure 8.1A), the median Pearson correlation of assigned AAWS and estimated
ones only decreases to about r = 0.5 (Figure 8.1C).
• Across all noise levels, recovered signal intensities show higher correlation coefficients
with original signal intensities than with noise-introduced ones (Section 8.1, Figure
8.2).
• The number of significantly predictive latent components is reduced with increased
noise levels (Figure 8.3).
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8.2 Assessment of the effect of varying peptide library parameters on predictive
performance and estimated AAWS in the presence of noise
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Figure 8.2: Simulations show that for unbiased mixtures, recovered signal intensities (Sˆrecovered =
Xw⃗) (Original vs. Recovered) show a higher Pearson correlation with original signal intensities
than with noise-altered ones (Original vs. Noise SIs) across all tested noise magnitudes. Signal
intensity profiles are those simulated for Figure 8.1. Legend: “Diff” is the pairwise difference
in correlation coefficients of “Original vs. Recovered” and “Original vs. Noise SIs” intensities;
Noise: Gaussian noise; Noise SI: noise-introduced signal intensities; Recovered: recovered signal
intensities; Original: original normalized signal intensities without noise; Residuals: residuals ε⃗
determined with the regression model (Equation 4.8).
8.2 The decrease in predictive performance upon introduction
of noise into signal intensities depends on both peptide
library size and peptide length
8.2.1 The impact of noise on the recovery of assigned AAWS is dependent
on peptide library size
The predictive performance and recovery of assigned AAWS were shown above to depend
only slightly on peptide library size in the case of unbiased mixtures (Section 6.1, Figure
6.1). However, when Gaussian noise is introduced into antibody binding profiles, the
influence of peptide library size on recovery of assigned AAWS is increased within the
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Figure 8.3: The optimal number of latent variables found with PLSR for each simulation run in
Figure 8.1 decreases with increasing Gaussian noise introduced into simulated signal intensities.
The optimal number of latent components was determined by evaluating the best predictive
performance value (Q2) for a given number of components (Section 3.7.2).
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Figure 8.4: Simulated original signal intensities (Original SI ) versus noise-introduced ones
(Noise SI ) are displayed and Pearson correlated. For each noise amplitude (N (µ = 0, σ = 0 : 0.1)),
the normalized simulated signal intensities of one simulation run of Figure 8.1 are shown.
tested range (50–5000 peptides): even though the predictive performance is zero at a
noise amplitude of N (µ = 0, σ = 0.1) (Figure 8.5A), the recovery of both assigned AAWS
(Figure 8.5C) and of original simulated signal intensities (Figure 8.5E) tends to perfection
at high peptide library sizes (5000 peptides).
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8.2 Assessment of the effect of varying peptide library parameters on predictive
performance and estimated AAWS in the presence of noise
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Figure 8.5: In the presence of noise, the recovery of assigned AAWS is positively dependent on
peptide library size. Antibody binding profiles of unbiased mixtures (nAb = 10000) were simulated
with varying noise amplitudes and peptide library sizes. (A) Predictive performance (Q2), (B)
Pearson correlation (r) between all pairs of estimated AAWS (w⃗isim) as well as (C) the recovery of
assigned AAWS (⃗h) are shown in function of peptide library size and noise amplitude. (D) The
correlation of normalized original signal intensity profiles (signal intensities before introduction of
noise, original SI ) with noise-introduced ones (noise SI ) and (E) the correlation of original with
recovered signal intensity profiles (Sˆrecovered = Xw⃗, recovered SI ) are shown. In (A–E), random
peptide libraries with associated AACMs (Xsim) of varying size (50–5000 peptides) with 14-mers
and assigned AAWS (⃗h) were generated once and were kept constant across all simulation runs.
For each peptide library size and noise amplitude, 50 simulations with newly generated unbiased
mixtures were run. Antibody binding profiles were computed using Equation 4.1. Corresponding
AAWS (w⃗isim) were determined using Equation 4.8. Gaussian noise was introduced into signal
intensity profiles with N (µ = 0, σ = x) with x ranging from 0 to 0.1.
8.2.2 The impact of noise on the recovery of assigned AAWS is dependent
on peptide length
The peptide length contributes to the modulation of the impact of noise on predictive
performance and recovery of signal intensities and assigned AAWS. For the tested range of
peptide lengths2 (5–25 amino acids), the susceptibility to noise increases with increasing
peptide length (Figures 8.6). Thus, noise increases the negative effect the peptide length
2The size of antibody binding sites is reported to lie within the tested range of peptide lengths (Section
1.4.2).
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8 Technological analysis of antibody-peptide reactivity data
has on predictive performance (Q2) and recovery of assigned AAWS h⃗ (Figure 6.1).
Simulations are consistent with the experimental data, in that for a given peptide
library, 13-mers show consistently higher predictive performance values than 15-mers
both for human and murine sera (Figure 5.4). Nevertheless, AAWS of 13-mer and
15-mer-libraries are highly correlated: usually Pearson correlation coefficients are above
r = 0.9 (data not shown).
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Figure 8.6: Higher peptide lengths render predictive performance, pairwise correlation and
recovery of assigned signal intensities and AAWS (⃗h) more susceptible to noise. Antibody binding
profiles of unbiased mixtures (nAb = 10000) were simulated at varying noise amplitudes and
peptide lengths. (A) Predictive performance (Q2), (B) Pearson correlation (r) between all pairs of
estimated AAWS (w⃗isim) as well as (C) the recovery of assigned AAWS (⃗h) are shown in function
of peptide length and noise amplitude. (D) The correlation of normalized original signal intensity
profiles (signal intensities before introduction of noise, original SI ) with noise-introduced ones
(noise SI ) is shown as is (E) the correlation of original with recovered signal intensity profiles
(Sˆrecovered = Xw⃗, recovered SI ). In (A–E), random peptide libraries with associated AACMs
(Xsim) of 1000 14-mers and assigned AAWS (⃗h) were generated once and were kept constant
across all simulation runs. Peptide lengths were varied from 5 to 25 amino acids. For each
peptide length and noise amplitude, 50 simulations with newly generated unbiased mixtures were
run. Antibody binding profiles were computed using Equation 4.1. Corresponding AAWS (w⃗isim)
were determined using Equation 4.8. Gaussian noise was introduced multiplicatively into signal
intensity profiles with (N (µ = 0, σ = x) with x ranging from 0 to 0.1.
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8.3 Estimated AAWS are consistent across microarray batches but differ by
manufacturer and species
8.2.3 Summary II
• In the presence of noise, the recovery of assigned AAWS (⃗h) (Section 8.2.1, Figure
8.5C) and original simulated signal intensities (Figure 8.5E) depends positively on
peptide library size.
• Higher peptide lengths render predictive performance (Q2, Figure 8.6A), recovery
of assigned AAWS (⃗h) (Section 8.2.2, Figure 8.6C) as well as the recovery of original
signal intensities increasingly susceptible to noise (Figure 8.6E).
8.3 Estimated AAWS are consistent across microarray batches
but differ by manufacturer and species
AAWS of healthy3 individuals of experimental studies described in Methods (Section 3.5,
n = 158) were correlated and presented in a heatmap to study their Pearson correlation-
based clustering. For inclusion in the heatmap, AAWS had to originate from the following
libraries: J25514-mer, J335215-mer, J341815-mer, J362615-mer or P 94215-mer. AAWS based on 13-mer libraries
were excluded.
The heatmap (Figure 8.7) shows clustering of AAWS by species and manufacturer.
Exemplary representative comparisons of AAWS between pairs of experimental studies
are summarized in Table 8.1 and Section A.6.
8.3.1 Summary III
• The correlation of AAWS across experimental studies is high provided that (i)
AAWS are compared among studies performed on the same platform (JPT, Pepscan)
and (ii) the compared samples originate from the same species (human, mouse)
(Table 8.1, Appendix A.5, Figures S.5–S.11). Indeed, AAWS cluster by species
(mouse, human) and by manufacturer (JPT, Pepscan, Figure 8.7). AAWS clustering
by species and manufacturer is independent of the correlation method (Pearson,
Spearman) used (Figure S.12).
• AAWS are consistent across (i) murine genetic backgrounds (NOD, C57BL/6,
BALB/c) and (ii) microarray batches (Section A.6, Figure 8.7, Table 8.1). The
batch consistency of AAWS contrasts with the batch inconsistency of signal intensity
profiles (Section 3.5, Figure S.9, Table S.2, [259]).
3Analogous to Figure 5.4 in Chapter 5, for both the NephroFIT and the NephroFIT-Pepscan study,
“No rejection” individuals were assessed in Figure 8.7 because no more than two samples of healthy
controls were incubated in these studies.
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8 Technological analysis of antibody-peptide reactivity data
Manufacturer, Species Pairwise comparison of
studies by AAWS
Overall median
correlation coefficient
Reference
JPT, Human
SHS, Glioma 09 r = 0.73 Figure 8.7
Glioma 09, NephroFIT r = 0.74 Figure S.8
Glioma 08, Glioma 09 r = 0.77 Table S.2
JPT, Mouse MS (BALB/c,C57BL/6)
r = 0.91 Figure S.5
NS (C57BL/6), MS
(C57BL/6)
r = 0.77 Figure S.6
JPT,
Human versus Mouse
MS (BALB/c), SHS r = −0.28 Figure S.7
NS (C57BL/6), SHS r = 0.26 Figure 8.7
Pepscan, Human NephrOT,
NephroFIT-Pepscan
r = 0.76 Figure S.9
Pepscan versus JPT,
Human
SHS, NephrOT r = −0.02 Figure 8.7
NephroFIT,
NephroFIT-Pepscan
r = 0.10 Figure S.10
Pepscan versus JPT,
Mouse versus Human
MS (BALB/c),
NephrOT
r = −0.02 Figure S.11
Table 8.1: The correlation of AAWS between experimental studies is high provided that (i)
AAWS are compared among studies performed on the same platform (JPT, Pepscan) and (ii)
the compared samples originate from the same species (human, mouse). Exemplarily, but
representatively, AAWS of healthy individuals used in Figure 8.7 were Pearson correlated between
experimental studies in a pairwise fashion. The term “overall median correlation coefficient”
denotes the median of all unique Pearson correlation coefficients for a comparison of AAWS of
two experimental studies. Please refer to Appendix A.5 for the corresponding graphs. Legend:
MS; Mouse study, NS; NOD study, SHS; Slovenian healthy study.
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8.3 Estimated AAWS are consistent across microarray batches but differ by
manufacturer and species
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Figure 8.7: Heatmap of AAWS of healthy individuals of all experimental studies assessed in
this thesis shows Pearson-based clustering of AAWS by species (human: red, mouse: blue) and
manufacturer (JPT: pink, Pepscan: green). Number of total AAWS clustered: 158. (For both the
NephroFIT and the NephroFIT-Pepscan study, “No rejection” individuals were assessed in this
Figure, because no more than two samples of healthy controls were incubated in these studies).
AAWS of 13-mer libraries were excluded from this thesis. The weight of cysteine (C) was removed
from all AAWS of cysteine-containing libraries (J25514-mer, Table 3.1). Antibody binding profiles
were measured with the respective libraries and AAWS were determined with Equation 4.8. The
heatmap was built by Pearson-based correlation as detailed in Section 3.9.2. The correlation
method (Pearson, Spearman) has no major impact on the clustering by species or manufacturer
(Figure S.12).
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9 Discussion
Parts of this Chapter were recently published [104].
9.1 Assessing the consistency of in silico and in vitro
antibody-peptide reactivity data
9.1.1 Unbiased antibody mixtures show ensemble properties
A mathematical model for antibody-peptide binding based on the law of mass action
was proposed (Section 4.2). Herein, the binding signals for a given simulated monoclonal
antibody depend nonlinearly on the amino acid’s position in a given peptide. In this
context, a property vector h⃗ was defined, which characterizes each peptide’s amino acid
binding strength. The model was analyzed and ported to a simulation framework.
The analysis of the model highlighted ensemble properties of a special case of mixtures,
termed unbiased, which were defined as having (i) a highly diverse, (ii) i.i.d. antibody
repertoire, and (iii) showing no antibody dominance. Antibody dominance is defined as
the relative concentration increase of a small portion of the antibody mixture (Section
4.3). The derived ensemble properties of unbiased mixtures result in a linear relationship
of peptide signal intensity and peptide sequence. This linear relationship led to the
formulation of a linearly solvable regression model. The regression model yields estimated
AAWS (w⃗) as near perfect predictors of signal intensity profiles, which recover assigned
AAWS (⃗h). For antibody-dominated—also termed biased—mixtures, the predictive
performance of the regression model depends on the bias (Section 4.3.4, Figure 4.3).
The ensemble properties’ implications for signal intensity profiles of unbiased mixtures
are twofold: (i) the simulated signal intensity profile is specific for a given peptide library
with given assigned AAWS: it is obtained independently of any unbiased mixture (Figure
4.2). (ii) AAWS are a compact, lossless representation of antibody binding profiles. They
represent a (near perfect) dimension reduction of antibody binding profiles from the signal
intensity space onto the amino acid space (Section A.8.2). In this amino acid space, the
peptide’s amino acid composition, and no longer its ordered sequence, is determinative
of a peptide’s signal intensity (Sections 4.3.2 and A.8.2).
In this work, antibody sequences were drawn from a Gaussian distribution in order
to analytically derive the exclusive dependence of signal intensities on peptide amino
acid composition for unbiased mixtures (Equation 4.7). Nonetheless, all simulations,
being performed with an underlying uniform distribution, indicated that mathematical
predictions and simulation results were in full accord (Section 4.3). The choice of the
distribution is rather outweighed by the need for small components both in assigned
AAWS (⃗h) and antibody sequences (Footnote 3, page 53).
9 Discussion
The regression model’s predictive performance was found to be robust against changes
(i) in the total antibody concentration (Sections 6.2 and 6.3), (ii) in the distribution of
assigned AAWS (Section 6.4) and (iii) in the simulated peptide library (Sections 4.3.3
and 6.1). However, the predictive performance is sensitive to a violation of the i.i.d.
generation of antibody repertoires (Figure 6.11), a biasing of the repertoire (antibody
dominance, Figure 4.3) and an introduction of noise into simulated signal intensities
(Section 8.1).
9.1.2 Predictions of the mathematical model are validated by in vitro
antibody-peptide reactivity data
The major prediction of the proposed mathematical model is that highly diverse serum
antibody mixtures—in contrast to low-diversity antibody mixtures—show a convergence
to a signal intensity profile which is linearly predictable to near perfection by the peptides’
amino acid composition (AACM). In this thesis, two extreme cases were used to validate
this prediction. Monoclonal and serum antibodies1 were incubated on the same peptide
library: the predictive performance, a measure for the quality of the AACM-based
regression model, was significantly higher for serum than for monoclonal antibodies
(Figure 5.1).
In accord with the mathematical predictions, AAWS, and to a lesser extent signal
intensity profiles, were largely consistent across healthy individuals, both human and
murine (Figure 5.4), and therefore independent of an individual’s serum antibody compo-
sition. While it could be argued that antibody mixtures of inbred mice as used in the
Mouse study (Section 3.5.8) are likely to be similar2, this argument does certainly not
hold with respect to the utilized human sera. Thus, serum antibodies show ensemble
properties that were predicted by the mathematical model.
A corollary of the derivation of serum antibody ensemble properties (Equation 4.6)
is that antibody dominance leads to a decrease in predictive performance (Sections
4.3.4 and 6.5), Figure 4.3). It is known that during a primary immune response in
immunocompetent hosts, antigen-specific antibodies are produced in high abundance
[2, 256]. Therefore, it could be expected that sera of infected mice show reduced predictive
performance values, altered measured signal intensity profiles and estimated AAWS, as
was confirmed by experimental data (Figures 5.2, S.2 and S.3).
1Human monoclonal and murine serum antibodies were incubated to validate the mathematical pre-
dictions (Figure 5.1). The antibodies’ origin is unimportant as both of these entities are studied
separately and only predictive performance values (Q2) are being compared. Murine serum IgG
antibodies yield predictive performance values similar to those of the shown IgM isotype [104].
2Mice bred under SPF conditions (Section 3.5.8) were also shown to harbor GCs even in non-immunized
conditions [123]. This suggests a mouse-to-mouse variation of antibody repertoires. Also, AAWS were
similar across mouse strains (Figures 8.7 and S.5).
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9.1.3 The concept of unbiased mixtures best approximates sera of healthy
individuals
In view of the relatively high predictive performance of antibody binding profiles of serum
samples of healthy individuals, it was postulated that these sera exhibit properties of
unbiased mixtures [104].
The first prerequisite for an unbiased mixture is high diversity (Section 4.3.3). This
requirement appears to be met since at any given time at which an individual is not
undergoing an acute immune response, the composition of serum antibodies is reported
to be provided mostly by a rather constant number of antibody secreting cells (Section
1.6, [112, 290]). The functional IgM diversity is estimated to be of the order of 104 clones
[103]3 and the potential antibody diversity is very high [79].
However, the fulfillment of the second requirement, the independent and identical
distribution of antibody binding sites, is harder to claim. Even though the antibody
repertoire is composed of germ line sequences and shaped by clonal selection, V(D)J
recombination and—at later stages of the immune response—somatic hypermutation
arrange and mutate these segments in a largely random fashion [3]. This is consistent with
the hypothesis that antibody repertoires can potentially recognize the entire antigenic
universe (Section 1.4.4, [66, 291]).
The third requirement, the absence of antibody dominance, is likely not met by sera
of healthy individuals since this would entail a complete lack of specificity4. Indeed,
data from the Slovenian healthy study showed evidence of slight antibody dominance
which I suggested to be responsible for the clustering of ranks of antibody profiles by
healthy volunteer (Sections 6.3 and 9.2.1). The presence of antibody dominance and
correlated antibody repertoires likely also contributed to the fact that the predictive
performance values did not reach perfection in vitro (Figure 5.4) as it was the case for
unbiased mixtures (Figure 4.2A). In addition, low predictive performance values may
also be due to noise (Section 9.2.3).
9.2 Discussion of results in light of antibody profiling and
serological diagnostics
The experimental validation of the mathematical model’s predictions unifies the simulation
framework and the experimental system used into a novel integrated systems framework
3The correspondence of the diversity of the BCR repertoire (Section 1.5.3) and that of the antibody
repertoire remains as of yet unclear (Section 1.6.3).
4Unbiased mixtures are amino acid composition-specific (Sections 4.3.1 and 9.1.1). Thus, two peptide
sequences, which differ by amino acid order but not composition, could not be differentiated by an
unbiased mixture. Therefore, if sera of healthy individuals were to function as unbiased mixtures, the
fine differentiation between sequences would be abolished to a great extent. In fact, Bachmann and
colleagues showed that in vivo protective capacities of a panel of monoclonal IgG antibodies to the
VSV glycoprotein were independent of Ig subclass, avidity, neutralization rate constant, and in vitro
neutralizing activity; above a minimal avidity threshold, protection depended simply on a minimum
serum concentration [292]—or in terms of this thesis—on a minimum level of antibody dominance.
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for both the theoretico-statistical and experimental analysis of antibody-peptide reactivity
data [293].
9.2.1 Assessing the classifiability of antibody binding profiles
The analysis of the mathematical model suggests that differences in antibody binding
profiles can only be realized by (i) changes in the total antibody concentration (Section
6.3) or (ii) by relative antibody concentration differences (antibody dominance, correlated
antibody repertoires, Sections 4.3.4, 6.5 and 7.1).
Both types of concentration changes were shown to have an impact on the clustering
of simulated signal intensity profiles, depending on the correlation coefficient (Pearson,
Spearman) used (Section 6.2, Figures 4.3, 6.9 and S.13, Table S.3). Due to the monotonic
influence of total antibody concentration on simulated signal intensities (Figure 6.4A),
total concentration differences have no bearing on their ranks (Figure 6.4B), Only a
relative change in the antibody composition of the tested mixture, which is caused by
antibody dominance, can induce a change of ranks (Figure 4.3).
In summary, in silico findings suggest the following for serological diagnostics: if
total concentration varies across antibody mixtures, both antibody dominance and total
antibody concentration differences can cause group-specific antibody binding profiles,
thus allowing for a separation of antibody mixtures. If the total antibody concentration is
constant across antibody mixtures, only a shared antibody dominance allows a separation
of antibody binding profiles by inducing a higher inter-group than intra-group variance
(Figure 7.1C): randomly biased antibody mixtures lead to isotropically distributed signal
intensity profiles in the variance space (Figure 7.1A).
The intra-group consistency of antibody-peptide binding behavior is a basic premise of
serological diagnostics (Section 1.8): the mathematical model does not only fulfill this
premise, but also predicts antibody dominance5 as a condition which is able to establish
classifiable intra-group consistency.
Thus, the fact that signal intensity profiles in the Slovenian healthy study (SHS)
show, in addition to Pearson-based clustering (Figure 6.8A and B), also Spearman-based
clustering by healthy volunteer (Figure 6.8C and D), suggests that (i) most tested
human volunteers possess dominant antibodies with different peptide-library binding
behavior, (ii) which did not change over the course of the experiment. Individual antibody
dominance would thus prevail in its influence on clustering over the evidenced total
antibody concentration differences (Figure 6.7).
Baseline studies such as the SHS are important for serological diagnostics as they show
that even if antibody binding profiles and AAWS are relatively highly correlated due
to suggested ensemble properties of serum antibodies (Figure 5.4), sera are still biased
enough to exhibit clustering. Consequently, if disease groups are to be separated based
on their profiles, disease-induced dominant antibodies must have a stronger influence
on binding signals than the individual bias. The individual variability must be taken
into account for serological diagnostics to detect group-specific differences in antibody
5Unbiased mixtures are special cases of biased ones (Section 4.3.3).
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binding profiles.
Samples of BALB/c mice (Section 3.5.8, Figure 3.1) were divided into three groups :
healthy, acute phase and early chronic phase. These groups could be differentiated by
PCA based on signal intensity6, ranks7 and AAWS (Figures 5.3, S.2 and S.3). Both,
signal intensities and ranks, showed high classification accuracies using only a small
percentage of the analyzed library (Section 5.3, Table 5.3). The high balanced accuracy
was accompanied by a reduction of (i) the predictive performance (Figure 5.2A), (ii) the
pairwise correlation of signal intensity profiles (Table 5.1) and (iii) AAWS (Figure 5.2B).
The above described simulations results thus suggest that a shared (consistent) antibody
dominance contributed primarily to the classification of the murine antibody binding
profiles. The dependence of mean signal intensity on antibody concentration was low
and not significant (Table 6.1). Rank changes during acute immune responses were also
noted by Stafford and colleagues8 [210].
Convergent—or shared—B-cell responses against an antigen across individuals rep-
resent a phenomenon that has long been described. For some antigens, this has been
characterized as repertoire bias, where particular genes from the germline repertoire are
favored in the panel of antibodies that is raised during the immune process [295–297]. In
addition to repertoire bias, identical CDR3 sequences were found to be shared across
rodents immunized with both Tetanus toxin [298] and other peptide antigens [295]. In
addition, matching CDR3 sequences were also observed across healthy individuals (human,
zebra fish) [93, 299].
It is unknown, however, how in vitro antibody dominance relates to in silico antibody
dominance (see also Section 9.1.2). Simulated mixtures start to show ensemble properties
if their number exceeds 50 antibodies (Figures 4.2 and 4.3). The human Tetanus-specific
repertoire has been estimated to be of the order of 100 distinct B-cell clones [298, 300].
Similarly, the murine VSV-specific repertoire shows about 102 to 104 specificities [135].
Further, humoral immune responses were found to be correlated [298] such that—according
to simulation results—also higher clonal diversities could be responsible for a decrease in
predictive performance (Figure 6.11).
9.2.2 The profiles of unbiased mixtures are crucial to isolating the signal of
dominant antibodies
If dominant antibodies are important for the classification of sera (Section 9.2.1), it would
be of interest to isolate their signal from the background [290]. Assuming the background
to behave as an unbiased mixture, the signal of the dominant antibody can be, to a
6In light of the high classificatory power of IgM profiles, it is worth noting that IgM has been shown to
be non-protective against HB (Section 1.8.2, [256]).
7While ranks represent a highly helpful means to control for the origin of high classificatory power
of a data set (total antibody concentration or antibody dominance), such as in the early stages of
lead discovery, their usefulness remains limited for multi-parameter diagnostics which pursues the
goal to single out a small subset of peptides with high classificatory power (see e.g. [210, 294]): the
classificatory power of ranks decreases with decreasing peptide library size.
8“Sera from infected individuals demonstrate generally higher reactivity for some peptides, but some
peptides indicate less reactivity relative to normal controls” (Figure 8 in Stafford and colleagues [210]).
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certain extent, isolated (Section 4.3.5, Equation 4.9). Since assigned AAWS are likely to
be recovered well by sera from healthy individuals (Section 9.1.3), they could be used to
recover the signal of an unbiased serum (S⃗ = Xw⃗healthy serum), which can subsequently be
used for the isolation of the signal of dominant antibodies.
To test this mathematical concept in vitro, further experiments involving incubations
of monoclonal antibodies of different concentration mixed with serum from healthy
individuals have to be performed. Such experiments have been recently published by
Stafford and colleagues who show that the signal of antibodies diluted in 10x and 100x
excess IgG (biased mixture) still allowed high correlations of the signal of the monoclonal
antibody with the biased antibody mixture [210]. If the derived formula (Equation 4.9)
held true in vitro, the correlation of the dilution of the monoclonal antibody and the
recovery of its signal would have to be determined. In fact, simulations showed that this
correlation depends both on the dilution and the diversity of the dominant antibodies
(Figure 4.4). Replicating simulations in vitro would allow the determination of a threshold
giving the minimum concentration necessary for a faithful isolation of the dominant
antibody’s signal.
9.2.3 Technological implications of the AAWS concept
Amino acid-associated weights are a means for comparing the signal of peptide
libraries across microarray batches
The methodological variability of antibody profiling studies is high (Section 1.8.1, Ta-
ble 1.1, [245]). Studies vary with respect to peptide manufacturer, peptide library
(random-sequence peptides, protein libraries), dilution of sera (dilution of serum/plasma,
normalization of Ig-concentration across samples) as well as data normalization and
bioinformatic means used to analyze antibody-peptide reactivity data. Adding to the
methodological variability of studies is the batch-to-batch variability of (random) peptide
arrays [259]. In fact, peptide microarray studies are far less comparable [238, 245] than
cDNA based microarray studies, which are performed based on highly standardized
protocols [240–244].
AAWS of healthy individuals were found to be highly consistent by study (Section
5.4). This is in accord with the mathematical prediction that for a given peptide library
AAWS are not function of the composition variability of unbiased mixtures (Sections 4.3.1
and 9.1.2). Due to the minimality of the proposed mathematical model, the influence
of parameters such as species, microarray batch and manufacturer on the estimation
of AAWS is, however, unknown. In the following, the parameters’ impact on AAWS is
discussed.
AAWS of human as well as murine samples incubated on the JPT platform were
found to be consistent across batches and peptide libraries (Section A.6, Figure 8.7,
Table 8.1), which contrasts with a high signal intensity batch variability (Section 3.5,
Figure S.9, Table S.2, [259]). In addition, murine AAWS are relatively consistent across
genetic backgrounds (NOD, BALB/c, C57BL/6, Figures 8.7, S.5 and S.6). Likewise,
AAWS determined from human sera incubated with Pepscan arrays showed considerable
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consistency across batches (Figures 8.7 and S.9).
In contrast, Pepscan-AAWS correlated poorly with both human- and mouse-AAWS
determined on the JPT-platform (Figures 8.7 and S.12, Table 8.1). Pepscan-AAWS
showed highest correlations with tested physico-chemical properties (Table 5.4) and
propensity scales (Table 5.5). Thus, with respect to the studied batches in this thesis, the
estimation of AAWS is influenced by the array-producing company. In fact, production
of arrays and peptides9 differed by manufacturer (Section 3.1.1), which could explain the
observed difference in estimated AAWS.
The influence of the printing technology on estimated AAWS seems limited as C57BL/6-
AAWS of the NOD study (JPT-contact) were highly correlated to C57BL/6-AAWS of
the Mouse study (JPT-non-contact) despite the high difference in predictive performance
values10 (Figures 5.4 and S.6). However, the non-contact-printed J25514-mer library was the
only one not showing a significant correlation with total IgM concentration (Table 6.1)
hinting to the fact that printing methods influence antibody-peptide binding to a certain
extent.
Furthermore, AAWS of human and murine samples (on the JPT-platform) correlated
poorly; while C57BL/6-AAWS of the NOD study were relatively highly correlated to
C57BL/6-AAWS of the Mouse study (Figure S.6), they only showed low correlations with
AAWS of human serum/plasma samples. How could these differences arise? According to
the minimal model (Section 4.2), these differences can either result from different antibody
dominances or different (printing-specific) assigned AAWS (⃗h). (i) However, since murine
AAWS both on non-contact and contact-printed arrays where highly correlated (Figure
S.6), different assigned AAWS are unlikely the reason for the found discrepancy. (ii) The
poor correlation of murine and human AAWS cannot be explained by the low predictive
performance11 of human samples on 15-mer JPT-libraries since 13-mer-AAWS—which
show increased predictive performance values—and 15-mer-AAWS are highly correlated
(Section 8.2.2). (iii) AAWS of human and murine sera differed in their correlation pattern
with estimated AAWS of human monoclonal antibodies (Figure 7.4). Thus, differences
in human and murine AAWS could either result from different antibody repertoires
or relative antibody concentration differences in antibody mixtures (different antibody
dominances). Indeed, murine and human antibody repertoires are quite different from
one another (Section 1.5.1, [84]). In order to further study the dependence of AAWS on
species, incubations of peptide arrays of the same batch with human and murine serum
samples are needed.
Taken together, it has been shown that the manufacturing process (JPT versus Pepscan,
Section 3.1) has a considerable impact on estimated AAWS. This difference in estimated
AAWS could be due to differences in assigned AAWS which would have—according to the
model—consequences for the binding of antibody mixtures to peptides. Manufacturer-
dependent assigned AAWS imply that the same peptide library, made by different
manufacturers, is not only likely to yield absolute but also relative signal intensity
9The majority of peptides are likely not folded or are only transiently non-linear [210].
10Differences in predictive performance values were high if comparing 14- to 15-mers, but rather low for
13-mers compared to 14-mers (Figure 5.4).
11A low predictive performance could lead to a biased estimation of AAWS (Figure 4.2).
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differences: peptides would show different ranks in function of the difference in assigned
AAWS12. It is therefore possible that with respect to one peptide library, serum samples
clustered by disease status whereas the other one would fail to show a discrimination
of samples. Indeed, simulations indicated that changing the assigned AAWS (⃗h) of a
peptide library altered monoclonal antibody binding behavior: strong antibodies turned
into weak ones (Section 7.3, Figure 7.3).
Thus, AAWS could be useful for array manufacturing companies for assessing the
batch-to-batch bias with respect to the underlying amino acid binding behavior. This
could increase rank consistency and thereby comparability of measured signals across mi-
croarray batches. Furthermore, the AAWS may be a beneficial concept for normalization
approaches13. Indeed, AAWS have, in contrast to signal intensity profiles, the advantage
of being independent of the peptide library’s dimension (Figures 8.7 and S.12). In this
thesis, numerous types of peptide libraries were used (Table 3.1), which are impossible to
compare based on their signal intensity profiles.
Recovery of assigned AAWS is high due to the noise resistance of estimated AAWS
Low predictive performance values, may—in addition to being caused by the violation of
the assumptions of unbiased mixtures—be a result of technological noise. Noise could
originate from varying peptide spot quality on microarrays and by the experimental
procedure itself. In this vein, it has been recently shown that peptide density has a
considerable effect on measured peptide signal intensity [210, 302]. To model to some
degree the influence of noise14 on the predictive performance of profiles of unbiased
mixtures, simulated signal intensity profiles were overlaid with increasing amplitudes
of noise. Noise lead to a decrease in both predictive performance and recovery of
assigned AAWS h⃗. However, even at higher noise amplitudes with predictive performance
nearing zero, the recovery of assigned AAWS (Figure 8.1) and consequently that of signal
intensities (Figure 8.2) was rather high (Section 8.1).
Simulations showed that a higher consistency of AAWS estimation is achieved with
short peptides and higher peptide library sizes (Figures 8.5 and 8.6). While shorter
12The NephroFIT (Section 3.5.4) and the NephroFIT-Pepscan study (Section 3.5.5) are inappropriate
for a comparison of balanced accuracies since these studies were incubated by (i) different researchers
(Juliane Lück (NephroFIT-Pepscan study), Bodo Steckel (NephroFIT study)), (ii) the BK virus status,
which was not checked for each sample beforehand, could skew results [301] and (iii) samples were
incubated with different techniques (manual (NephroFIT-Pepscan study) and automated incubation
(NephroFIT study)).
13In this work, normalization of BALB/c signal intensity profiles prior to PCA or P-SVM analysis
(Chapter 5) was not performed (Section 3.4.1) due to their low technological variability compared to
their high biological variability (Tables 5.1 and 5.2). Low technological variability is a phenomenon
observed throughout all experimental studies (Section 3.5, page 32). In addition, this work suggests
that the understanding of antibody-peptide reactivity data is incomplete. However, the application of
normalization approaches must be knowledge-driven.
14Increasing noise amplitudes decrease the AACM-explicability of simulated signal intensity profiles of
unbiased mixtures. The introduction of noise into antibody binding profiles reflects to some extent
the presence of systematic noise in an in vitro setting. More generally, (i) this noise models the non-
correspondence of mathematical model and simulated signal intensity profiles, (ii) and consequently
the lack of explicative power of the here formulated model to fully reconstruct in vitro measurements.
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9.2 Discussion of results in light of antibody profiling and serological diagnostics
peptides alleviate the problem of the approximation of linearized signal intensity15, high
peptide library sizes increase the resolution of the data16. If further validated in vitro,
large peptide libraries with short peptides could be used by manufacturers to estimate
AAWS with greater precision (Section 9.2.3).
In simulations the observed noise resistance of estimated AAWS is mostly owed to
partial least squares regression (PLSR) which reduces the dimensionality of the data by
filtering for signal variance (Figure 8.3) [270]. Thus, even though the high consistency of
in vitro estimated AAWS across samples, microarray batches and libraries (Figure 5.4
and 8.7, Table 8.1), may ultimately be due to ensemble properties of serum antibodies,
simulations suggest (Figures 8.2 and 8.3) that PLSR is driving to a large extent the
consistency’s detectability.
Technological features may bias amino acid-associated weights
Average AAWS differed mostly by species (mouse, human) and array platform (JPT,
Pepscan) (Figure 5.5). Whereas for murine samples, mainly aromatic amino acids are
top positive contributors to signal intensity, top ranking amino acids for human samples
incubated on JPT arrays are methionine and proline. Average AAWS of human samples
incubated on Pepscan arrays showed mainly lysine, histidine, proline and tryptophane as
positively contributing amino acids.
However, average AAWS (Figure 5.5) should be interpreted with caution. In addition
to being interpreted as both amino acid antibody binding preferences (Section 4.2, Table
5.5) and physico-chemical properties (Section 5.5, Table 5.4), signal intensity profiles
may also be influenced by at least two other factors: (i) the accessibility of peptides and
(ii) a possible interaction of aromatic amino acids and aromatic labeling dyes.
Accessibility may bias the resulting signal intensities systematically. As to the J25514-mer
library, it was found that cysteine contributes negatively to the signal intensity. This could
be partly due to its ability to form disulfide bonds, which causes increased aggregation
of cystein-containing peptides, and diminishes their surface exposure. Consequently, this
would lead to reduced antibody-peptide binding and accordingly to a reduced signal
intensity. In general, it cannot be ruled out that aromatic amino acids interact via
π-stacking with the aromatic labeling dyes Alexa Fluor 546 and 647 which are coupled
to the secondary antibodies. Indeed, it has recently been found that TAMRA, another
aromatic dye, cross-reacts with individual amino acids in a peptide sequence [303].
In order to minimize this effect, secondary-antibody correction on the log-transformed
signal intensities was performed for AAWS determination (Figure S.4).
15Higher peptide lengths increase the uncertainty in the model. Recall that for unbiased mixtures,
the peptide signal intensity is neared by a function of the sum of components of the peptide vector
(Equation 4.8). Increasing the number of terms in that sum, increases the uncertainty in the derived
approximation.
16Higher peptide library sizes increase predictive performance as they provide the regression model with
more input thereby increasing the reliability of estimated AAWS.
109
9 Discussion
9.3 Discussion of results in light of B-cell epitope mapping
The prediction of linear B-cell epitopes was first done by using propensity scales (Section
1.7.3, [177, 182, 192]). These scales assign a propensity value to every amino acid based
on a priori studies of their physico-chemical properties. Average AAWS (Figure 5.5)
correlated poorly with widely used propensity scales for epitope prediction with the
exception of Pepscan-AAWS (Table 5.5).
Blythe and Flower tested 484 amino acid propensity scales on a set of 50 epitope-
mapped proteins. They found that even the best set of scales performed only marginally
better than random17 [172]. This thesis shows that unbiased mixtures represent a special
case for which the converse holds true: antibody binding profiles of unbiased mixtures
can be predicted based on AAWS. Further, this work suggests that the use of amino
acid scales becomes increasingly less justified with increasing dominance of antibodies
in a serum (Figures 4.3, 5.1 and 5.2). In fact, each of Blythe and Flower’s experiments
used polyclonal antibodies raised against the whole protein [172]. It can therefore be
conjectured that the used polyclonal antibody mixtures were biased, meaning that they
contained dominant antibodies [174]. In this regard, this work provides a possible
explanation to Blythe and Flower’s findings. More generally, it is suggested here that
results obtained with polyclonal antibody mixtures tend to be skewed by their inherent
ensemble properties, which obscure the affinities of epitope-specific antibodies.
It was suggested that (i) “overall poor performance [of B-cell epitope prediction
approaches] may reflect the generality of antigenicity and hence the inability to decipher
B-cell epitopes as an intrinsic feature of the protein. It is an open question as to whether
ultimately discriminatory features can be found” (Section 1.4.1, [30]). (ii) Stretches of
protein sequences may not per se constitute epitopes—the context of antibody-peptide
binding may be crucial for epitope definition [15, 50, 174, 304]. However, even though
context-related epitope definition may play a role in vivo, the fact that antibody binding
profiles, at least for some diseases, could be classified (Table 1.1 and 5.3), suggests
that epitopes are shared across individuals, which would contradict universal epitope
randomness.
Similarly to antibody profiling studies, B-cell epitope approaches differ extensively
with respect to the used methodology [177], which explains why B-cell epitope prediction
studies suffer from the same lack of comparability as serological diagnostics (Section
9.2.3). In fact, the increase of machine learning methods (Section 1.7.3) for epitope
prediction purposes crucially relies on correct B-cell epitope predictions method, since
machine learning can only develop new rules [303] based on preexisting knowledge. In
this respect, it should be noted that most support vector machines give binary answers18
[177]. Using signal intensity distributions, as done in this work, might do more justice to
the data and would abolish the need for a discrete representation of B-cell epitopes.
17A similar finding has been made for protein-peptide docking programs [168].
18Multi-class support vector machine approaches also exist [276].
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9.4 Assessing the specificity of antibody-peptide reactivity data
While for both unbiased and biased mixtures, the nonlinear interaction of antibody and
peptide sequence lays the basis for the simulated binding signals, ensemble properties of
highly diverse antibody mixtures cause the genesis of binding signals of unbiased mixtures
to be a linear phenomenon.
For both kinds of mixtures, simulated antibody-peptide binding was shown to be
non-bijective (Section A.8.1, Equation 4.1): given a binding signal, it is impossible to
infer the diversity of the mixture19. Ensemble properties add to the non-bijectivity of the
Equation for signal intensity generation (Equation 4.1) by abolishing sequence specificity
and establishing amino acid composition specificity (Sections 4.3 and A.8.2). As to the
experimental setting, the recording of signal intensities, allowed to range continuously
between 1 an 65000 [245], is a dimension reduction of high-dimensional binding events in
the process of which information is certainly lost.
Even though information is most likely lost in the process of signal intensity recording,
numerous studies have shown the potential of antibody binding profiles to discriminate
serum samples of different disease stages (Table 1.1). To a certain degree, these profiles
even mirror antibody diversity (Section 9.1.2). However, (i) it is incompletely understood
how much of the classifiable information of the antibody mixture is actually captured
by antibody-peptide binding profiles. (ii) It is also unknown how the classifiability of
sera depends on the manufacturer20 (Section 9.2.3) and the peptide library; removing
the highly discriminatory peptides from the data set greatly diminishes classification
accuracy (Table S.1) thus calling the diagnostic versatility of random-sequence peptide
arrays into question [210]. (iii) Admittedly, signals were found to change upon acute
infections (Table 1.1), but to what extent are they disease-specific21 [210]? (iv) In fact,
what do the terms healthy and diseased signify for antibody binding profiles? Is there a
such a thing as a signature of health? Concepts such as unbiased mixture and antibody
dominance as well as the analysis of baseline studies (SHS) are indispensable first steps
for answering these questions. Therefore, in order to investigate how and if antibody
profile specificity can emerge, the interplay of background serum antibodies [290] and
dominant antibodies has to be studied [210].
19Concededly, determining the predictive performance of the mixture’s signal intensity profile provides
one with a rough idea of its diversity (Section 9.1.2).
20In the proposed model (Section 4.2), assigned AAWS (⃗h) are binding priorities, which are unilaterally
coded in the amino acids: antibody binding is modeled to be sequence-specific but not amino acid-
specific: antibodies cannot be, for example, alanine-affine or averse. A positive component in position
two of the antibody sequence impacts the simulated peptide signal intensity positively irrespective of
the amino acid in position two of the peptide. Therefore, in order to assess how good an approximation
the suggested model is, the statistical properties of antibody binding as well as the immunogenicity of
amino acids have to be further investigated. The fact that antigenicity propensity scales for epitope
prediction [288] do not perform better than random models [172] (Section 9.3), does not exclude an
involvement of amino acid preferences in antibody-peptide binding.
21The isolation of the signal of dominant antibodies (Section 4.3.5) may be helpful to study the disease
specificity of signals.
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9.5 Conclusion
This work shows that the genesis of antibody binding profiles differs with respect to low
and high diversity antibody mixtures. Due to ensemble properties of unbiased mixtures,
a peptide library’s amino acid composition alone is sufficient for binding prediction. In
this respect, the agreement of experimental data with model predictions was found to
be high as evidenced by both relatively high predictive performance values of mixtures
of healthy individuals and a high consistency of AAWS and signal intensities across
individuals. The concept of the unbiased mixture is crucial to this work as it offers a deeper
understanding of the genesis of antibody binding profiles. Mixtures of healthy individuals
were conjectured to comply best with the properties of unbiased mixtures. Furthermore,
even in cases of low predictive performance values, the consistency of AAWS was—thanks
to their suggested noise resistance—high across individuals, microarray batches, peptide
libraries and array printing techniques. Thus, even though the mathematical model
used is minimal in its assumptions, it is able to reflect major traits of antibody-peptide
reactivity data.
It could be argued that the predictive performance represents under certain assumptions
a measure of antibody diversity. However, the direct correspondence of in silico and in
vitro antibody diversity with respect to predictive performance is a matter of further
investigations.
Serological diagnostics demand both a high degree of consistency across individuals
of a given group and a certain degree of difference with respect to any other. The
mathematical model predicts that biased mixtures dominated by antibodies with similar
binding behavior implement this premise.
Furthermore, it became apparent that, in addition to total antibody concentration
and antibody dominance, classifiability may depend on the technology used. Therefore,
from a biological point of view, measured differences in signal intensity profiles, can, at
the current state of technology, be solely interpreted in relative terms (signal intensity,
rank and AAWS differences). Absolute signal intensities are of technological nature.
Understanding how both technology and antibody mixture together give rise to signal
intensities, would open new possibilities for standardizations and quality control as well
as the assessment of the specificity of antibody binding profiles [210, 238, 245, 246, 305].
As to B-cell epitope mapping, unbiased mixtures were discovered as an important
special case for which amino-acid scale prediction of peptide binding is justified. For
other cases, alternative methods have to be sought.
This thesis indicates that a knowledge of both a polyclonal mixture’s diversity and
composition is essential for the interpretation of antibody binding profiles with respect
to both serological diagnostics and B-cell epitope mapping. The statistical binding
properties of antibodies merit further study to consolidate these conclusions.
The importance of understanding the emergence of ensemble properties by building
quantitative models has been recently indicated by Mora and colleagues [97]. This
work presents a new framework for investigating antibody-peptide reactivity data in an
unbiased fashion. Thanks to its minimal assumptions approach, the model is a priori
applicable to a wide range of questions involving the binding of protein mixtures.
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Appendix A
A.1 PLSR: Extended mathematical background
The following extended mathematical background on PLSR is based on articles by Wold,
Burnham and colleagues [270, 306].
Consider a dataset where k variables, x⃗ = (x1, x2, . . . , xk), are measured as predictor
variables and some corresponding response variables y⃗ = (y1, y2, . . . , yk). The assumption
is that both x⃗ and y⃗ have a common underlying latent structure such that the process
under observation is actually driven by a set of a ≤ k latent variables (also termed
components) z⃗ = (z1, z2, . . . , za). These variables are not observable, but their influence
can be seen in the measured variables x⃗. Their relationship is modeled by:
x⃗ = z⃗P+ ε⃗ (S.1)
where z⃗ is of dimension 1× a, P of dimension a× k, and ε⃗ of dimension 1× k. The last
term in the model, ε⃗, is considered to be random error. Since z⃗ is unobservable and P is
unknown, z⃗ is not identifiable in Equation S.1. In fact, the same values for x⃗ would arise
if z⃗ and P are, respectively, replaced with z⃗∗ = z⃗ ×C and P∗ = C−1 ×P, where C is
any non-singular a× a matrix. Thus, the model is more commonly given as:
x⃗ = t⃗×P+ ε⃗ (S.2)
where t⃗ is understood to be some transform z⃗C of the actual latent variables z⃗. The
transformation of z⃗ to t⃗ is simply a change of basis so that the points in t⃗ would lie in the
same vector space as those in z⃗ but expressed in a different basis. In general, the actual
latent variables are not as important as the overall space they generate. Therefore, any
basis, t⃗, will be sufficient to define this space. For a given set of n observations following
Equation S.2, the model can be written as:
X = TP+E, (S.3)
where X is n× k, T is n× a and E is n× k [306]. In analogy to Equation S.3:
Y = TQ+ F, (S.4)
where again F is assumed to be random error. T are also called x-scores. They are
predictors of Y and also model X (Equations S.3 and S.4).

Appendix B
A.2 Kernel density estimates of monoclonal and serum signal
intensity profiles
Figure S.1: Gaussian kernel density estimates of signal intensity profiles of human monoclonal
IgG (Section 3.5.9) and murine serum IgM antibodies (BALB/c, Mouse study, Section 3.5.8)
incubated on the J25514-mer library are shown. Densities of serum samples of the Mouse study are
color-coded by stage of infection (black: HE, red: AP, blue: CP). Panels are named according to
the convention: Serum/mAb-(Stage of immune response)-Serum/mAb label.

Appendix C
A.3 Principal component analysis of IgM signal intensity
profiles and their ranks
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Figure S.2: Stages of immune response differ in their IgM signal intensity profiles. Principal
component analysis was applied to the 255× 58 signal intensity matrix (255 analyzed peptide
signal intensities of library J25514-mer times 58 BALB/c samples of the Mouse study, Section 3.5.8).
The loadings of the first 4 principal components are shown. The first two principal components
(PC1, PC2) separate HE and diseased (AP, CP) mice whereas the first and the fourth principal
component (PC1, PC4) tend to separate AP and CP samples. Four components explain (PC1–
PC4) 83% of the variance in the data. Sample numbers for the respective groups are: HE, 15;
AP, 28; CP, 15.
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Figure S.3: Stages of immune response differ in their ranks of IgM signal intensity profiles.
Principal component analysis was applied to the 255× 58 rank matrix (ranks of 255 analyzed
peptide signal intensities of library J25514-mer times 58 BALB/c samples of the Mouse study, Section
3.5.8). The first two principal components (PC1, PC2) separate HE and diseased (AP, CP) mice
whereas the second and the fourth principal component (PC2, PC4) tend to separate AP and CP
samples. Four components (PC1–PC4) explain 81% of the variance in the data. Sample numbers
for the respective groups are: HE, 15; AP, 28; CP, 15.
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P-SVM classification results after removal of selected peptides
A.4 P-SVM classification results after removal of selected
peptides
IgM signal intensity profiles
Subproblem BACC [%] Sensitivity [%] Specificity [%] Significance
(p-value)
Number of
removed
peptides
HE–AP 89.5 85.7 93.3 0 6
HE–CP 63.4 40.0 86.7 0.072 9
AP–CP 57.0 53.3 60.7 0.108 11
Ranks
Subproblem BACC [%] Sensitivity [%] Specificity [%] Significance
(p-value)
Number of
removed
peptides
HE–AP 92.9 85.7 100 0 6
HE–CP 36.7 53.3 20.0 1 15
AP–CP 36.7 73.3 0 1 6
Table S.1: Assessment of the P-SVM balanced classification accuracy (BACC) for both IgM
signal intensity profiles and their ranks of subproblems of the Mouse study (BALB/c, Section 3.5.8,
Figure 3.1) after removal of previously selected peptides. For each subproblem, prior to nested
cross-validation with P-SVM, unique peptides selected for optimal classification results (Table
5.3) were removed from the data set (Section 3.8.2). The BACC is highest for the subproblem
HE–AP and lowest for AP–CP. Signal intensity profiles were determined with the J25514-mer library.
Sample numbers for the respective groups are: HE, 15; AP, 28; CP, 15.
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A.5 Secondary-antibody correction of signal intensity profiles
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Figure S.4: Assessment of predictive performance values before and after secondary-antibody
correction (Mouse study, BALB/c, Section 3.5.8). (A) The predictive performance values (Q2)
were calculated for monoclonal (mAb, Section 3.5.9) and serum IgM (sIgM) antibody binding
profiles before (red) and after (blue) correction of the measured log-transformed signal intensities
by removal of the polyclonal secondary antibody-correlated signals using PLSR (Section 3.4.2).
(B) The pairwise Pearson correlation (r) of the corresponding AAWS w⃗j are shown. For the two
statistical measures, signal correction entails a significant decrease in the mAb median, whereas
sIgM medians remain largely unchanged. Sample numbers for the respective groups are: mAb,
13; sIgM, 58. Antibody binding profiles were measured with the J25514-mer library. Corresponding
AAWS (w⃗j) were determined with Equation 4.8.
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A.6 Assessment of the consistency of AAWS across microarray
batches, manufacturers and species
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Figure S.5: Mouse study: Comparison between AAWS of BALB/c and C57BL/6 mice shows
that AAWS are mostly similar between the two mouse strains. The correlation between AAWS
of healthy BALB/c and healthy C57BL/6 mice is shown (overall median Pearson correlation
coefficient: r = 0.91, orange dashed line). Antibody binding profiles were determined using the
J25514-mer library. Corresponding AAWS were calculated using Equation 4.8. Number of serum
samples: BALB/c (healthy), 15; C57BL/6 (healthy), 15 (Section 3.5.8).
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Figure S.6: NOD study, Mouse study: The correlation between AAWS of C57BL/6 mice of
NOD and Mouse study is high (overall median correlation coefficients: r = 0.77, orange dashed
line). (Note that in order to be able to compare AAWS of both studies, the weight of cysteine
had to be removed from all Mouse study-AAWS vectors (Table 3.2).) Antibody binding profiles
were determined using the libraries J25514-mer (Mouse study) and J362615-mer (NOD study). AAWS
were determined using Equation 4.8. Number of serum samples: C57BL/6 (healthy, Mouse study,
Section 3.5.8), 15; C57BL/6 (healthy, NOD study, Section 3.5.7), 5.
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Figure S.7: Mouse study, Slovenian healthy study: the correlation between AAWS of healthy
BALB/c mice (MS) and healthy human volunteers (SHS) is poor (overall median correlation
coefficient: r = −0.28, orange dashed line). (Note that in order to be able to compare AAWS
of the MS with AAWS of the SHS, the weight of cysteine had to be removed from all Mouse
Study-AAWS vectors (Table 3.2).) Antibody binding profiles were determined using the peptide
libraries J25514-mer (MS) and J341815-mer (SHS). AAWS were determined using Equation 4.8. Number
of serum samples: BALB/c (healthy, MS, Section 3.5.8), 15; human healthy volunteers (SHS,
Section 3.5.1), 48.
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Figure S.8: Glioma 09 study, NephroFIT study: the correlation of AAWS between healthy
individuals from the Glioma 09 study and “No rejection” individuals from the NephroFIT study
is high (overall median correlation coefficient: r = 0.74, orange dashed line). Antibody binding
profiles were determined using the libraries J335215-mer (Glioma 09 study) and J341815-mer (NephroFIT
Study). AAWS were determined using Equation 4.8. Number of serum samples: “No rejection”
(NephroFIT study, Section 3.5.4), 14; healthy humans (Glioma 09 study, Section 3.5.2), 17.
Median correlation coefficient
of matched pairs (r)
Median correlation coefficient
of all possible pairs (r)
AAWS 0.86 0.77
Signal intensity profiles 0.60 0.44
Table S.2: Glioma 08 study, Glioma 09 study: AAWS and signal intensity profiles of matched
pairs of both Glioma studies are higher correlated than non-matched ones. AAWS show higher
correlations than signal intensity profiles. Serum samples of both studies were matched: 48
samples were assessed in both of the studies. Their signal intensities and AAWS were determined
and the median of 48 Pearson correlation coefficients calculated (1st column). As a control, signal
intensity profiles and AAWS of matching samples were correlated in a pairwise fashion: sample 1
of Glioma 08 with samples 1 through 48 of Glioma 09, sample 2 of Glioma 08 with samples 1
through 48 of Glioma 09 and so forth such that the median of all pairwise Pearson correlation
coefficients could be determined (2nd column). The correlation of signal intensity profiles of the
blanks of both studies was found to be low: r = 0.22. As the Glioma 08 (J341815-mer) and the Glioma
09 studies (J335215-mer) were done on different peptide libraries (Table 3.1), only signal intensities
of matching peptides (n = 3352) were used for correlation. Signal intensity profiles were not
normalized.
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Figure S.9: NephrOT, NephroFIT-Pepscan study: correlation between AAWS of healthy indi-
viduals from the NephrOT study and “No rejection” individuals from the NephroFIT-Pepscan
study is high (overall median correlation coefficient: r = 0.76, orange dashed line). The overall
median coefficient for raw (unnormalized, not log-transformed) signal intensities is r = 0.23. The
correlation of signal intensities of respective blanks is r = 0.35. Antibody binding profiles were
determined with the library P 94215-mer. AAWS were determined using Equation 4.8. Number of
serum samples: “No rejection” (NephroFIT-Pepscan study, Section 3.5.5), 13; healthy humans
(NephrOT study, Section 3.5.6), 9.
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Figure S.10: NephroFIT, NephroFIT-Pepscan study: correlation between AAWS of the
NephroFIT-Pepscan and NephroFIT studies (both “No rejection”) is low (overall median cor-
relation coefficient: r = 0.10, orange dashed line). Antibody binding profiles were determined
using the libraries P 94215-mer (NephroFIT-Pepscan) and J341815-mer (NephroFIT Study). AAWS were
determined using Equation 4.8. Number of serum samples: “No rejection” (NephroFIT-Pepscan
study, Section 3.5.5), 13; “No rejection” (NephroFIT study, Section 3.5.4), 14.
126
Assessment of the consistency of AAWS across microarray batches, manufacturers and
species
BALB/c sera
C
or
re
la
tio
n 
of
 A
AW
S
: N
ep
hr
O
T 
st
ud
y 
(h
um
an
, h
ea
lth
y)
 v
s.
 M
ou
se
 S
tu
dy
 (B
A
LB
/c
, h
ea
lth
y)
(r
)
−0.3
−0.2
−0.1
0.0
0.1
0.2
0.3
C1 C8 C2 C13 C3 C14 C4 C5 C6 C7 C9 C10 C11 C12 C15
Figure S.11: Mouse study (BALB/c), NephrOT study: correlation between AAWS of healthy
BALB/c mice (Mouse study) and healthy individuals from the NephrOT study is low (overall
median correlation coefficient: r = −0.02, orange dashed line). Antibody binding profiles were
determined using the libraries J25514-mer (Mouse study) and P 94215-mer (NephrOT study). AAWS were
determined using Equation 4.8. Number of serum samples: BALB/c (healthy, Mouse study,
Section 3.5.8), 15; healthy humans (NephrOT study, Section 3.5.6), 9.
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Figure S.12: Heatmap of AAWS of healthy individuals of all experimental studies assessed in
this thesis shows Spearman-based clustering of AAWS by species (mouse: blue, human: red) and
manufacturer (Pepscan: green, JPT: pink). Number of total AAWS clustered: 158. (For both the
NephroFIT and the NephroFIT-Pepscan study, “No rejection” individuals were assessed in this
Figure, because no more than two samples of healthy controls were incubated in these studies).
AAWS of 13-mer libraries were excluded from this thesis. The weight of cysteine (C) was removed
from all AAWS of cysteine-containing libraries (J25514-mer, Table 3.1). Antibody binding profiles
were measured with the respective libraries and AAWS were determined with Equation 4.8. The
heatmap was built by Spearman-based correlation as detailed in Section 3.9.2.
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A.7 PCA and P-SVM nested cross-validation of antibody
binding profiles of unbiased mixtures differing by total
antibody concentration
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Figure S.13: Antibody binding profiles simulated with different total antibody concentrations
cluster when applied to PCA. Signal intensity profiles simulated for Figure 6.9 are shown in the
space spanned by first two principal components (PC1, PC2). Together, PC1 and PC2 explain
nearly 100% of the variance in the data. Please refer to Figure 6.9 for simulation details.
Simulated signal intensity profiles
Subproblem BACC [%] Sensitivity [%] Specificity [%] Significance
(p-value)
Low–Middle 83.3 93.3 73.3 0
Low–High 91.7 96.7 86.7 0
Middle–High 88.7 96.7 80.7 0
Table S.3: Assessment of the P-SVM balanced classification accuracy (BACC) for signal intensity
profiles simulated with different antibody concentrations. Signal intensity profiles are those
simulated for Figure 6.9. Please refer to Figure 6.9 for simulation details.

Appendix G
A.8 A minimal model of antibody-peptide binding: further
mathematical analyses
A.8.1 Signal intensity simulation is a non-bijective process
Let f be a function of the vectors a⃗k and p⃗ i, and of the scalar nAb.
f : Rl × Rl × N≥1 → (0, 1), with
f (⃗ak, p⃗ i, nAb) = Si =
nAb
k=1[Ab]kKi,k
1 +nAbk=1[Ab]kKi,k . (S.5)
Let A1 and A2 be two antibody repertoires of cardinality 2, with a⃗1, a⃗2 ∈ A1 and
a⃗3, a⃗4 ∈ A2, and AM1 = A1,AM2 = A2. Also, let a⃗3 = a⃗1 + a⃗2, a⃗4 = 0⃗ and p⃗ i =
(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1)T. Then, it follows:
f(AM1(⃗a1, a⃗2, nAb1), p⃗ i) = Si = f(AM2(⃗a3, a⃗4, nAb2), p⃗ i). (S.6)
Therefore, f is not injective22 and thereby not bijective. The simulation of signal
intensities is a process which does not preserve the entire information (e.g. antibody
repertoire size) of the input space.
A.8.2 Unbiased mixtures reduce the dimensionality of the signal intensity
space
Signal intensity profiles of unbiased mixtures are predictable by AAWS (Section 4). This
finding implies that signal intensity profiles of unbiased mixtures span a dimensionally
reduced signal intensity space since peptides with different antibody sequences but the
same amino acid composition are predicted to yield the same signal intensity.
Given an unbiased mixture, the number of unique peptide sequences—with respect
to amino acid order—drawn from an arbitrary amino acid alphabet AA is reduced
− log Γkn/nk-fold.
Γkn/nk = 1
nk

n+ k − 1
k

, (S.7)
22If nAb were 1 and the signal intensity profile with the respective peptide sequences and assigned AAWS
(⃗h) were known, then the antibody sequence of the one antibody could be largely recovered thanks to
the approximation obtained by the Taylor series expansion of the exponential function, exp(x) = 1+x,
and linear regression.
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where n = #AA is the size of the amino acid alphabet and l is the peptide sequence
length.
Let l amino acids be drawn from a set of n different amino acids with repetitions
allowed and the order of drawing is relevant. The number of possible amino acid sequences
(peptides) is then nk. Therefore, the aim is to show that the numerator of Equation
S.7 yields the number of all possible combinations of peptide sequences (i) if, for one
sequence, k out of n amino acids are drawn randomly, (ii) if the order of the drawn amino
acids is of no importance and (iii) drawing repetitively the same amino acid is allowed. If
drawing repetitively the same amino acid was not allowed, the above assumptions would
lead to:

n
k

. Using the ansatz to mapping bijectively the “repetition” case onto the
“non-repetition” case yields Equation S.7 [307].
Setting the size of the amino acid alphabet to #AA = 20 and the peptide sequence
length l to 14 (Figure 4.2), Equation S.7 yields 4.99 × 10−10, which signifies that the
number of unique sequences with respect to amino acid order is reduced ≈ 1010-fold.
A.8.3 Derivation of the isolation of the signal of dominant antibodies from
a biased mixture’s signal
The approximative isolation of the signal of the dominant antibodies Si,D (Equation 4.9)
can be derived as follows.
Si,U-D =
nAb,U-D
k=1 [Ab]kKi,k
1 +nAb,U-Dk=1 [Ab]kKi,k (S.8)
Si,U-D =
nAb,U-D−nAb,D
k=1 [Ab]kKi,k +
nAb,D
k=1 [Ab]kKi,k
1 +nAb,U-D−nAb,Dk=1 [Ab]kKi,k +nAb,Dk=1 [Ab]kKi,k (S.9)
Si,U-D ≈ si,U + si,D1 + si,U + si,D (S.10)
(1 + si,U + si,D)Si,U-D = si,U + si,D (S.11)
(1 + si,U)Si,U-D + si,DSi,U-D = si,U + si,D (S.12)
si,D(Si,U-D − 1) = si,U − (1 + si,U)Si,U-D (S.13)
si,D =
si,U − (1 + si,U)Si,U-D
Si,U-D − 1 (S.14)
si,D =
−Si,U
Si,U−1 − (1 +
−Si,U
Si,U−1)Si,U-D
Si,U-D − 1 (S.15)
si,D =
Si,U-D
1
Si,U−1 −
Si,U
Si,U−1
Si,U-D − 1 (S.16)
si,D =
Si,U-D − Si,U
(Si,U-D − 1)(Si,U − 1) (S.17)
132
Bibliography
[1] Javier Mestas and Christopher C. W Hughes. Of Mice and Not Men: Differences Between Mouse
and Human Immunology. The Journal of Immunology, 172(5):2731–2738, 2004.
[2] C. Janeway, M. J. Shlomchik, and Walport. Immunobiology. Garland Science, 6 edition, 2004.
[3] A R Abbas, D Baldwin, Y Ma, W Ouyang, A Gurney, F Martin, S Fong, M van Lookeren
Campagne, P Godowski, P M Williams, A C Chan, and H F Clark. Immune response in silico
(IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes
and Immunity, 6(4):319–331, 2005.
[4] Thomas Heams, Philippe Huneman, Guillaume Lecointre, and Marc Silberstein. Les mondes
darwiniens. L’évolution de l’évolution. Editions Syllepse, 2009.
[5] IR Cohen, U Hershberg, and S Solomon. Antigen-receptor degeneracy and immunological paradigms.
Molecular Immunology, 40(14-15):996, 993, 2004.
[6] Danielle L Drayton, Shan Liao, Rawad H Mounzer, and Nancy H Ruddle. Lymphoid organ
development: from ontogeny to neogenesis. Nature Immunology, 7(4):344–353, 2006.
[7] Björn Hartmann, René Riedel, Katharina Jörss, Christoph Loddenkemper, Andreas Steinmeyer,
Ulrich Zügel, Magda Babina, Andreas Radbruch, and Margitta Worm. Vitamin D receptor
activation improves allergen-triggered eczema in mice. The Journal of Investigative Dermatology,
132(2):330–336, 2012.
[8] Ruslan Medzhitov and Charles A Janeway Jr. Innate immune recognition and control of adaptive
immune responses. Seminars in Immunology, 10(5):351–353, 1998.
[9] William A McEwan, Donna L Mallery, David A Rhodes, John Trowsdale, and Leo C James.
Intracellular antibody-mediated immunity and the role of TRIM21. BioEssays, 33(11):803–809,
2011.
[10] Thomas Pradeu. L’immunologie et la définition de l’identité biologique. Philosophy, l’Université de
Paris 1 Panthéon-Sorbonne, 2007.
[11] J A Berzofsky. Intrinsic and extrinsic factors in protein antigenic structure. Science (New York,
N.Y.), 229(4717):932–940, 1985.
[12] Marc H. V. van Regenmortel. The Recognition of Proteins and Peptides by Antibodies. Journal of
Immunoassay, 21(2-3):85–108, 2000.
[13] Sir; Mavis Freeman; A V Jackson; Dora Lush F M Burnet. The Production of Antibodies. A Review
and a Theoretical Discussion. Melbourne, London, Macmillan and Co. Ltd., 1941.
[14] Sir Frank Macfarlane Burnet. Self and not-self: Cellular Immunology, 1. Melbourne University
Press, 1969.
[15] Thomas Pradeu and Edgardo D. Carosella. On the definition of a criterion of immunogenicity.
Proceedings of the National Academy of Sciences, 103(47):17858–17861, 2006.
Bibliography
[16] Rodney E. Langman. The specificity of immunological reactions. Molecular Immunology, 37(10):
555–561, 2000.
[17] Gary W. Litman, Jonathan P. Rast, and Sebastian D. Fugmann. The origins of vertebrate adaptive
immunity. Nat Rev Immunol, 10(8):543–553, 2010.
[18] Zvi Grossman and William E. Paul. Self-tolerance: context dependent tuning of T cell antigen
recognition. Seminars in Immunology, 12(3):197–203, 2000.
[19] Polly Matzinger. The Danger Model: A Renewed Sense of Self. Science, 296(5566):301–305, 2002.
[20] I R Cohen. The cognitive principle challenges clonal selection. Immunology Today, 13(11):441–4,
1992.
[21] Arthur M. Silverstein and Noel R. Rose. On the mystique of the immunological self. Immunological
Reviews, 159(1):197–206, 1997.
[22] Alfred I. Tauber. The Immune Self: Theory or Metaphor? Cambridge University Press, reprint
edition, 1996.
[23] P Matzinger. Tolerance, danger, and the extended family. Annual Review of Immunology, 12:
991–1045, 1994.
[24] NS Greenspan, DA Dacek, and LJ Cooper. Cooperative binding of two antibodies to independent
antigens by an Fc-dependent mechanism. The FASEB Journal, 3(10):2203–2207, 1989.
[25] M M Morelock, R. Rothlein, S M Bright, M K Robinson, E T Graham, J P Sabo, R. Owens,
D J King, S H Norris, and D S Scher. Isotype Choice for Chimeric Antibodies Affects Binding
Properties. Journal of Biological Chemistry, 269(17):13048–13055, 1994.
[26] Tarun K Dam, Marcela Torres, C. Fred Brewer, and Arturo Casadevall. Isothermal titration
calorimetry reveals differential binding thermodynamics of variable region-identical antibodies
differing in constant region for a univalent ligand. Journal of Biological Chemistry, 283(46):
31366–31370, 2008.
[27] Nicole Wittenbrink. New perspectives in the evolution of B lymphocytes in germinal centers. PhD
thesis, Humboldt Universität zu Berlin, 2007.
[28] Heinz Penzlin. Lehrbuch der Tierphysiologie. Spektrum Akademischer Verlag, 2008.
[29] Bjoern Peters, John Sidney, Phil Bourne, Huynh-Hoa Bui, Soeren Buus, Grace Doh, Ward
Fleri, Mitch Kronenberg, Ralph Kubo, Ole Lund, David Nemazee, Julia V Ponomarenko, Muthu
Sathiamurthy, Stephen Schoenberger, Scott Stewart, Pamela Surko, Scott Way, Steve Wilson, and
Alessandro Sette. The Immune Epitope Database and Analysis Resource: From Vision to Blueprint.
PLoS Biology, 3(3), 2005.
[30] Julia V Ponomarenko and Philip E Bourne. Antibody-protein interactions: benchmark datasets
and prediction tools evaluation. BMC Structural Biology, 7(1):64, 2007.
[31] N. S Greenspan. Epitopes, paratopes and other topes : do immunologists know what they are
talking about? Bulletin de l’Institut Pasteur, 90(4):267–279, 1992.
[32] M H Van Regenmortel. Structural and functional approaches to the study of protein antigenicity.
Immunology Today, 10(8):266–272, 1989.
[33] D R Davies and G H Cohen. Interactions of protein antigens with antibodies. Proceedings of the
National Academy of Sciences, 93(1):7–12, 1996.
134
Bibliography
[34] D J Barlow, M S Edwards, and J M Thornton. Continuous and discontinuous protein antigenic
determinants. Nature, 322(6081):747–748, 1986.
[35] W G Laver, G M Air, R G Webster, and S J Smith-Gill. Epitopes on protein antigens: misconcep-
tions and realities. Cell, 61(4):553–556, 1990.
[36] J A Schroer, T Bender, R J Feldmann, and K J Kim. Mapping epitopes on the insulin molecule
using monoclonal antibodies. European Journal of Immunology, 13(9):693–700, 1983.
[37] Eric J Sundberg, Roy A Mariuzza, Joel Janin, and Shoshana J. Wodak. Molecular recognition in
antibody-antigen complexes. In Protein Modules and Protein-Protein Interaction, volume Volume
61, pages 119–160. Academic Press, 2002.
[38] Vered Kunik, Bjoern Peters, and Yanay Ofran. Structural Consensus among Antibodies Defines
the Antigen Binding Site. PLoS Computational Biology, 8(2), 2012.
[39] T B Lavoie, W N Drohan, and S J Smith-Gill. Experimental analysis by site-directed mutagenesis of
somatic mutation effects on affinity and fine specificity in antibodies specific for lysozyme. Journal
of Immunology (Baltimore, Md.: 1950), 148(2):503–513, 1992.
[40] Ronald Frank. The SPOT-synthesis technique: Synthetic peptide arrays on membrane supports–
principles and applications. Journal of Immunological Methods, 267(1):13–26, 2002.
[41] I.Saira Mian, Arthur R. Bradwell, and Arthur J. Olson. Structure, function and properties of
antibody binding sites. Journal of Molecular Biology, 217(1):133–151, 1991.
[42] S. Sheriff, E W Silverton, E A Padlan, G H Cohen, S J Smith-Gill, B C Finzel, and D R Davies.
Three-dimensional structure of an antibody-antigen complex. Proceedings of the National Academy
of Sciences, 84(22):8075–8079, 1987.
[43] Wesley E. Stites. Protein-Protein Interactions: Interface Structure, Binding Thermodynamics, and
Mutational Analysis. Chem. Rev., 97(5):1233–1250, 1997.
[44] E A Kabat, T T Wu, and H Bilofsky. Unusual distributions of amino acids in complementarity-
determining (hypervariable) segments of heavy and light chains of immunoglobulins and their
possible roles in specificity of antibody-combining sites. The Journal of Biological Chemistry, 252
(19):6609–6616, 1977.
[45] E.A. Padlan. On the nature of antibody combining sites: unusual structural features that may
confer on these sites an enhanced capacity for binding ligands. Proteins: Structure, Function, and
Bioinformatics, 7(2):112–124, 1990.
[46] T N Bhat, G A Bentley, T O Fischmann, G Boulot, and R J Poljak. Small rearrangements in
structures of Fv and Fab fragments of antibody D1.3 on antigen binding. Nature, 347(6292):
483–485, 1990.
[47] D R Davies, E A Padlan, and S Sheriff. Antibody-antigen complexes. Annual Review of Biochemistry,
59:439–473, 1990.
[48] Shoshana J Wodak, Joël Janin, Joel Janin, and Shoshana J. Wodak. Structural basis of macro-
molecular recognition. In Protein Modules and Protein-Protein Interaction, volume Volume 61,
pages 9–73. Academic Press, 2002.
[49] Q X Hua, S E Shoelson, M Kochoyan, and M A Weiss. Receptor binding redefined by a structural
switch in a mutant human insulin. Nature, 354(6350):238–241, 1991.
[50] Neil S Greenspan. Cohen’s Conjecture, Howard’s Hypothesis, and Ptashne’s Ptruth: an exploration
of the relationship between affinity and specificity. Trends in Immunology, 31(4):138–143, 2010.
135
Bibliography
[51] Bertrand Friguet, Alain F. Chaffotte, Lisa Djavadi-Ohaniance, and Michel E. Goldberg. Measure-
ments of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked
immunosorbent assay. Journal of Immunological Methods, 77(2):305–319, 1985.
[52] Ibrahim Abdulhalim, Mohammad Zourob, and Akhlesh Lakhtakia. Surface Plasmon Resonance for
Biosensing: A Mini-Review. Electromagnetics, 28(3):214–242, 2008.
[53] J M Pitarke, V M Silkin, E V Chulkov, and P M Echenique. Theory of surface plasmons and
surface-plasmon polaritons. Reports on Progress in Physics, 70(1):1–87, 2007.
[54] A. N. Glazer. On the Prevalence of „Nonspecific” Binding at the Specific Binding Sites of Globular
Proteins*. Proceedings of the National Academy of Sciences of the United States of America, 65(4):
1057–1063, 1970.
[55] Herman N. Eisen and Gregory W. Siskind. Variations in Affinities of Antibodies during the Immune
Responses. Biochemistry, 3(7):996–1008, 1964.
[56] Gregory A Michaud, Michael Salcius, Fang Zhou, Rhonda Bangham, Jaclyn Bonin, Hong Guo,
Michael Snyder, Paul F Predki, and Barry I Schweitzer. Analyzing antibody specificity with whole
proteome microarrays. Nature Biotechnology, 21(12):1509–1512, 2003.
[57] Paul F Predki, Dawn Mattoon, Rhonda Bangham, Barry Schweitzer, and Gregory Michaud. Protein
microarrays: a new tool for profiling antibody cross-reactivity. Human Antibodies, 14(1-2):7–15,
2005.
[58] Ulrich Reineke, Claudia Ivascu, Marén Schlief, Christiane Landgraf, Seike Gericke, Grit Zahn,
Hanspeter Herzel, Rudolf Volkmer-Engert, and Jens Schneider-Mergener. Identification of distinct
antibody epitopes and mimotopes from a peptide array of 5520 randomly generated sequences.
Journal of Immunological Methods, 267(1):37–51, 2002.
[59] F.F. Richards and WH Konigsberg. Speculations how specific are antibodies? Immunochemistry,
10(8):545–553, 1973.
[60] F F Richards, W H Konigsberg, R W Rosenstein, and J M Varga. On the specificity of antibodies.
Science (New York, N.Y.), 187(4172):130–137, 1975.
[61] David Schubert, Ann Roman, and Melvin Cohn. Anti-Nucleic Acid Specificities of Mouse Myeloma
Immunoglobulins. , Published online: 10 January 1970; | doi:10.1038/225154a0, 225(5228):154–158,
1970.
[62] Karl Landsteiner. The Specificity of Serological Reactions Revised Edition. Harvard University
Press, 1947.
[63] Kai W. Wucherpfennig, Paul M. Allen, Franco Celada, Irun R. Cohen, Rob De Boer, K. Christopher
Garcia, Byron Goldstein, Ralph Greenspan, David Hafler, Philip Hodgkin, Erik S. Huseby, David C.
Krakauer, David Nemazee, Alan S. Perelson, Clemencia Pinilla, Rol, K. Strong, and Eli E. Sercarz.
Polyspecificity of T cell and B cell receptor recognition. Seminars in Immunology, 19(4):216–224,
2007.
[64] AR Williamson. Extent and control of antibody diversity. Biochemical Journal, 130(2):325, 1972.
[65] Frederik W Wiegel and Alan S Perelson. Some Scaling Principles for the Immune System.
Immunology and Cell Biology, 82(2):127–131, 2004.
[66] Alan S. Perelson and George F. Oster. Theoretical studies of clonal selection: Minimal antibody
repertoire size and reliability of self-non-self discrimination. Journal of Theoretical Biology, 81(4):
645–670, 1979.
136
Bibliography
[67] J. Haimovich and L. Du Pasquier. Specificity of antibodies in amphibian larvae possessing a small
number of lymphocytes. Proceedings of the National Academy of Sciences, 70(6):1898, 1973.
[68] Alan S. Perelson and Gérard Weisbuch. Immunology for physicists. Reviews of Modern Physics, 69
(4):1219, 1997.
[69] R J de Boer and A S Perelson. Size and connectivity as emergent properties of a developing immune
network. Journal of Theoretical Biology, 149(3):381–424, 1991.
[70] R. M Zinkernagel. Uncertainties- discrepancies in immunology. Immunological reviews, 185(1):
103–125, 2002.
[71] N S Greenspan. Affinity, complementarity, cooperativity, and specificity in antibody recognition.
Current Topics in Microbiology and Immunology, 260:65–85, 2001.
[72] Ilona Mandrika, Peteris Prusis, Sviatlana Yahorava, Kaspars Tars, and Jarl E.S. Wikberg. QSAR
of multiple mutated antibodies. Journal of Molecular Recognition, 20(2):97–102, 2007.
[73] Ilona Mandrika, Peteris Prusis, Sviatlana Yahorava, Medya Shikhagaie, and Jarl E.S. Wikberg.
Proteochemometric modelling of antibody-antigen interactions using SPOT synthesised peptide
arrays. Protein Engineering, Design and Selection, page gzm022, 2007.
[74] Hedda Wardemann, Sergey Yurasov, Anne Schaefer, James W Young, Eric Meffre, and Michel C
Nussenzweig. Predominant autoantibody production by early human B cell precursors. Science
(New York, N.Y.), 301(5638):1374–1377, 2003.
[75] Hugo Mouquet, Johannes F. Scheid, Markus J. Zoller, Michelle Krogsgaard, Rene G. Ott, Shetha
Shukair, Maxim N. Artyomov, John Pietzsch, Mark Connors, Florencia Pereyra, Bruce D. Walker,
David D. Ho, Patrick C. Wilson, Michael S. Seaman, Herman N. Eisen, Arup K. Chakraborty,
Thomas J. Hope, Jeffrey V. Ravetch, Hedda Wardemann, and Michel C. Nussenzweig. Polyreactivity
increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 467(7315):591–595,
2010.
[76] Thomas Tiller, Makoto Tsuiji, Sergey Yurasov, Klara Velinzon, Michel C. Nussenzweig, and Hedda
Wardemann. Autoreactivity in human IgG+ memory B cells. Immunity, 26(2):205–213, 2007.
[77] David W. Talmage. Immunological Specificity: Unique combinations of selected natural globulins
provide an alternative to the classical concept. Science, 129(3364):1643–1648, 1959.
[78] Arturo Casadevall and Liise-anne Pirofski. A new synthesis for antibody-mediated immunity. Nat
Immunol, 13(1):21–28, 2012.
[79] C. Berek, G. M. Griffiths, and C. Milstein. Molecular events during maturation of the immune
response to oxazolone. Nature, 316(6027):412–418, 1985.
[80] Jean-Claude Weill and Claude-Agnès Reynaud. Rearrangement/hypermutation/gene conversion:
when, where and why? Immunology Today, 17(2):92–97, 1996.
[81] Claudia Berek and César Milstein. The dynamic nature of the antibody repertoire. Immunological
Reviews, 105:5–26, 1988.
[82] Michael S Neuberger and César Milstein. Somatic hypermutation. Current Opinion in Immunology,
7(2):248–254, 1995.
[83] Susumu Tonegawa. Somatic generation of antibody diversity. Nature, 302(5909):575–581, 1983.
137
Bibliography
[84] J.C. Almagro, I. Hernández, M.C. Ramírez, and E. Vargas-Madrazo. Structural differences
between the repertoires of mouse and human germline genes and their evolutionary implications.
Immunogenetics, 47(5):355–363, 1998.
[85] I C M MacLennan. Germinal Centers. Annual Review of Immunology, 12(1):117–139, 1994.
[86] D. McKean, K. Huppi, M. Bell, L. Staudt, W. Gerhard, and M. Weigert. Generation of antibody
diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proceedings of
the National Academy of Sciences, 81(10):3180–3184, 1984.
[87] NS Levy, UV Malipiero, SG Lebecque, and PJ Gearhart. Early onset of somatic mutation in
immunoglobulin VH genes during the primary immune response. J. Exp. Med., 169(6):2007–2019,
1989.
[88] Nancy S. Longo and Peter E. Lipsky. Why do B cells mutate their immunoglobulin receptors?
Trends in Immunology, 27(8):374–380, 2006.
[89] A G Betz, C Rada, R Pannell, C Milstein, and M S Neuberger. Passenger transgenes reveal intrinsic
specificity of the antibody hypermutation mechanism: clustering, polarity, and specific hot spots.
Proceedings of the National Academy of Sciences of the United States of America, 90(6):2385–2388,
1993.
[90] Armin A Weiser, Nicole Wittenbrink, Lei Zhang, Andrej I Schmelzer, Atijeh Valai, and Michal
Or-Guil. Affinity maturation of B cells involves not only a few but a whole spectrum of relevant
mutations. International Immunology, 23(5):345–356, 2011.
[91] Adrian F. Ochsenbein, Daniel D. Pinschewer, Sophie Sierro, Edit Horvath, Hans Hengartner,
and Rolf M. Zinkernagel. Protective long-term antibody memory by antigen-driven and T help-
dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of
secondary lymphoid organs. Proceedings of the National Academy of Sciences, 97(24):13263 –13268,
2000.
[92] Edward S. Golub. Somatic mutation: Diversity and regulation of the immune repertoire. Cell, 48
(5):723–724, 1987.
[93] Joshua A. Weinstein, Ning Jiang, Richard A. White, Daniel S. Fisher, and Stephen R. Quake.
High-Throughput Sequencing of the Zebrafish Antibody Repertoire. Science, 324(5928):807–810,
2009.
[94] Jennifer Benichou, Rotem Ben-Hamo, Yoram Louzoun, and Sol Efroni. Rep-Seq: uncovering the
immunological repertoire through next-generation sequencing. Immunology, 135(3):183–191, 2012.
[95] Jay Shendure and Hanlee Ji. Next-generation DNA sequencing. Nature Biotechnology, 26(10):
1135–1145, 2008.
[96] Marcel Margulies, Michael Egholm, William E. Altman, Said Attiya, Joel S. Bader, Lisa A. Bemben,
Jan Berka, Michael S. Braverman, Yi-Ju Chen, Zhoutao Chen, Scott B. Dewell, Lei Du, Joseph M.
Fierro, Xavier V. Gomes, Brian C. Godwin, Wen He, Scott Helgesen, Chun He Ho, Gerard P.
Irzyk, Szilveszter C. Jando, Maria L. I. Alenquer, Thomas P. Jarvie, Kshama B. Jirage, Jong-Bum
Kim, James R. Knight, Janna R. Lanza, John H. Leamon, Steven M. Lefkowitz, Ming Lei, Jing
Li, Kenton L. Lohman, Hong Lu, Vinod B. Makhijani, Keith E. McDade, Michael P. McKenna,
Eugene W. Myers, Elizabeth Nickerson, John R. Nobile, Ramona Plant, Bernard P. Puc, Michael T.
Ronan, George T. Roth, Gary J. Sarkis, Jan Fredrik Simons, John W. Simpson, Maithreyan
Srinivasan, Karrie R. Tartaro, Alexander Tomasz, Kari A. Vogt, Greg A. Volkmer, Shally H. Wang,
Yong Wang, Michael P. Weiner, Pengguang Yu, Richard F. Begley, and Jonathan M. Rothberg.
Genome sequencing in microfabricated high-density picolitre reactors. Nature, 437(7057):376–380,
2005.
138
Bibliography
[97] Thierry Mora, Aleksandra M. Walczak, William Bialek, and Curtis G. Callan. Maximum entropy
models for antibody diversity. Proceedings of the National Academy of Sciences, 107(12):5405–5410,
2010.
[98] Ning Jiang, Joshua A. Weinstein, Lolita Penland, Richard A. White, Daniel S. Fisher, and
Stephen R. Quake. Determinism and stochasticity during maturation of the zebrafish antibody
repertoire. Proceedings of the National Academy of Sciences, 108(13):5348 –5353, 2011.
[99] Ponraj Prabakaran, Weizao Chen, Maria G Singarayan, Claudia C Stewart, Emily Streaker, Yang
Feng, and Dimiter S Dimitrov. Expressed antibody repertoires in human cord blood cells: 454
sequencing and IMGT/HighV-QUEST analysis of germline gene usage, junctional diversity, and
somatic mutations. Immunogenetics, 2011.
[100] Jacob Glanville, Wenwu Zhai, Jan Berka, Dilduz Telman, Gabriella Huerta, Gautam R. Mehta,
Irene Ni, Li Mei, Purnima D. Sundar, Giles M. R. Day, David Cox, Arvind Rajpal, and Jaume
Pons. Precise determination of the diversity of a combinatorial antibody library gives insight into
the human immunoglobulin repertoire. Proceedings of the National Academy of Sciences, 106(48):
20216–20221, 2009.
[101] Ramy Arnaout, William Lee, Patrick Cahill, Tracey Honan, Todd Sparrow, Michael Weiand,
Chad Nusbaum, Klaus Rajewsky, and Sergei B. Koralov. High-Resolution Description of Antibody
Heavy-Chain Repertoires in Humans. PLoS ONE, 6(8):e22365, 2011.
[102] E. A Martin and Oxford University Press. Concise medical dictionary. Oxford University Press,
Oxford; New York, 2007.
[103] Caroline Brissac, Alberto Nobrega, Jorge Carneiro, and John Stewart. Functional diversity of
natural IgM. Int. Immunol., 11(9):1501–1507, 1999.
[104] Victor Greiff, Henning Redestig, Juliane Luck, Nicole Bruni, Atijeh Valai, Susanne Hartmann,
Sebastian Rausch, Johannes Schuchhardt, and Michal Or-Guil. A minimal model of peptide binding
predicts ensemble properties of serum antibodies. BMC Genomics, 13(1):79, 2012.
[105] E. Helmreich, M. Kern, and H. N Eisen. The secretion of antibody by isolated lymph node cells.
Journal of Biological Chemistry, 236(2):464, 1961.
[106] Toshifumi Hibi and Hans-Michael Dosch. Limiting dilution analysis of the B cell compartment in
human bone marrow. European Journal of Immunology, 16(2):139–145, 1986.
[107] Sergio Arce, Elke Luger, Gwendolin Muehlinghaus, Giuliana Cassese, Anja Hauser, Alexander
Horst, Katja Lehnert, Marcus Odendahl, Dirk Hönemann, Karl-Dieter Heller, Harald Kleinschmidt,
Claudia Berek, Thomas Dörner, Veit Krenn, Falk Hiepe, Ralf Bargou, Andreas Radbruch, and
Rudolf A Manz. CD38 Low IgG-Secreting Cells Are Precursors of Various CD38 High-Expressing
Plasma Cell Populations. Journal of Leukocyte Biology, 75(6):1022–1028, 2004.
[108] J J Haaijman, H R Schuit, and W Hijmans. Immunoglobulin-containing cells in different lymphoid
organs of the CBA mouse during its life-span. Immunology, 32(4):427–434, 1977.
[109] J A Brieva, E Roldán, M L De la Sen, and C Rodriguez. Human in vivo-induced spontaneous
IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional
level of maturation. Immunology, 72(4):580–583, 1991.
[110] Elizabeth J. Blink, Amanda Light, Axel Kallies, Stephen L. Nutt, Philip D. Hodgkin, and David M.
Tarlinton. Early appearance of germinal center-derived memory B cells and plasma cells in blood
after primary immunization. J. Exp. Med., 201(4):545–554, 2005.
139
Bibliography
[111] P Vieira and K Rajewsky. The half-lives of serum immunoglobulins in adult mice. European
Journal of Immunology, 18(2):313–316, 1988.
[112] Rudolf A. Manz, Anja E. Hauser, Falk Hiepe, and Andreas Radbruch. Maintenance of serum
antibody levels. Annual Review of Immunology, 23(1):367–386, 2005.
[113] M A Kerr. The structure and function of human IgA. Biochemical Journal, 271(2):285–296, 1990.
[114] H Metzger. Structure and function of gamma M macroglobulins. Advances in Immunology, 12:
57–116, 1970.
[115] R. M. E. Parkhouse, Brigitte A. Askonas, and R. R. Dourmashkin. Electron microscopic studies of
mouse immunoglobulin M; structure and reconstitution following reduction. Immunology, 18(4):
575–584, 1970.
[116] L A Herzenberg, A M Stall, P A Lalor, C Sidman, W A Moore, D R Parks, and L A Herzenberg.
The Ly-1 B cell lineage. Immunological Reviews, 93:81–102, 1986.
[117] P Casali and E W Schettino. Structure and function of natural antibodies. Current Topics in
Microbiology and Immunology, 210:167–179, 1996.
[118] Stephen V. Boyden, F.J. Dixon, and J.H. Humphrey. Natural Antibodies and the Immune Response.
In Advances in Immunology, volume Volume 5, pages 1–28. Academic Press, 1966.
[119] Yang Yang, Eliver Eid Bou Ghosn, Leah E Cole, Tetyana V Obukhanych, Patricia Sadate-Ngatchou,
Stefanie N Vogel, Leonard A Herzenberg, and Leonore A Herzenberg. Antigen-Specific Antibody
Responses in B-1a and Their Relationship to Natural Immunity. Proceedings of the National
Academy of Sciences, 109(14):5382–5387, 2012.
[120] F. Martin and J.F. Kearney. B-cell subsets and the mature preimmune repertoire. Marginal zone
and B1 B cells as part of a “natural immune memory”. Immunological reviews, 175(1):70–79, 2000.
[121] S. Bao, KW Beagley, AM Murray, V. Caristo, KI Matthaei, IG Young, and AJ Husband. Intestinal
IgA plasma cells of the B1 lineage are IL-5 dependent. Immunology, 94(2):181–188, 1998.
[122] James W Tung, Matthew D Mrazek, Yang Yang, Leonard A Herzenberg, and Leonore A Herzenberg.
Phenotypically Distinct B Cell Development Pathways Map to the Three B Cell Lineages in the
Mouse. Proceedings of the National Academy of Sciences, 103(16):6293–6298, 2006.
[123] Atijeh Valai. Migration and differentiation of murine germinal center derived B cell subsets in the
course of the NP-specific immune response. PhD thesis, Freie Universität Berlin, 2012.
[124] Christopher D.C. Allen, Takaharu Okada, and Jason G. Cyster. Germinal-Center Organization
and Cellular Dynamics. Immunity, 27(2):190–202, 2007.
[125] Ian C. M. MacLennan, Kai-Michael Toellner, Adam F. Cunningham, Karine Serre, Daniel M.-Y.
Sze, Elina Zuniga, Matthew C. Cook, and Carola G. Vinuesa. Extrafollicular antibody responses.
Immunological Reviews, 194(1):8–18, 2003.
[126] H. P Roost, M. F Bachmann, A. Haag, U. Kalinke, V. Pliska, H. Hengartner, and R. M Zinkernagel.
Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of
affinity. Proceedings of the National Academy of Sciences of the United States of America, 92(5):
1257, 1995.
[127] Rudolf A. Manz, Andreas Thiel, and Andreas Radbruch. Lifetime of plasma cells in the bone
marrow. Nature, 388(6638):133–134, 1997.
140
Bibliography
[128] Mark K Slifka, Rustom Antia, Jason K Whitmire, and Rafi Ahmed. Humoral Immunity Due to
Long-Lived Plasma Cells. Immunity, 8(3):363–372, 1998.
[129] Erika Hammarlund, Matthew W Lewis, Scott G Hansen, Lisa I Strelow, Jay A Nelson, Gary J
Sexton, Jon M Hanifin, and Mark K Slifka. Duration of antiviral immunity after smallpox
vaccination. Nat Med, 9(9):1131–1137, 2003.
[130] Ian J Amanna, Nichole E Carlson, and Mark K Slifka. Duration of humoral immunity to common
viral and vaccine antigens. The New England Journal of Medicine, 357(19):1903–1915, 2007.
[131] Eric J Kunkel and Eugene C Butcher. Plasma-cell homing. Nature Reviews. Immunology, 3(10):
822–829, 2003.
[132] Stuart G. Tangye. Staying alive: regulation of plasma cell survival. Trends in Immunology, 32(12):
595–602, 2011.
[133] G Cassese, S Lindenau, B de Boer, S Arce, A Hauser, G Riemekasten, C Berek, F Hiepe, V
Krenn, A Radbruch, and R A Manz. Inflamed kidneys of NZB / W mice are a major site for the
homeostasis of plasma cells. European Journal of Immunology, 31(9):2726–2732, 2001.
[134] Taketoshi Yoshida, Henrik Mei, Thomas Dörner, Falk Hiepe, Andreas Radbruch, Simon Fillatreau,
and Bimba F Hoyer. Memory B and memory plasma cells. Immunological Reviews, 237(1):117–139,
2010.
[135] M.F. Bachmann, T.M. Kundig, C.P. Kalberer, H. Hengartner, and R.M. Zinkernagel. How many
specific B cells are needed to protect against a virus? The Journal of Immunology, 152(9):4235–4241,
1994.
[136] D Fleury, R S Daniels, J J Skehel, M Knossow, and T Bizebard. Structural evidence for recognition
of a single epitope by two distinct antibodies. Proteins, 40(4):572–578, 2000.
[137] Andrew C.R. Martin, Janet C. Cheetham, Anthony R. Rees, and John J. Langone. [6] Molecular
modeling of antibody combining sites. InMolecular Design and Modeling: Concepts and Applications
Part B: Antibodies and Antigens, Nucleic Acids, Polysaccharides, and Drugs, volume Volume 203,
pages 121–153. Academic Press, 1991.
[138] M K Gilson, J A Given, B L Bush, and J A McCammon. The statistical-thermodynamic basis for
computation of binding affinities: a critical review. Biophysical Journal, 72(3):1047–1069, 1997.
[139] Stephanie Leavitt and Ernesto Freire. Direct measurement of protein binding energetics by
isothermal titration calorimetry. Current Opinion in Structural Biology, 11(5):560–566, 2001.
[140] T Wiseman, S Williston, J F Brandts, and L N Lin. Rapid measurement of binding constants and
heats of binding using a new titration calorimeter. Analytical Biochemistry, 179(1):131–137, 1989.
[141] J E Ladbury and B Z Chowdhry. Sensing the heat: the application of isothermal titration
calorimetry to thermodynamic studies of biomolecular interactions. Chemistry & Biology, 3(10):
791–801, 1996.
[142] Stephen E. Harding and Babur Z. Chowdhry, editors. Protein-ligand Interactions: Hydrodynamics
and Calorimetry. OUP Oxford, 2000.
[143] J. J. Christensen, R. M. Izatt, L. D. Hansen, and J. A. Partridge. Entropy Titration. A Calorimetric
Method for the Determination of ∆G, ∆H, and ∆S from a Single Thermometric Titration. J. Phys.
Chem., 70(6):2003–2010, 1966.
[144] J.Doyne Farmer, Norman H Packard, and Alan S Perelson. The immune system, adaptation, and
machine learning. Physica D: Nonlinear Phenomena, 22(1–3):187–204, 1986.
141
Bibliography
[145] R. Hightower, S. Forrest, and A.S. Perelson. The Evolution of Cooperation in Immune System
Gene Libraries l. Working Paper, 1992.
[146] D Lancet, E Sadovsky, and E Seidemann. Probability model for molecular recognition in biological
receptor repertoires: significance to the olfactory system. Proceedings of the National Academy of
Sciences of the United States of America, 90(8):3715–3719, 1993.
[147] J D Farmer, S A Kauffman, N H Packard, and A S Perelson. Adaptive dynamic networks as models
for the immune system and autocatalytic sets. Annals of the New York Academy of Sciences, 504:
118–131, 1987.
[148] Frederic A. Fellouse, Bing Li, Deanne M. Compaan, Andrew A. Peden, Sarah G. Hymowitz, and
Sachdev S. Sidhu. Molecular Recognition by a Binary Code. Journal of Molecular Biology, 348(5):
1153–1162, 2005.
[149] A. Sircar, E. T. Kim, and J. J. Gray. RosettaAntibody: antibody variable region homology modeling
server. Nucleic Acids Research, 37(Web Server):W474–W479, 2009.
[150] Louis A. Clark, P. Ann Boriack-Sjodin, John Eldredge, Christopher Fitch, Bethany Friedman,
Karl J.M. Hanf, Matthew Jarpe, Stefano F. Liparoto, You Li, Alexey Lugovskoy, Stephan Miller,
Mia Rushe, Woody Sherman, Kenneth Simon, and Herman Van Vlijmen. Affinity enhancement
of an in vivo matured therapeutic antibody using structure-based computational design. Protein
Science : A Publication of the Protein Society, 15(5):949–960, 2006.
[151] Annemarie Honegger, Alain Daniel Malebranche, Daniela Röthlisberger, and Andreas Plückthun.
The Influence of the Framework Core Residues on the Biophysical Properties of Immunoglobulin
Heavy Chain Variable Domains. Protein Engineering Design and Selection, 22(3):121–134, 2009.
[152] Peter T. Jones, Paul H. Dear, Jefferson Foote, Michael S. Neuberger, and Greg Winter. Replacing
the complementarity-determining regions in a human antibody with those from a mouse. , Published
online: 29 May 1986; | doi:10.1038/321522a0, 321(6069):522–525, 1986.
[153] Martin Schlapschy, Marton Fogarasi, Helga Gruber, Oliver Gresch, Claudia Schäfer, Yasmine
Aguib, and Arne Skerra. Functional Humanization of an Anti-CD16 Fab Fragment: Obstacles of
Switching from Murine λ to Human λ or κ Light Chains. Protein Engineering Design and Selection,
22(3):175–188, 2009.
[154] Shuchismita Dutta, Kyle Burkhardt, Jasmine Young, Ganesh J Swaminathan, Takanori Matsuura,
Kim Henrick, Haruki Nakamura, and Helen M Berman. Data deposition and annotation at the
worldwide protein data bank. Molecular Biotechnology, 42(1):1–13, 2009.
[155] Arvind Sivasubramanian, Aroop Sircar, Sidhartha Chaudhury, and Jeffrey J Gray. Toward high-
resolution homology modeling of antibody Fv regions and application to antibody-antigen docking.
Proteins: Structure, Function, and Bioinformatics, 74(2):497–514, 2009.
[156] D.M. Webster and A.R. Rees. Molecular modeling of antibody-combining sites. Methods Mol Biol,
51:17–49, 1995.
[157] D.M. Webster, J. Pedersen, D. Staunton, A. Jones, and A.R. Rees. Antibody-combining sites.
Applied Biochemistry and Biotechnology, 47(2):119–134, 1994.
[158] D R Davies and H Metzger. Structural Basis of Antibody Function. Annual Review of Immunology,
1(1):87–115, 1983.
[159] Gary Walsh. Biopharmaceutical benchmarks 2006. Nature Biotechnology, 24(7):769–776, 2006.
142
Bibliography
[160] Janice Reichert and Alex Pavlou. Monoclonal antibodies market. Nature Reviews Drug Discovery,
3(5):383–384, 2004.
[161] C Chothia and A M Lesk. Canonical structures for the hypervariable regions of immunoglobulins.
Journal of Molecular Biology, 196(4):901–917, 1987.
[162] B Al-Lazikani, A M Lesk, and C Chothia. Standard conformations for the canonical structures of
immunoglobulins. Journal of Molecular Biology, 273(4):927–948, 1997.
[163] Veronica Morea, Arthur M. Lesk, and Anna Tramontano. Antibody Modeling: Implications for
Engineering and Design. Methods, 20(3):267–279, 2000.
[164] Benjamin North, Andreas Lehmann, and Roland L. Dunbrack Jr. A New Clustering of Antibody
CDR Loop Conformations. Journal of Molecular Biology, 406(2):228–256, 2011.
[165] Yoonjoo Choi and Charlotte M Deane. Predicting antibody complementarity determining region
structures without classification. Molecular bioSystems, 7(12):3327–3334, 2011.
[166] N. Whitelegg and A.R. Rees. Antibody Variable Regions. Antibody engineering: methods and
protocols, 248:51, 2004.
[167] Paolo Marcatili, Alessandra Rosi, and Anna Tramontano. PIGS: Automatic Prediction of Antibody
Structures. Bioinformatics, 24(17):1953–1954, 2008.
[168] Gregory L. Warren, C. Webster Andrews, Anna-Maria Capelli, Brian Clarke, Judith LaLonde,
Millard H. Lambert, Mika Lindvall, Neysa Nevins, Simon F. Semus, Stefan Senger, Giovanna
Tedesco, Ian D. Wall, James M. Woolven, Catherine E. Peishoff, and Martha S. Head. A Critical
Assessment of Docking Programs and Scoring Functions. J. Med. Chem., 49(20):5912–5931, 2005.
[169] S. Wold. Chemometrics; what do we mean with it, and what do we want from it? Chemometrics
and Intelligent Laboratory Systems, 30(1):109–115, 1995.
[170] Salvador Eugenio C. Caoili. Benchmarking B-Cell Epitope Prediction for the Design of Peptide-
Based Vaccines: Problems and Prospects. Journal of Biomedicine and Biotechnology, 2010:1–15,
2010.
[171] Marc H. V. Van Van Regenmortel. The rational design of biological complexity: A deceptive
metaphor. PROTEOMICS, 7(6):965–975, 2007.
[172] Martin J. Blythe and Darren R. Flower. Benchmarking B cell epitope prediction: Underperformance
of existing methods. Protein Science : A Publication of the Protein Society, 14(1):246–248, 2005.
[173] Galina F Denisova, Dimitri A Denisov, and Jonathan L Bramson. Applying bioinformatics
for antibody epitope prediction using affinity-selected mimotopes – relevance for vaccine design.
Immunome Research, 6(Suppl 2):S6, 2010.
[174] Virginie Lollier, Sandra Denery-Papini, Colette Larré, and Dominique Tessier. A generic approach
to evaluate how B-cell epitopes are surface-exposed on protein structures. Molecular Immunology,
48(4):577–585, 2011.
[175] Lilian Lacerda Bueno, Francisco Pereira Lobo, Cristiane Guimarães Morais, Luíza Carvalho
Mourão, Ricardo Andrez Machado de Ávila, Irene Silva Soares, Cor Jesus Fontes, Marcus Vinícius
Lacerda, Carlos Chavez Olórtegui, Daniella Castanheira Bartholomeu, Ricardo Toshio Fujiwara,
and Érika Martins Braga. Identification of a Highly Antigenic Linear B Cell Epitope within
Plasmodium vivax Apical Membrane Antigen 1 (AMA-1). PLoS ONE, 6(6):e21289, 2011.
[176] Darren R. Flower. Immunoinformatics: Predicting Immunogenicity In Silico. Humana Press, 1
edition, 2007.
143
Bibliography
[177] Yasser EL-Manzalawy and Vasant Honavar. Recent advances in B-cell epitope prediction methods.
Immunome Research, 6(Suppl 2):S2, 2010.
[178] I.M. Roitt and P.J. Delves. Roitt’s Essential Immunology. Essentials Series. Blackwell Science,
2001. ISBN 9780632059027. URL http://books.google.de/books?id=SEAVHm1QQQAC.
[179] Julia Ponomarenko, Nikitas Papangelopoulos, Dirk M. Zajonc, Bjoern Peters, Alessandro Sette,
and Philip E. Bourne. IEDB-3D: structural data within the immune epitope database. Nucleic
Acids Research, 39(Database issue):D1164–D1170, 2011.
[180] J. K. Scott and G. P. Smith. Searching for Peptide Ligands with an Epitope Library. Science, 249
(4967):386–390, 1990.
[181] R H Meloen, W C Puijk, and J W Slootstra. Mimotopes: realization of an unlikely concept. Journal
of Molecular Recognition: JMR, 13(6):352–359, 2000.
[182] Jason A Greenbaum, Pernille Haste Andersen, Martin Blythe, Huynh-Hoa Bui, Raul E Cachau,
James Crowe, Matthew Davies, A. S Kolaskar, Ole Lund, Sherrie Morrison, Brendan Mumey,
Yanay Ofran, Jean-Luc Pellequer, Clemencia Pinilla, Julia V Ponomarenko, G. P. S Raghava,
Marc H. V van Regenmortel, Erwin L Roggen, Alessandro Sette, Avner Schlessinger, Johannes
Sollner, Martin Zand, and Bjoern Peters. Towards a consensus on datasets and evaluation metrics
for developing B-cell epitope prediction tools. Journal of Molecular Recognition, 20(2):75–82, 2007.
[183] A Zvirbliene, I Kucinskaite, I Sezaite, D Samuel, and K Sasnauskas. Mapping of B cell epitopes in
measles virus nucleocapsid protein. Archives of Virology, 152(1):25–39, 2007.
[184] M Fernandez-Alonso, G Lorenzo, L Perez, R Bullido, A Estepa, N Lorenzen, and J M Coll. Mapping
of linear antibody epitopes of the glycoprotein of VHSV, a salmonid rhabdovirus. Diseases of
Aquatic Organisms, 34(3):167–176, 1998.
[185] John Mark Carter and Larry Loomis-Price. B cell epitope mapping using synthetic peptides.
Current Protocols in Immunology / Edited by John E. Coligan ... [et Al.], Chapter 9:Unit 9.4, 2004.
[186] J M Carter. Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. Methods in
Molecular Biology (Clifton, N.J.), 36:207–223, 1994.
[187] Achim Kramer and Jens Schneider-Mergener. Synthesis and Screening of Peptide Libraries on
Continuous Cellulose Membrane Supports. In Shmuel Cabilly, editor, Combinatorial Peptide Library
Protocols, volume 87 of Methods in Molecular Biology, pages 25–39. Humana Press, 1998.
[188] Juliane Bongartz, Nicole Bruni, and Michal Or-Guil. Epitope mapping using randomly generated
peptide libraries. Methods in Molecular Biology (Clifton, N.J.), 524:237–246, 2009.
[189] Joseph Barten Legutki, D Mitchell Magee, Phillip Stafford, and Stephen Albert Johnston. A general
method for characterization of humoral immunity induced by a vaccine or infection. Vaccine, 28
(28):4529–4537, 2010.
[190] Ulrich Reineke and Robert Sabat. Antibody epitope mapping using SPOT peptide arrays. Methods
in Molecular Biology (Clifton, N.J.), 524:145–167, 2009.
[191] M Sandberg, L Eriksson, J Jonsson, M Sjöström, and S Wold. New chemical descriptors relevant
for the design of biologically active peptides. A multivariate characterization of 87 amino acids.
Journal of Medicinal Chemistry, 41(14):2481–2491, 1998.
[192] T P Hopp and K R Woods. Prediction of protein antigenic determinants from amino acid sequences.
Proceedings of the National Academy of Sciences of the United States of America, 78(6):3824–3828,
1981.
144
Bibliography
[193] M Levitt. A simplified representation of protein conformations for rapid simulation of protein
folding. Journal of Molecular Biology, 104(1):59–107, 1976.
[194] J M Parker, D Guo, and R S Hodges. New hydrophilicity scale derived from high-performance liquid
chromatography peptide retention data: correlation of predicted surface residues with antigenicity
and X-ray-derived accessible sites. Biochemistry, 25(19):5425–5432, 1986.
[195] P. A. Karplus and G. E. Schulz. Prediction of chain flexibility in proteins. Naturwissenschaften, 72
(4):212–213, 1985.
[196] J.L. Pellequer, E. Westhof, M.H.V. Van Regenmortel, and John J. Langone. [8] Predicting location
of continuous epitopes in proteins from their primary structures. In Molecular Design and Modeling:
Concepts and Applications Part B: Antibodies and Antigens, Nucleic Acids, Polysaccharides, and
Drugs, volume Volume 203, pages 176–201. Academic Press, 1991.
[197] E A Emini, J V Hughes, D S Perlow, and J Boger. Induction of hepatitis A virus-neutralizing
antibody by a virus-specific synthetic peptide. Journal of Virology, 55(3):836–839, 1985.
[198] J L Pellequer, E Westhof, and M H Van Regenmortel. Correlation between the location of antigenic
sites and the prediction of turns in proteins. Immunology Letters, 36(1):83–99, 1993.
[199] A J Alix. Predictive estimation of protein linear epitopes by using the program PEOPLE. Vaccine,
18(3-4):311–314, 1999.
[200] Michael Odorico and Jean-Luc Pellequer. BEPITOPE: predicting the location of continuous
epitopes and patterns in proteins. Journal of Molecular Recognition: JMR, 16(1):20–22, 2003.
[201] J Chen, H Liu, J Yang, and K-C Chou. Prediction of linear B-cell epitopes using amino acid pair
antigenicity scale. Amino Acids, 33(3):423–428, 2007.
[202] Jens Erik Pontoppidan Larsen, Ole Lund, and Morten Nielsen. Improved method for predicting
linear B-cell epitopes. Immunome Research, 2:2, 2006.
[203] Randi Vita, Laura Zarebski, Jason A. Greenbaum, Hussein Emami, Ilka Hoof, Nima Salimi, Rohini
Damle, Alessandro Sette, and Bjoern Peters. The Immune Epitope Database 2.0. Nucleic Acids
Research, 38(Database issue):D854–D862, 2010.
[204] Johannes Söllner and Bernd Mayer. Machine learning approaches for prediction of linear B-cell
epitopes on proteins. Journal of Molecular Recognition, 19(3):200–208, 2006.
[205] Sudipto Saha and G P S Raghava. Prediction of continuous B-cell epitopes in an antigen using
recurrent neural network. Proteins, 65(1):40–48, 2006.
[206] Michael J Sweredoski and Pierre Baldi. COBEpro: a novel system for predicting continuous B-cell
epitopes. Protein Engineering, Design & Selection: PEDS, 22(3):113–120, 2009.
[207] Y Feng, F Jacobs, E Van Craeyveld, J Lievens, J Snoeys, S Van Linthout, and B De Geest. The
impact of antigen expression in antigen-presenting cells on humoral immune responses against the
transgene product. Gene Therapy, 17(2):288–293, 2010.
[208] Arthur M. Silverstein. A History of Immunology, Second Edition. Academic Press, 2 edition, 2009.
[209] F JFrancisco J. Quintana, Y Merbl, E Sahar, E Domany, and I R Cohen. Antigen-chip technology
for accessing global information about the state of the body. Lupus, 15(7):428–430, 2006.
[210] Phillip Stafford, Rebecca Halperin, Joseph Bart Legutki, Dewey Mitchell Magee, John Galgiani, and
Stephen Albert Johnston. Physical Characterization of the “Immunosignaturing Effect”. Molecular
& Cellular Proteomics, 11(4), 2012.
145
Bibliography
[211] A Nobrega, M Haury, A Grandien, E Malanchère, A Sundblad, and A Coutinho. Global analysis of
antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus"
of antibodies in normal serum. European Journal of Immunology, 23(11):2851–2859, 1993.
[212] M Haury, A Grandien, A Sundblad, A Coutinho, and A Nobrega. Global analysis of antibody
repertoires. 1. An immunoblot method for the quantitative screening of a large number of reactivities.
Scandinavian Journal of Immunology, 39(1):79–87, 1994.
[213] Jens Rauch and Olivier Gires. SEREX, Proteomex, AMIDA, and beyond: Serological screening
technologies for target identification. PROTEOMICS - CLINICAL APPLICATIONS, 2(3):355–371,
2008.
[214] Lina Cekaite, Ola Haug, Ola Myklebost, Magne Aldrin, Bjørn Østenstad, Marit Holden, Arnoldo
Frigessi, Eivind Hovig, and Mouldy Sioud. Analysis of the humoral immune response to immunose-
lected phage-displayed peptides by a microarray-based method. PROTEOMICS, 4(9):2572–2582,
2004.
[215] Paul J. Mintz, Jeri Kim, Kim-Anh Do, Xuemei Wang, Ralph G. Zinner, Massimo Cristofanilli,
Marco A. Arap, Waun Ki Hong, Patricia Troncoso, Christopher J. Logothetis, Renata Pasqualini,
and Wadih Arap. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat
Biotech, 21(1):57–63, 2003.
[216] Madhumita Chatterjee, Saroj Mohapatra, Alexei Ionan, Gagandeep Bawa, Rouba Ali-Fehmi, Xiaoju
Wang, James Nowak, Bin Ye, Fatimah A. Nahhas, Karen Lu, Steven S. Witkin, David Fishman,
Adnan Munkarah, Robert Morris, Nancy K. Levin, Natalie N. Shirley, Gerard Tromp, Judith
Abrams, Sorin Draghici, and Michael A. Tainsky. Diagnostic Markers of Ovarian Cancer by
High-Throughput Antigen Cloning and Detection on Arrays. Cancer Res, 66(2):1181–1190, 2006.
[217] Atsushi Kuno, Noboru Uchiyama, Shiori Koseki-Kuno, Youji Ebe, Seigo Takashima, Masao Yamada,
and Jun Hirabayashi. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for
glycan profiling. Nature Methods, 2(11):851–856, 2005.
[218] Oyindasola Oyelaran and Jeffrey C Gildersleeve. Glycan arrays: recent advances and future
challenges. Current Opinion in Chemical Biology, 13(4):406–413, 2009.
[219] Henning Ulrich and Carsten Wrenger. Disease-specific biomarker discovery by aptamers. Cytometry
Part A, 75A(9):727–733, 2009.
[220] Kyung-Mi Song, Seonghwan Lee, and Changill Ban. Aptamers and Their Biological Applications.
Sensors (Basel, Switzerland), 12(1):612–631, 2012.
[221] Andrew D. Ellington and Jack W. Szostak. In vitro selection of RNA molecules that bind specific
ligands. , Published online: 30 August 1990; | doi:10.1038/346818a0, 346(6287):818–822, 1990.
[222] Asaf Madi, Inbal Hecht, Sharron Bransburg-Zabary, Yifat Merbl, Adi Pick, Merav Zucker-Toledano,
Francisco J Quintana, Alfred I Tauber, Irun R Cohen, and Eshel Ben-Jacob. Organization of the
autoantibody repertoire in healthy newborns and adults revealed by system level informatics of
antigen microarray data. Proceedings of the National Academy of Sciences of the United States of
America, 106(34):14484–14489, 2009.
[223] Heiko Andresen and Carsten Grotzinger. Deciphering the Antibodyome - Peptide Arrays for Serum
Antibody Biomarker Diagnostics. Current Proteomics, 6:1–12, 2009.
[224] Yifat Merbl, Royi Itzchak, Tal Vider-Shalit, Yoram Louzoun, Francisco J. Quintana, Ezra Vadai,
Lea Eisenbach, and Irun R Cohen. A systems immunology approach to the host-tumor interaction:
large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice. PloS
One, 4(6):e6053, 2009.
146
Bibliography
[225] Yu M Foong, Jiaqi Fu, Shao Q Yao, and Mahesh Uttamchandani. Current advances in peptide and
small molecule microarray technologies. Current Opinion in Chemical Biology, 16(1–2):234–242,
2012.
[226] Stephen F. Kingsmore. Multiplexed protein measurement: technologies and applications of protein
and antibody arrays. Nature Reviews Drug Discovery, 5(4):310–321, 2006.
[227] Marie-Laure Lesaicherre, Mahesh Uttamchandani, Grace Y.J Chen, and Shao Q Yao. Developing
site-Specific immobilization strategies of peptides in a microarray. Bioorganic & Medicinal Chemistry
Letters, 12(16):2079–2083, 2002.
[228] Gavin MacBeath and Stuart L. Schreiber. Printing Proteins as Microarrays for High-Throughput
Function Determination. Science, 289(5485):1760 –1763, 2000.
[229] Tadashi Okamoto, Tomohiro Suzuki, and Nobuko Yamamoto. Microarray fabrication with covalent
attachment of DNA using Bubble Jet technology. Nature Biotechnology, 18(4):438–441, 2000.
[230] Virginia Espina, Elisa C. Woodhouse, Julia Wulfkuhle, Heather D. Asmussen, Emanuel F. Petricoin
III, and Lance A. Liotta. Protein microarray detection strategies: focus on direct detection
technologies. Journal of Immunological Methods, 290(1–2):121–133, 2004.
[231] Armin A. Weiser, Michal Or-Guil, Victor Tapia, Astrid Leichsenring, Johannes Schuchhardt,
Cornelius Frömmel, and Rudolf Volkmer-Engert. SPOT synthesis: Reliability of array-based
measurement of peptide binding affinity. Analytical Biochemistry, 342(2):300–311, 2005.
[232] Victor Tapia, Juliane Bongartz, Mike Schutkowski, Nicole Bruni, Armin Weiser, Bernhard Ay,
Rudolf Volkmer, and Michal Or-Guil. Affinity profiling using the peptide microarray technology:
A case study. Analytical Biochemistry, 363(1):108–118, 2007.
[233] Kaitlin Kroening, Stephen Albert Johnston, and Joseph Barten Legutki. Autoreactive antibodies
raised by self derived de novo peptides can identify unrelated antigens on protein microarrays. Are
autoantibodies really autoantibodies? Experimental and molecular pathology, 92(3):304–311, 2012.
[234] Wolfgang Hueber, Brian A. Kidd, Beren H. Tomooka, Byung J. Lee, Bonnie Bruce, James F. Fries,
Grete Sønderstrup, Paul Monach, Jan W. Drijfhout, Walther J. van Venrooij, Paul J. Utz, Mark C.
Genovese, and William H. Robinson. Antigen microarray profiling of autoantibodies in rheumatoid
arthritis. Arthritis & Rheumatism, 52(9):2645–2655, 2005.
[235] William H. Robinson, Carla DiGennaro, Wolfgang Hueber, Brian B. Haab, Makoto Kamachi,
Erik J. Dean, Sylvie Fournel, Derek Fong, Mark C. Genovese, Henry E. Neuman de Vegvar, Karl
Skriner, David L. Hirschberg, Robert I. Morris, Sylviane Muller, Ger J. Pruijn, Walther J. van
Venrooij, Josef S. Smolen, Patrick O. Brown, Lawrence Steinman, and Paul J. Utz. Autoantigen
microarrays for multiplex characterization of autoantibody responses. Nat Med, 8(3):295–301, 2002.
[236] William H Robinson, Paulo Fontoura, Byung J Lee, Henry E Neuman de Vegvar, Jennifer Tom,
Rosetta Pedotti, Carla D DiGennaro, Dennis J Mitchell, Derek Fong, Peggy P-K Ho, Pedro J Ruiz,
Emanual Maverakis, David B Stevens, Claude C A Bernard, Roland Martin, Vijay K Kuchroo,
Johannes M van Noort, Claude P Genain, Sandra Amor, Tomas Olsson, Paul J Utz, Hideki
Garren, and Lawrence Steinman. Protein microarrays guide tolerizing DNA vaccine treatment of
autoimmune encephalomyelitis. Nat Biotech, 21(9):1033–1039, 2003.
[237] Simani Gaseitsiwe, Davide Valentini, Shahnaz Mahdavifar, Isabelle Magalhaes, Daniel F. Hoft,
Johannes Zerweck, Mike Schutkowski, Jan Andersson, Marie Reilly, and Markus J. Maeurer. Pattern
Recognition in Pulmonary Tuberculosis Defined by High Content Peptide Microarray Chip Analysis
Representing 61 Proteins from M. tuberculosis. PLoS ONE, 3(12):e3840, 2008.
147
Bibliography
[238] Michael Hecker, Peter Lorenz, Felix Steinbeck, Li Hong, Gabriela Riemekasten, Yixue Li, Uwe K.
Zettl, and Hans-Jürgen Thiesen. Computational analysis of high-density peptide microarray data
with application from systemic sclerosis to multiple sclerosis. Autoimmunity Reviews, 11(3):180–190,
2012.
[239] M. Muralidhar Reddy, Rosemary Wilson, Johnnie Wilson, Steven Connell, Anne Gocke, Linda
Hynan, Dwight German, and Thomas Kodadek. Identification of Candidate IgG Biomarkers for
Alzheimer’s Disease via Combinatorial Library Screening. Cell, 144:132–142, 2011.
[240] Audrey Kauffmann, Robert Gentleman, and Wolfgang Huber. arrayQualityMetrics–a bioconductor
package for quality assessment of microarray data. Bioinformatics, 25(3):415–416, 2009.
[241] Jeremy Gollub, Catherine A Ball, Gail Binkley, Janos Demeter, David B Finkelstein, Joan M
Hebert, Tina Hernandez-Boussard, Heng Jin, Miroslava Kaloper, John C Matese, Mark Schroeder,
Patrick O Brown, David Botstein, and Gavin Sherlock. The Stanford Microarray Database: Data
Access and Quality Assessment Tools. Nucleic Acids Research, 31(1):94–96, 2003.
[242] John Quackenbush. Microarray data normalization and transformation. Nature Genetics, 32(Supp):
496–501, 2002.
[243] George C Tseng, Min-Kyu Oh, Lars Rohlin, James C Liao, and Wing Hung Wong. Issues in
cDNA Microarray Analysis: Quality Filtering, Channel Normalization, Models of Variations and
Assessment of Gene Effects. Nucleic Acids Research, 29(12):2549–2557, 2001.
[244] Leming Shi, Laura H Reid, Wendell D Jones, Richard Shippy, Janet A Warrington, Shawn C
Baker, Patrick J Collins, Francoise de Longueville, Ernest S Kawasaki, Kathleen Y Lee, Yuling
Luo, Yongming Andrew Sun, James C Willey, Robert A Setterquist, Gavin M Fischer, Weida
Tong, Yvonne P Dragan, David J Dix, Felix W Frueh, Frederico M Goodsaid, Damir Herman,
Roderick V Jensen, Charles D Johnson, Edward K Lobenhofer, Raj K Puri, Uwe Schrf, Jean
Thierry-Mieg, Charles Wang, Mike Wilson, Paul K Wolber, Lu Zhang, Shashi Amur, Wenjun Bao,
Catalin C Barbacioru, Anne Bergstrom Lucas, Vincent Bertholet, Cecilie Boysen, Bud Bromley,
Donna Brown, Alan Brunner, Roger Canales, Xiaoxi Megan Cao, Thomas A Cebula, James J
Chen, Jing Cheng, Tzu-Ming Chu, Eugene Chudin, John Corson, J Christopher Corton, Lisa J
Croner, Christopher Davies, Timothy S Davison, Glenda Delenstarr, Xutao Deng, David Dorris,
Aron C Eklund, Xiao-Hui Fan, Hong Fang, Stephanie Fulmer-Smentek, James C Fuscoe, Kathryn
Gallagher, Weigong Ge, Lei Guo, Xu Guo, Janet Hager, Paul K Haje, Jing Han, Tao Han, Heather C
Harbottle, Stephen C Harris, Eli Hatchwell, Craig A Hauser, Susan Hester, Huixiao Hong, Patrick
Hurban, Scott A Jackson, Hanlee Ji, Charles R Knight, Winston P Kuo, J Eugene Leclerc, Shawn
Levy, Quan-Zhen Li, Chunmei Liu, Ying Liu, Michael J Lombardi, Yunqing Ma, Scott R Magnuson,
Botoul Maqsodi, Tim McDaniel, Nan Mei, Ola Myklebost, Baitang Ning, Natalia Novoradovskaya,
Michael S Orr, Terry W Osborn, Adam Papallo, Tucker A Patterson, Roger G Perkins, Elizabeth H
Peters, Ron Peterson, Kenneth L Philips, P Scott Pine, Lajos Pusztai, Feng Qian, Hongzu Ren,
Mitch Rosen, Barry A Rosenzweig, Raymond R Samaha, Mark Schena, Gary P Schroth, Svetlana
Shchegrova, Dave D Smith, Frank Staedtler, Zhenqiang Su, Hongmei Sun, Zoltan Szallasi, Zivana
Tezak, Danielle Thierry-Mieg, Karol L Thompson, Irina Tikhonova, Yaron Turpaz, Beena Vallanat,
Christophe Van, Stephen J Walker, Sue Jane Wang, Yonghong Wang, Russ Wolfinger, Alex Wong,
Jie Wu, Chunlin Xiao, Qian Xie, Jun Xu, Wen Yang, Liang Zhang, Sheng Zhong, Yaping Zong, and
William Slikker. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform
reproducibility of gene expression measurements. Nature Biotechnology, 24(9):1151–1161, 2006.
[245] Justin R Brown, Phillip Stafford, Stephen A Johnston, and Valentin Dinu. Statistical methods for
analyzing immunosignatures. BMC Bioinformatics, 12:349, 2011.
[246] M. Kukreja, S.A. Johnston, and P. Stafford. Comparative study of classification algorithms for
immunosignaturing data. BMC bioinformatics, 13(1):139, 2012.
148
Bibliography
[247] T. Nahtman, A. Jernberg, S. Mahdavifar, J. Zerweck, M. Schutkowski, M. Maeurer, and M. Reilly.
Validation of peptide epitope microarray experiments and extraction of quality data. Journal of
Immunological Methods, 328(1-2):1–13, 2007.
[248] Marie Reilly and Davide Valentini. Visualisation and pre-processing of peptide microarray data.
Methods in Molecular Biology (Clifton, N.J.), 570:373–389, 2009.
[249] Bernhard Renard, Martin Lower, Yvonne Kuhne, Ulf Reimer, Andree Rothermel, Ozlem Tureci,
John Castle, and Ugur Sahin. rapmad: Robust analysis of peptide microarray data. BMC
Bioinformatics, 12(1):324, 2011.
[250] Shu-Wen W Chen, Marc H V Van Regenmortel, and Jean-Luc Pellequer. Structure-activity
relationships in peptide-antibody complexes: implications for epitope prediction and development
of synthetic peptide vaccines. Current Medicinal Chemistry, 16(8):953–964, 2009.
[251] Fabien Pamelard, Gael Even, Costin Apostol, Cristian Preda, Clarisse Dhaenens, Vronique Fafeur,
Rémi Desmet, and Oleg Melnyk. PASE: A Web-Based Platform for Peptide/Protein Microarray
Experiments. Methods Mol Biol., 570:413–430, 2009.
[252] J M Behnke, D M Menge, and H Noyes. Heligmosomoides bakeri: a model for exploring the biology
and genetics of resistance to chronic gastrointestinal nematode infections. Parasitology, 136(12):
1565–1580, 2009.
[253] Jerzy Behnke and Phil D Harris. Heligmosomoides bakeri: a new name for an old worm? Trends
in Parasitology, 2010.
[254] F G Monroy and F J Enriquez. Heligmosomoides polygyrus: a model for chronic gastrointestinal
helminthiasis. Parasitology Today (Personal Ed.), 8(2):49–54, 1992.
[255] Robert M Anthony, Joseph F Urban, Farhang Alem, Hossein A Hamed, Cristina T Rozo, Jean-Luc
Boucher, Nico Van Rooijen, and William C Gause. Memory TH2 cells induce alternatively activated
macrophages to mediate protection against nematode parasites. Nature medicine, 12(8):955–960,
2006.
[256] Kathy D. McCoy, Maaike Stoel, Rebecca Stettler, Patrick Merky, Katja Fink, Beatrice M. Senn,
Corinne Schaer, Joanna Massacand, Bernhard Odermatt, Hans C. Oettgen, Rolf M. Zinkernagel,
Nicolaas A. Bos, Hans Hengartner, Andrew J. Macpherson, and Nicola L. Harris. Polyclonal and
Specific Antibodies Mediate Protective Immunity against Enteric Helminth Infection. Cell Host &
Microbe, 4(4):362–373, 2008.
[257] Nicola Harris and William C. Gause. To B or not to B: B cells and the Th2-type immune response
to helminths. Trends in Immunology, 32(2):80–88, 2011.
[258] Wojciech Wojciechowski, David P. Harris, Frank Sprague, Betty Mousseau, Melissa Makris, Kim
Kusser, Tasuko Honjo, Katja Mohrs, Markus Mohrs, and Troy Randall. Cytokine-Producing
Effector B Cells Regulate Type 2 Immunity to H. polygyrus. Immunity, 30(3):421–433, 2009.
[259] Juliane Lück. Technologische Bewertung von Peptid-Mikroarrays als Methode der serologischen
Diagnostik. Biowissenschaften, Biologie, Humboldt-Universität zu Berlin, Berlin, 2012.
[260] Kristina Gruden, Matjaž Hren, Ana Herman, Andrej Blejec, Tanja Albrecht, Joachim Selbig, Chris
Bauer, Johannes Schuchardt, Michal Or-Guil, Klemen Zupančič, Urban Svajger, Borut Stabuc,
Alojz Ihan, Andreja Nataša Kopitar, Maja Ravnikar, Miomir Knežević, Primož Rožman, and
Matjaž Jeras. A "crossomics" study analysing variability of different components in peripheral
blood of healthy caucasoid individuals. PloS One, 7(1):e28761, 2012.
149
Bibliography
[261] K. Solez, R. B Colvin, L. C Racusen, M. Haas, B. Sis, M. Mengel, P. F Halloran, W. Baldwin,
G. Banfi, A. B Collins, F. Cosio, D. S. R David, C. Drachenberg, G. Einecke, A. B Fogo, I. W
Gibson, D. Glotz, S. S Iskandar, E. Kraus, E. Lerut, R. B Mannon, M. Mihatsch, B. J Nankivell,
V. Nickeleit, J. C Papadimitriou, P. Randhawa, H. Regele, K. Renaudin, I. Roberts, D. Seron,
R. N Smith, and M. Valente. Banff 07 Classification of Renal Allograft Pathology: Updates and
Future Directions. American Journal of Transplantation, 8(4):753–760, 2008.
[262] Lorraine C Racusen, Kim Solez, Robert B Colvin, Stephen M Bonsib, Maria C Castro, Tito Cavallo,
Byron P Croker, A Jake Demetris, Cynthia B Drachenberg, Agnes B Fogo, Peter Furness, Lillian W
Gaber, Ian W Gibson, Dennis Glotz, Julio C Goldberg, Joseph Grande, Philip F Halloran, H E
Hansen, Barry Hartley, Pekka J Hayry, Claire M Hill, Ernesto O Hoffman, Lawrence G Hunsicker,
Anne S Lindblad, Niels Marcussen, Michael J Mihatsch, Tibor Nadasdy, Peter Nickerson, T Steen
Olsen, John C Papadimitriou, Parmjeet S Randhawa, David C Rayner, Ian Roberts, Stephen Rose,
David Rush, Luis Salinas-Madrigal, Daniel R Salomon, Stale Sund, Eero Taskinen, Kiril Trpkov,
and Yutaka Yamaguchi. The Banff 97 working classification of renal allograft pathology. Kidney
International, 55(2):713–723, 1999.
[263] Eric Meffre, Anne Schaefer, Hedda Wardemann, Patrick Wilson, Eric Davis, and Michel C.
Nussenzweig. Surrogate Light Chain Expressing Human Peripheral B Cells Produce Self-reactive
Antibodies. The Journal of Experimental Medicine, 199(1):145–150, 2004.
[264] Thomas Tiller, Eric Meffre, Sergey Yurasov, Makoto Tsuiji, Michel C. Nussenzweig, and Hedda
Wardemann. Efficient generation of monoclonal antibodies from single human B cells by single cell
RT-PCR and expression vector cloning. Journal of immunological methods, 329(1-2):112–124, 2008.
[265] Shai Rosenwald, Ran Kafri, and Doron Lancet. Test of a Statistical Model for Molecular Recognition
in Biological Repertoires. Journal of Theoretical Biology, 216(3):327–336, 2002.
[266] Amnon Horovitz and Meir Rigbi. Protein-protein interactions: Additivity of the free energies of
association of amino acid residues. Journal of Theoretical Biology, 116(1):149–159, 1985.
[267] Spencer M. Free and James W. Wilson. A Mathematical Contribution to Structure-Activity Studies.
Journal of Medicinal Chemistry, 7(4):395–399, 1964.
[268] Khouloud A Alkhamis and Dale Eric Wurster. Prediction of adsorption from multicomponent
solutions by activated carbon using single-solute parameters. Part II–Proposed equation. AAPS
PharmSciTech, 3(3):E23, 2002.
[269] Anne-Laure Boulesteix and Korbinian Strimmer. Partial least squares: a versatile tool for the
analysis of high-dimensional genomic data. Brief Bioinform, 8(1):32–44, 2007.
[270] Svante Wold, Michael Sjöström, and Lennart Eriksson. PLS-regression: a basic tool of chemometrics.
Chemometrics and Intelligent Laboratory Systems, 58(2):109–130, 2001.
[271] Björn-Helge Mevik and Ron Wehrens. The pls Package: Principal Component and Partial Least
Squares Regression in R. Journal of Statistical Software, 18(2):1–24, 2007.
[272] R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna,
Austria, 2009.
[273] Christopher M. Bishop. Pattern Recognition and Machine Learning. Springer, Berlin, new edition
edition, 2007.
[274] Simon O. Haykin. Neural Networks and Learning Machines. Prentice Hall, 3 edition, 2008.
[275] Wolfram Stacklies, Henning Redestig, Matthias Scholz, Dirk Walther, and Joachim Selbig. pcaMeth-
ods a bioconductor package providing PCA methods for incomplete data. Bioinformatics, 23(9):
1164–1167, 2007.
150
Bibliography
[276] V. Franc and V. Hlavac. Multi-class support vector machine. In Pattern Recognition, 2002.
Proceedings. 16th International Conference on, volume 2, pages 236 – 239 vol.2, 2002.
[277] Vladimir N. Vapnik. Statistical Learning Theory. Wiley-Interscience, 1 edition, 1998.
[278] Sepp Hochreiter and Klaus Obermayer. Support vector machines for dyadic data. Neural Compu-
tation, 18(6):1472–1510, 2006.
[279] Wikipedia contributors. Pearson product-moment correlation coefficient, 2012.
[280] Wikipedia contributors. Spearman’s rank correlation coefficient, 2012.
[281] Fionn Murtagh. Correspondence Analysis and Data Coding with Java and R. Chapman & Hall/CRC,
1 edition, 2005.
[282] David W. Mount. Bioinformatics: Second Ed (P): Sequence and Genome Analysis. Cold Spring
Harbor Laboratory Press, 2004.
[283] Gregory R. Warnes. Includes R source code and/or documentation contributed by: Ben Bolker,
Lodewijk Bonebakker, Robert Gentleman, Wolfgang Huber Andy Liaw, Thomas Lumley, Martin
Maechler, Arni Magnusson, Steffen Moeller, Marc Schwartz, and Bill Venables. gplots: Various R
programming tools for plotting data, 2011.
[284] Rob J. De Boer and Alan S. Perelson. T Cell Repertoires and Competitive Exclusion. Journal of
Theoretical Biology, 169(4):375–390, 1994.
[285] Alan S. Perelson. Immune Network Theory. Immunological Reviews, 110(1):5–36, 1989.
[286] B Sulzer and A S Perelson. Equilibrium binding of multivalent ligands to cells: effects of cell and
receptor density. Mathematical Biosciences, 135(2):147–185, 1996.
[287] Sebastian Rausch, Jochen Huehn, Dennis Kirchhoff, Justyna Rzepecka, Corinna Schnoeller, Smitha
Pillai, Christoph Loddenkemper, Alexander Scheffold, Alf Hamann, Richard Lucius, and Susanne
Hartmann. Functional Analysis of Effector and Regulatory T Cells in a Parasitic Nematode
Infection. Infect. Immun., 76(5):1908–1919, 2008.
[288] A.S. Kolaskar and Prasad C. Tongaonkar. A semi-empirical method for prediction of antigenic
determinants on protein antigens. FEBS Letters, 276(1-2):172–174, 1990.
[289] P Y Chou and G D Fasman. Prediction of the secondary structure of proteins from their amino
acid sequence. Advances in Enzymology and Related Areas of Molecular Biology, 47:45–148, 1978.
[290] R. Benner, A. van Oudenaren, M. Björklund, F. Ivars, and D. Holmberg. [‘]Background’ im-
munoglobulin production: measurement, biological significance and regulation. Immunology Today,
3(9):243–249, 1982.
[291] N. K Jerne. The natural-selection theory of antibody formation. Proceedings of the National
Academy of Sciences of the United States of America, 41(11):849, 1955.
[292] M. F. Bachmann, U. Kalinke, A. Althage, G. Freer, C. Burkhart, H.-P. Roost, M. Aguet, H.
Hengartner, and R. M. Zinkernagel. The Role of Antibody Concentration and Avidity in Antiviral
Protection. Science, 276(5321):2024 –2027, 1997.
[293] Tapan Mehta, Murat Tanik, and David B Allison. Towards sound epistemological foundations of
statistical methods for high-dimensional biology. Nat Genet, 36(9):943–947, 2004.
[294] Sai T Reddy and George Georgiou. Systems analysis of adaptive immunity by utilization of
high-throughput technologies. Current Opinion in Biotechnology, 22(4):584–589, 2011.
151
Bibliography
[295] Martijn M. VanDuijn, Lennard J. M. Dekker, L. Zeneyedpour, Peter A. E. Sillevis Smitt, and
Theo M. Luider. Immune Responses Are Characterized by Specific Shared Immunoglobulin
Peptides That Can Be Detected by Proteomic Techniques. Journal of Biological Chemistry, 285
(38):29247–29253, 2010.
[296] D Y Loh, A L Bothwell, M E White-Scharf, T Imanishi-Kari, and D Baltimore. Molecular basis of
a mouse strain-specific anti-hapten response. Cell, 33(1):85–93, 1983.
[297] Peter S. Andersen, Margit Haahr-Hansen, Vincent W. Coljee, Frank R. Hinnerfeldt, Kim Varming,
Søren Bregenholt, and John S. Haurum. Extensive restrictions in the VH sequence usage of the
human antibody response against the Rhesus D antigen. Molecular Immunology, 44(4):412–422,
2007.
[298] Tine Rugh Poulsen, Per-Johan Meijer, Allan Jensen, Lars S. Nielsen, and Peter S. Andersen.
Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses Against Tetanus
Toxoid. The Journal of Immunology, 179(6):3841–3850, 2007.
[299] Dominique de Costa, Ingrid Broodman, Martijn M. VanDuijn, Christoph Stingl, Lennard J. M.
Dekker, Peter C. Burgers, Henk C. Hoogsteden, Peter A. E. Sillevis Smitt, Rob J. van Klaveren,
and Theo M. Luider. Sequencing and Quantifying IgG Fragments and Antigen-Binding Regions by
Mass Spectrometry. J. Proteome Res., 9(6):2937–2945, 2010.
[300] Daniela Frölich, Claudia Giesecke, Henrik E. Mei, Karin Reiter, Capucine Daridon, Peter E. Lipsky,
and Thomas Dorner. Secondary Immunization Generates Clonally Related Antigen-Specific Plasma
Cells and Memory B Cells. J Immunol, 185(5):3103–3110, 2010.
[301] Nina Babel, Juliane Fendt, Stoyan Karaivanov, Gantuja Bold, Steffen Arnold, Anett Sefrin, Evelyn
Lieske, Martin Hoffzimmer, Mikalai Dziubianau, Nicole Bethke, Christian Meisel, Gerald Grütz, and
Petra Reinke. Sustained BK Viruria as an Early Marker for the Development of BKV-Associated
Nephropathy: Analysis of 4128 Urine and Serum Samples. Transplantation, 88(1):89–95, 2009.
[302] G. Giraudi, I. Rosso, C. Baggiani, and C. Giovannoli. Affinity between immobilised monoclonal
and polyclonal antibodies and steroid-enzyme tracers increases sharply at high surface density.
Analytica Chimica Acta, 381(2–3):133–146, 1999.
[303] Carsten C Mahrenholz, Victor Tapia, Rolf D Stigler, and Rudolf Volkmer. A study to assess the
cross-reactivity of cellulose membrane-bound peptides with detection systems: an analysis at the
amino acid level. Journal of Peptide Science: An Official Publication of the European Peptide
Society, 16(6):297–302, 2010.
[304] Rolf M. Zinkernagel. Immunology Taught by Viruses. Science, 271(5246):173 –178, 1996.
[305] Holden T. Maecker, J. Philip McCoy, and Robert Nussenblatt. Standardizing immunophenotyping
for the Human Immunology Project. Nature Reviews Immunology, 2012.
[306] A. J Burnham, J. F MacGregor, and R. Viveros. Latent variable multivariate regression modeling.
Chemometrics and Intelligent Laboratory Systems, 48(2):167–180, 1999.
[307] Anders Björner and Richard P. Stanley. A combinatorial miscellany. L’Enseignement mathématique,
2010.
152
Selbständigkeitserklärung
Ich erkläre, dass ich die vorliegende Arbeit selbständig und nur unter Verwendung der
angegebenen Literatur und Hilfsmittel angefertigt habe.
Ich habe mich anderweitig nicht um einen Doktorgrad beworben und besitze auch keinen
entsprechenden Doktorgrad.
Mir ist die dem Verfahren zugrunde liegende Promotionsordnung bekannt.
Berlin, den 31. Juli 2012
Victor Greiff
